000183934112/312022Q3NoSeptember 30,
2022Core Scientific,
Inc./txhttp://fasb.org/us-gaap/2022#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2022#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2022#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortizationhttp://fasb.org/us-gaap/2022#AccruedLiabilitiesCurrenthttp://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrentP5DP5DP5DP30D00018393412022-01-012022-09-300001839341us-gaap:CommonStockMember2022-01-012022-09-300001839341us-gaap:WarrantMember2022-01-012022-09-3000018393412022-11-14xbrli:shares00018393412022-09-30iso4217:USD00018393412021-12-31iso4217:USDxbrli:shares0001839341core:HostingServiceCustomersMember2022-07-012022-09-300001839341core:HostingServiceCustomersMember2021-07-012021-09-300001839341core:HostingServiceCustomersMember2022-01-012022-09-300001839341core:HostingServiceCustomersMember2021-01-012021-09-300001839341core:HostingServiceRelatedPartiesMember2022-07-012022-09-300001839341core:HostingServiceRelatedPartiesMember2021-07-012021-09-300001839341core:HostingServiceRelatedPartiesMember2022-01-012022-09-300001839341core:HostingServiceRelatedPartiesMember2021-01-012021-09-300001839341core:EquipmentSalesCustomersMember2022-07-012022-09-300001839341core:EquipmentSalesCustomersMember2021-07-012021-09-300001839341core:EquipmentSalesCustomersMember2022-01-012022-09-300001839341core:EquipmentSalesCustomersMember2021-01-012021-09-300001839341core:EquipmentSalesRelatedPartiesMember2022-07-012022-09-300001839341core:EquipmentSalesRelatedPartiesMember2021-07-012021-09-300001839341core:EquipmentSalesRelatedPartiesMember2022-01-012022-09-300001839341core:EquipmentSalesRelatedPartiesMember2021-01-012021-09-300001839341core:DigitalAssetMiningServiceMember2022-07-012022-09-300001839341core:DigitalAssetMiningServiceMember2021-07-012021-09-300001839341core:DigitalAssetMiningServiceMember2022-01-012022-09-300001839341core:DigitalAssetMiningServiceMember2021-01-012021-09-3000018393412022-07-012022-09-3000018393412021-07-012021-09-3000018393412021-01-012021-09-300001839341core:HostingServiceMember2022-07-012022-09-300001839341core:HostingServiceMember2021-07-012021-09-300001839341core:HostingServiceMember2022-01-012022-09-300001839341core:HostingServiceMember2021-01-012021-09-300001839341core:EquipmentSalesMember2022-07-012022-09-300001839341core:EquipmentSalesMember2021-07-012021-09-300001839341core:EquipmentSalesMember2022-01-012022-09-300001839341core:EquipmentSalesMember2021-01-012021-09-300001839341us-gaap:PreferredStockMember2022-06-300001839341us-gaap:CommonStockMember2022-06-300001839341us-gaap:AdditionalPaidInCapitalMember2022-06-300001839341us-gaap:RetainedEarningsMember2022-06-300001839341us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-06-3000018393412022-06-300001839341us-gaap:RetainedEarningsMember2022-07-012022-09-300001839341us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-07-012022-09-300001839341us-gaap:AdditionalPaidInCapitalMember2022-07-012022-09-300001839341us-gaap:CommonStockMember2022-07-012022-09-300001839341us-gaap:PreferredStockMember2022-09-300001839341us-gaap:CommonStockMember2022-09-300001839341us-gaap:AdditionalPaidInCapitalMember2022-09-300001839341us-gaap:RetainedEarningsMember2022-09-300001839341us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-09-300001839341us-gaap:PreferredStockMember2021-12-310001839341us-gaap:CommonStockMember2021-12-310001839341us-gaap:AdditionalPaidInCapitalMember2021-12-310001839341us-gaap:RetainedEarningsMember2021-12-310001839341us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310001839341us-gaap:RetainedEarningsMember2022-01-012022-09-300001839341us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-09-300001839341us-gaap:AdditionalPaidInCapitalMember2022-01-012022-09-300001839341us-gaap:CommonStockMember2022-01-012022-09-300001839341us-gaap:PreferredStockMember2022-01-012022-09-300001839341us-gaap:PreferredStockMember2021-06-300001839341us-gaap:CommonStockMember2021-06-300001839341us-gaap:AdditionalPaidInCapitalMember2021-06-300001839341us-gaap:RetainedEarningsMember2021-06-3000018393412021-06-300001839341us-gaap:RetainedEarningsMember2021-07-012021-09-300001839341us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-07-012021-09-300001839341us-gaap:CommonStockMember2021-07-012021-09-300001839341us-gaap:AdditionalPaidInCapitalMember2021-07-012021-09-300001839341us-gaap:PreferredStockMember2021-09-300001839341us-gaap:CommonStockMember2021-09-300001839341us-gaap:AdditionalPaidInCapitalMember2021-09-300001839341us-gaap:RetainedEarningsMember2021-09-300001839341us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-09-3000018393412021-09-300001839341srt:ScenarioPreviouslyReportedMemberus-gaap:PreferredStockMember2020-12-310001839341srt:ScenarioPreviouslyReportedMemberus-gaap:CommonStockMember2020-12-310001839341srt:ScenarioPreviouslyReportedMemberus-gaap:AdditionalPaidInCapitalMember2020-12-310001839341srt:ScenarioPreviouslyReportedMemberus-gaap:RetainedEarningsMember2020-12-310001839341srt:ScenarioPreviouslyReportedMember2020-12-310001839341us-gaap:PreferredStockMembersrt:RestatementAdjustmentMember2020-12-310001839341us-gaap:CommonStockMembersrt:RestatementAdjustmentMember2020-12-310001839341us-gaap:AdditionalPaidInCapitalMembersrt:RestatementAdjustmentMember2020-12-310001839341srt:RestatementAdjustmentMember2020-12-310001839341us-gaap:PreferredStockMember2020-12-310001839341us-gaap:CommonStockMember2020-12-310001839341us-gaap:AdditionalPaidInCapitalMember2020-12-310001839341us-gaap:RetainedEarningsMember2020-12-3100018393412020-12-310001839341us-gaap:RetainedEarningsMember2021-01-012021-09-300001839341us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-09-300001839341us-gaap:CommonStockMember2021-01-012021-09-300001839341us-gaap:AdditionalPaidInCapitalMember2021-01-012021-09-300001839341core:PowerDigitalInfrastructureAcquisitionCorpMemberus-gaap:CommonClassAMember2022-01-180001839341core:PowerDigitalInfrastructureAcquisitionCorpMemberus-gaap:CommonClassBMember2022-01-180001839341core:NewCoreCommonStockMember2022-01-1800018393412022-01-19xbrli:pure0001839341core:PowerDigitalInfrastructureAcquisitionCorpMember2022-01-182022-01-180001839341core:PowerDigitalInfrastructureAcquisitionCorpMemberus-gaap:CommonClassAMember2022-01-190001839341core:PowerDigitalInfrastructureAcquisitionCorpMember2022-01-190001839341core:FormerCoreScientificStockholdersMember2022-01-190001839341core:FormerXPDIPublicStockholdersMember2022-01-190001839341core:XPDISponsorMember2022-01-1900018393412021-01-012021-12-310001839341us-gaap:SeriesAPreferredStockMember2022-01-190001839341core:ConversionOfSeriesAPreferredStockToCommonStockMember2022-01-180001839341us-gaap:SeriesBPreferredStockMember2022-01-190001839341core:ConversionOfSeriesBPreferredStockToCommonStockMember2022-01-180001839341core:ConversionOfXPDIClassBCommonStockToNewCoreCommonStockMember2022-01-1800018393412022-01-1800018393412022-01-182022-01-180001839341core:ConversionOfXPDIsCommonStockToNewCoreCommonStockMember2022-01-180001839341core:PowerDigitalInfrastructureAcquisitionCorpMembercore:PublicWarrantsMember2022-01-180001839341core:PowerDigitalInfrastructureAcquisitionCorpMembercore:PrivatePlacementWarrantsMember2022-01-180001839341core:BitcoinMember2022-07-012022-09-30iso4217:USDcore:Unit0001839341core:BitcoinMember2022-04-012022-06-3000018393412022-04-012022-06-300001839341us-gaap:SubsequentEventMemberus-gaap:BridgeLoanMember2022-10-31core:note0001839341us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2022-09-300001839341us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2021-12-310001839341us-gaap:ConstructionInProgressMember2022-09-300001839341us-gaap:ConstructionInProgressMember2021-12-310001839341core:DigitalAssetMiningServiceMember2022-09-300001839341core:DigitalAssetMiningServiceMember2022-01-012022-09-300001839341core:DigitalAssetMiningServiceMember2022-07-012022-09-300001839341us-gaap:SubsequentEventMember2022-11-012022-11-21core:self-mine0001839341srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2021-12-310001839341srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember2022-01-0100018393412022-01-010001839341core:BlockcapIncMember2021-07-300001839341core:BlockcapIncMemberus-gaap:CommonStockMember2021-07-302021-07-300001839341core:BlockcapIncMemberus-gaap:RestrictedStockMember2021-07-302021-07-300001839341us-gaap:OptionOnSecuritiesMembercore:BlockcapIncMember2021-07-302021-07-300001839341core:BlockcapIncMember2022-07-012022-09-300001839341core:BlockcapIncMemberus-gaap:StockCompensationPlanMember2021-07-302021-07-300001839341core:BlockcapIncMember2021-07-302021-07-300001839341core:BlockcapIncMembercore:BitcoinMember2021-07-300001839341core:BlockcapIncMembercore:EthereumMember2021-07-300001839341core:BitcoinCashMembercore:BlockcapIncMember2021-07-300001839341core:BlockcapIncMembercore:SiacoinMember2021-07-300001839341core:BlockcapIncMembercore:DigitalAssetsOtherMember2021-07-300001839341core:BlockcapIncMemberus-gaap:TechnologyBasedIntangibleAssetsMember2021-07-300001839341core:BlockcapIncMemberus-gaap:CustomerRelationshipsMember2021-07-300001839341core:BlockcapIncMemberus-gaap:TechnologyBasedIntangibleAssetsMember2021-07-302021-07-300001839341core:A2022RestructuringMember2022-07-012022-09-300001839341core:A2022RestructuringMember2022-09-300001839341core:A2022RestructuringMemberus-gaap:EmployeeSeveranceMember2022-07-012022-09-300001839341core:A2022RestructuringMember2022-01-012022-09-300001839341core:MiningSegmentMember2022-07-012022-09-300001839341core:MiningSegmentMember2022-01-012022-09-300001839341core:EquipmentSalesAndHostingSegmentMember2022-07-012022-09-300001839341core:EquipmentSalesAndHostingSegmentMember2022-01-012022-09-300001839341us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMemberus-gaap:SoftwareAndSoftwareDevelopmentCostsMembercore:AtrioAndRStorMember2022-03-310001839341us-gaap:SoftwareAndSoftwareDevelopmentCostsMember2022-06-012022-06-300001839341core:EquipmentSalesAndHostingSegmentMember2021-12-310001839341core:MiningSegmentMember2021-12-310001839341core:EquipmentSalesAndHostingSegmentMember2022-01-012022-09-300001839341core:MiningSegmentMember2022-01-012022-09-300001839341core:EquipmentSalesAndHostingSegmentMember2022-09-300001839341core:MiningSegmentMember2022-09-300001839341core:MiningSegmentMember2022-04-012022-06-300001839341core:MiningSegmentMember2022-07-012022-09-300001839341core:EquipmentSalesAndHostingSegmentMember2022-06-300001839341core:EquipmentSalesAndHostingSegmentMember2022-07-012022-09-300001839341core:PublicWarrantsMember2022-09-300001839341core:PrivatePlacementWarrantsMember2022-09-300001839341core:PublicWarrantsMembercore:RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds1800Member2022-09-300001839341core:PublicWarrantsMembercore:RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds1800Member2022-01-012022-09-300001839341core:PublicWarrantsMembercore:RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds1000Member2022-09-300001839341core:PublicWarrantsMembercore:RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds1000Member2022-01-012022-09-300001839341core:PrivatePlacementWarrantsMembercore:RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds1000Member2022-09-300001839341core:PrivatePlacementWarrantsMembercore:RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds1000Member2022-01-012022-09-300001839341core:PublicWarrantsMember2022-07-012022-09-300001839341core:PrivatePlacementWarrantsMember2022-07-012022-09-300001839341core:PublicWarrantsMember2022-01-012022-09-300001839341core:PrivatePlacementWarrantsMember2022-01-012022-09-300001839341core:KentuckyNoteMembercore:NotesPayableMember2022-09-300001839341core:KentuckyNoteMembercore:NotesPayableMember2021-12-310001839341core:NotesPayableMembercore:GenesisLoanMember2022-09-300001839341core:NotesPayableMembercore:GenesisLoanMember2021-12-310001839341core:NotesPayableMembercore:NYDIGLoanMember2022-09-300001839341core:NotesPayableMembercore:NYDIGLoanMember2021-12-310001839341core:NotesPayableMembercore:StockholderLoanMember2022-09-300001839341core:NotesPayableMembercore:StockholderLoanMember2021-12-310001839341core:NotesPayableMembercore:TrinityLoanMember2022-09-300001839341core:NotesPayableMembercore:TrinityLoanMember2021-12-310001839341core:NotesPayableMembercore:BremerLoanMember2022-09-300001839341core:NotesPayableMembercore:BremerLoanMember2021-12-310001839341core:NotesPayableMembercore:BlockfiLoanMember2022-09-300001839341core:NotesPayableMembercore:BlockfiLoanMember2021-12-310001839341core:NotesPayableMembercore:AnchorLabsLoanMember2022-09-300001839341core:NotesPayableMembercore:AnchorLabsLoanMember2021-12-310001839341core:NotesPayableMembercore:MassMutualBaringsMember2022-09-300001839341core:NotesPayableMembercore:MassMutualBaringsMember2021-12-310001839341core:NotesPayableMembercore:BRileyBridgeNotesMember2022-09-300001839341core:NotesPayableMembercore:BRileyBridgeNotesMember2021-12-310001839341core:NotesPayableMembercore:LibertyLoanMember2022-09-300001839341core:NotesPayableMembercore:LibertyLoanMember2021-12-310001839341core:NotesPayableMembercore:SecuredConvertibleNotesIssuedApril2021Member2022-09-300001839341core:NotesPayableMembercore:SecuredConvertibleNotesIssuedApril2021Member2021-12-310001839341core:NotesPayableMembercore:OtherUnsecuredConvertibleNotesMember2022-09-300001839341core:NotesPayableMembercore:OtherUnsecuredConvertibleNotesMember2021-12-310001839341core:NotesPayableMembercore:OtherDebtInstrumentMember2022-09-300001839341core:NotesPayableMembercore:OtherDebtInstrumentMember2021-12-310001839341core:NotesPayableMember2022-09-300001839341core:NotesPayableMember2021-12-310001839341core:SecuredConvertibleNotesIssuedApril2021Member2022-09-300001839341core:SecuredConvertibleNotesIssuedApril2021Member2021-12-310001839341core:OtherUnsecuredConvertibleNotesMember2022-09-300001839341core:KentuckyNoteMembercore:SecuredPromissoryNotesPayableMember2018-12-012018-12-310001839341core:KentuckyNoteMembercore:SecuredPromissoryNotesPayableMember2018-12-310001839341us-gaap:SecuredDebtMembercore:GenesisLoanMember2020-07-310001839341us-gaap:SecuredDebtMembercore:GenesisLoanMember2020-07-012020-07-310001839341us-gaap:LineOfCreditMemberus-gaap:SecuredDebtMembercore:GenesisLoanMember2020-07-012020-07-31core:installment0001839341us-gaap:LineOfCreditMemberus-gaap:SecuredDebtMembercore:GenesisLoanMember2020-07-310001839341core:NYDIGLoanMembercore:EquipmentLoanMember2020-10-012020-10-310001839341core:NYDIGLoanMembercore:EquipmentLoanMember2021-03-012021-03-310001839341core:NYDIGLoanMembercore:EquipmentLoanMember2020-10-310001839341core:NYDIGLoanMembercore:EquipmentLoanMember2021-05-012021-05-310001839341core:NYDIGLoanMembercore:EquipmentLoanMember2021-05-310001839341core:NYDIGLoanMembercore:EquipmentLoanMember2021-07-012021-07-310001839341core:NYDIGLoanMembercore:EquipmentLoanMember2021-07-310001839341core:NYDIGLoanMembercore:EquipmentLoanMember2021-11-012021-11-300001839341core:NYDIGLoanMembercore:EquipmentLoanMember2011-11-300001839341core:StockholderLoanMembercore:EquipmentLoanMember2021-01-310001839341core:StockholderLoanMembercore:EquipmentLoanMember2021-01-012021-01-310001839341core:StockholderLoanWarrantsMember2021-01-310001839341core:StockholderLoanMember2021-01-310001839341core:StockholderLoanWarrantsMember2021-01-012021-01-310001839341us-gaap:RevolvingCreditFacilityMembercore:TrinityLoanMember2021-08-310001839341us-gaap:RevolvingCreditFacilityMembercore:TrinityLoanMember2021-08-012021-08-310001839341us-gaap:RevolvingCreditFacilityMembercore:TrinityLoanMember2021-11-012021-11-300001839341us-gaap:RevolvingCreditFacilityMembercore:TrinityLoanMember2021-12-012021-12-310001839341us-gaap:RevolvingCreditFacilityMembercore:TrinityLoanMember2022-02-012022-02-280001839341core:BremerLoanMembercore:EquipmentLoanMember2021-10-310001839341core:BremerLoanMembercore:EquipmentLoanMember2021-10-012021-10-31core:tranche0001839341core:BremerLoanMembercore:EquipmentLoanMember2022-09-300001839341core:BremerLoanMembercore:EquipmentLoanMember2021-10-012021-12-310001839341core:BremerLoanMembercore:EquipmentLoanMember2022-01-012022-03-310001839341core:BremerLoanMembercore:EquipmentLoanMember2022-04-012022-04-300001839341core:BremerLoanMembersrt:ScenarioForecastMembercore:EquipmentLoanMember2022-12-310001839341core:BremerLoanMembercore:EquipmentLoanMember2022-01-012022-09-30core:employee0001839341core:BlockfiLoanMembercore:EquipmentLoanMember2021-12-31core:agreement0001839341core:BlockfiLoanCreditAgreementOneMembercore:EquipmentLoanMember2021-12-310001839341core:BlockfiLoanCreditAgreementOneMembercore:EquipmentLoanMember2021-12-012021-12-310001839341core:EquipmentLoanMembercore:BlockfiLoanCreditAgreementTwoMember2021-12-310001839341core:EquipmentLoanMembercore:BlockfiLoanCreditAgreementTwoMember2021-12-012021-12-310001839341core:BlockfiLoanMembercore:EquipmentLoanMember2021-12-012021-12-310001839341core:BlockfiLoanMembercore:EquipmentLoanMember2022-01-012022-01-310001839341core:BlockfiLoanMembercore:EquipmentLoanMember2022-09-300001839341core:AnchorLabsLoanMembercore:EquipmentLoanMember2022-03-310001839341core:AnchorLabsLoanMembercore:EquipmentLoanMember2022-03-012022-03-310001839341core:AnchorLabsLoanMembercore:EquipmentLoanMember2022-05-310001839341core:AnchorLabsLoanMembercore:EquipmentLoanMember2022-05-012022-05-310001839341core:MassMutualBaringsMembercore:EquipmentLoanMember2022-03-310001839341core:MassMutualBaringsMembercore:EquipmentLoanMember2022-03-012022-03-310001839341core:MassMutualBaringsMembercore:EquipmentLoanMember2022-04-012022-04-300001839341core:MassMutualBaringsMembercore:EquipmentLoanMember2022-09-300001839341core:MassMutualBaringsMembercore:EquipmentLoanMember2022-08-310001839341core:MassMutualBaringsMember2022-08-012022-08-310001839341us-gaap:BridgeLoanMembercore:BRileyCommercialCapitalLLCMembercore:BRileyBridgeNotesMember2022-04-300001839341us-gaap:BridgeLoanMembercore:AffiliateOfBRileyCommercialCapitalLLCMembercore:BRileyBridgeNotesMember2022-04-300001839341us-gaap:BridgeLoanMembercore:BRileyBridgeNotesMember2022-04-300001839341srt:ScenarioForecastMemberus-gaap:BridgeLoanMembercore:AmendedBRileyBridgeNotesMember2023-06-300001839341us-gaap:BridgeLoanMembercore:AmendedBRileyBridgeNotesMember2022-08-190001839341core:BRileySecuritiesIncMember2022-08-012022-08-010001839341core:LibertyLoanMembercore:EquipmentLoanMember2022-04-300001839341core:LibertyLoanMembercore:EquipmentLoanMember2022-04-012022-04-300001839341core:SecuredConvertibleNotesIssuedApril2021Memberus-gaap:ConvertibleDebtMember2021-04-300001839341core:UnsecuredConvertibleNotesIssuedAugNov2021Memberus-gaap:ConvertibleDebtMember2021-11-300001839341us-gaap:ConvertibleDebtMember2022-04-012022-09-300001839341us-gaap:ConvertibleDebtMember2022-09-300001839341us-gaap:ConvertibleDebtMember2021-12-310001839341us-gaap:ConvertibleDebtMember2022-01-190001839341core:SilverpeakLoanMember2021-04-012021-04-300001839341core:ConversionOfConvertibleNotesIntoCommonStockMember2022-01-012022-09-300001839341core:ConvertibleNotesMatureInApril2025Memberus-gaap:ConvertibleDebtMember2022-01-012022-09-300001839341us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMembercore:ConvertibleNotesMatureInApril2025Member2022-09-300001839341us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CarryingReportedAmountFairValueDisclosureMembercore:ConvertibleNotesMatureInApril2025Memberus-gaap:FairValueInputsLevel2Member2022-09-300001839341core:ConvertibleNotesMatureInApril2025Memberus-gaap:InterestExpenseMembercore:ConvertibleDebtInterestPaidInCashMemberus-gaap:ConvertibleDebtMember2022-07-012022-09-300001839341core:ConvertibleNotesMatureInApril2025Memberus-gaap:InterestExpenseMembercore:ConvertibleDebtInterestPaidInCashMemberus-gaap:ConvertibleDebtMember2022-01-012022-09-300001839341core:ConvertibleDebtPaidInKindInterestMembercore:ConvertibleNotesMatureInApril2025Memberus-gaap:InterestExpenseMemberus-gaap:ConvertibleDebtMember2022-07-012022-09-300001839341core:ConvertibleDebtPaidInKindInterestMembercore:ConvertibleNotesMatureInApril2025Memberus-gaap:InterestExpenseMemberus-gaap:ConvertibleDebtMember2022-01-012022-09-300001839341core:ConvertibleNotesMatureInApril2025Membercore:ConvertibleDebtInstrumentSpecificCreditRiskMemberus-gaap:OtherComprehensiveIncomeMemberus-gaap:ConvertibleDebtMember2022-07-012022-09-300001839341core:ConvertibleNotesMatureInApril2025Membercore:ConvertibleDebtInstrumentSpecificCreditRiskMemberus-gaap:OtherComprehensiveIncomeMemberus-gaap:ConvertibleDebtMember2022-01-012022-09-300001839341core:ConvertibleNotesMatureInApril2025Memberus-gaap:ConvertibleDebtMembercore:ConvertibleDebtOtherFairValueAdjustmentMemberus-gaap:OtherNonoperatingIncomeExpenseMember2022-07-012022-09-300001839341core:ConvertibleNotesMatureInApril2025Memberus-gaap:ConvertibleDebtMembercore:ConvertibleDebtOtherFairValueAdjustmentMemberus-gaap:OtherNonoperatingIncomeExpenseMember2022-01-012022-09-300001839341core:ConvertibleNotesMatureInApril2025Memberus-gaap:ConvertibleDebtMember2022-07-012022-09-300001839341core:ConvertibleNotesMatureInApril2025Memberus-gaap:InterestExpenseMembercore:ConvertibleDebtInterestPaidInCashMemberus-gaap:ConvertibleDebtMember2021-07-012021-09-300001839341core:ConvertibleNotesMatureInApril2025Memberus-gaap:InterestExpenseMembercore:ConvertibleDebtInterestPaidInCashMemberus-gaap:ConvertibleDebtMember2021-01-012021-09-300001839341core:ConvertibleDebtPaidInKindInterestMembercore:ConvertibleNotesMatureInApril2025Memberus-gaap:InterestExpenseMemberus-gaap:ConvertibleDebtMember2021-07-012021-09-300001839341core:ConvertibleDebtPaidInKindInterestMembercore:ConvertibleNotesMatureInApril2025Memberus-gaap:InterestExpenseMemberus-gaap:ConvertibleDebtMember2021-01-012021-09-300001839341core:ConvertibleNotesMatureInApril2025Membercore:ConvertibleDebtInstrumentSpecificCreditRiskMemberus-gaap:OtherComprehensiveIncomeMemberus-gaap:ConvertibleDebtMember2021-07-012021-09-300001839341core:ConvertibleNotesMatureInApril2025Membercore:ConvertibleDebtInstrumentSpecificCreditRiskMemberus-gaap:OtherComprehensiveIncomeMemberus-gaap:ConvertibleDebtMember2021-01-012021-09-300001839341core:ConvertibleNotesMatureInApril2025Memberus-gaap:ConvertibleDebtMembercore:ConvertibleDebtOtherFairValueAdjustmentMemberus-gaap:OtherNonoperatingIncomeExpenseMember2021-07-012021-09-300001839341core:ConvertibleNotesMatureInApril2025Memberus-gaap:ConvertibleDebtMembercore:ConvertibleDebtOtherFairValueAdjustmentMemberus-gaap:OtherNonoperatingIncomeExpenseMember2021-01-012021-09-300001839341core:ConvertibleNotesMatureInApril2025Memberus-gaap:ConvertibleDebtMember2021-07-012021-09-300001839341core:ConvertibleNotesMatureInApril2025Memberus-gaap:ConvertibleDebtMember2021-01-012021-09-300001839341core:ConvertibleNotesMatureInApril2025Memberus-gaap:InterestExpenseMemberus-gaap:ConvertibleDebtMember2021-07-012021-09-300001839341core:ConvertibleNotesMatureInApril2025Memberus-gaap:InterestExpenseMemberus-gaap:ConvertibleDebtMember2021-01-012021-09-300001839341core:ConvertibleNotesMatureInApril2025Member2022-01-190001839341core:NotesPayableMembercore:ConvertibleNotesMatureInApril2025Member2022-09-300001839341srt:MinimumMember2022-01-012022-09-300001839341srt:MaximumMember2022-01-012022-09-300001839341us-gaap:CarryingReportedAmountFairValueDisclosureMembercore:PublicWarrantsMember2022-09-300001839341us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel1Membercore:PublicWarrantsMember2022-09-300001839341us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel2Membercore:PublicWarrantsMember2022-09-300001839341us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel3Membercore:PublicWarrantsMember2022-09-300001839341us-gaap:EstimateOfFairValueFairValueDisclosureMembercore:PublicWarrantsMember2022-09-300001839341us-gaap:CarryingReportedAmountFairValueDisclosureMembercore:PrivatePlacementWarrantsMember2022-09-300001839341us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel1Membercore:PrivatePlacementWarrantsMember2022-09-300001839341us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel2Membercore:PrivatePlacementWarrantsMember2022-09-300001839341us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel3Membercore:PrivatePlacementWarrantsMember2022-09-300001839341us-gaap:EstimateOfFairValueFairValueDisclosureMembercore:PrivatePlacementWarrantsMember2022-09-300001839341us-gaap:CarryingReportedAmountFairValueDisclosureMember2022-09-300001839341us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel1Member2022-09-300001839341us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel2Member2022-09-300001839341us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel3Member2022-09-300001839341us-gaap:EstimateOfFairValueFairValueDisclosureMember2022-09-300001839341core:ConvertibleNotesIssuedOnApril192021Memberus-gaap:CarryingReportedAmountFairValueDisclosureMember2022-09-300001839341us-gaap:EstimateOfFairValueFairValueDisclosureMembercore:ConvertibleNotesIssuedOnApril192021Memberus-gaap:FairValueInputsLevel1Member2022-09-300001839341us-gaap:EstimateOfFairValueFairValueDisclosureMembercore:ConvertibleNotesIssuedOnApril192021Memberus-gaap:FairValueInputsLevel2Member2022-09-300001839341us-gaap:EstimateOfFairValueFairValueDisclosureMembercore:ConvertibleNotesIssuedOnApril192021Memberus-gaap:FairValueInputsLevel3Member2022-09-300001839341us-gaap:EstimateOfFairValueFairValueDisclosureMembercore:ConvertibleNotesIssuedOnApril192021Member2022-09-300001839341us-gaap:CarryingReportedAmountFairValueDisclosureMembercore:ConvertibleNotesIssuedOnApril212021Member2022-09-300001839341us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel1Membercore:ConvertibleNotesIssuedOnApril212021Member2022-09-300001839341us-gaap:EstimateOfFairValueFairValueDisclosureMembercore:ConvertibleNotesIssuedOnApril212021Memberus-gaap:FairValueInputsLevel2Member2022-09-300001839341us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel3Membercore:ConvertibleNotesIssuedOnApril212021Member2022-09-300001839341us-gaap:EstimateOfFairValueFairValueDisclosureMembercore:ConvertibleNotesIssuedOnApril212021Member2022-09-300001839341core:ConvertibleNotesIssuedOnApril232021Memberus-gaap:CarryingReportedAmountFairValueDisclosureMember2022-09-300001839341us-gaap:EstimateOfFairValueFairValueDisclosureMembercore:ConvertibleNotesIssuedOnApril232021Memberus-gaap:FairValueInputsLevel1Member2022-09-300001839341us-gaap:EstimateOfFairValueFairValueDisclosureMembercore:ConvertibleNotesIssuedOnApril232021Memberus-gaap:FairValueInputsLevel2Member2022-09-300001839341us-gaap:EstimateOfFairValueFairValueDisclosureMembercore:ConvertibleNotesIssuedOnApril232021Memberus-gaap:FairValueInputsLevel3Member2022-09-300001839341us-gaap:EstimateOfFairValueFairValueDisclosureMembercore:ConvertibleNotesIssuedOnApril232021Member2022-09-300001839341core:ConvertibleNotesIssuedOnApril262021Memberus-gaap:CarryingReportedAmountFairValueDisclosureMember2022-09-300001839341us-gaap:EstimateOfFairValueFairValueDisclosureMembercore:ConvertibleNotesIssuedOnApril262021Memberus-gaap:FairValueInputsLevel1Member2022-09-300001839341us-gaap:EstimateOfFairValueFairValueDisclosureMembercore:ConvertibleNotesIssuedOnApril262021Memberus-gaap:FairValueInputsLevel2Member2022-09-300001839341us-gaap:EstimateOfFairValueFairValueDisclosureMembercore:ConvertibleNotesIssuedOnApril262021Memberus-gaap:FairValueInputsLevel3Member2022-09-300001839341us-gaap:EstimateOfFairValueFairValueDisclosureMembercore:ConvertibleNotesIssuedOnApril262021Member2022-09-300001839341core:ConvertibleNotesIssuedOnAugust202021Memberus-gaap:CarryingReportedAmountFairValueDisclosureMember2022-09-300001839341us-gaap:EstimateOfFairValueFairValueDisclosureMembercore:ConvertibleNotesIssuedOnAugust202021Memberus-gaap:FairValueInputsLevel1Member2022-09-300001839341us-gaap:EstimateOfFairValueFairValueDisclosureMembercore:ConvertibleNotesIssuedOnAugust202021Memberus-gaap:FairValueInputsLevel2Member2022-09-300001839341us-gaap:EstimateOfFairValueFairValueDisclosureMembercore:ConvertibleNotesIssuedOnAugust202021Memberus-gaap:FairValueInputsLevel3Member2022-09-300001839341us-gaap:EstimateOfFairValueFairValueDisclosureMembercore:ConvertibleNotesIssuedOnAugust202021Member2022-09-300001839341us-gaap:CarryingReportedAmountFairValueDisclosureMembercore:ConvertibleNotesIssuedOnSeptember102021Member2022-09-300001839341us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel1Membercore:ConvertibleNotesIssuedOnSeptember102021Member2022-09-300001839341us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel2Membercore:ConvertibleNotesIssuedOnSeptember102021Member2022-09-300001839341us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel3Membercore:ConvertibleNotesIssuedOnSeptember102021Member2022-09-300001839341us-gaap:EstimateOfFairValueFairValueDisclosureMembercore:ConvertibleNotesIssuedOnSeptember102021Member2022-09-300001839341core:ConvertibleNotesIssuedOnSeptember232021Memberus-gaap:CarryingReportedAmountFairValueDisclosureMember2022-09-300001839341us-gaap:EstimateOfFairValueFairValueDisclosureMembercore:ConvertibleNotesIssuedOnSeptember232021Memberus-gaap:FairValueInputsLevel1Member2022-09-300001839341us-gaap:EstimateOfFairValueFairValueDisclosureMembercore:ConvertibleNotesIssuedOnSeptember232021Memberus-gaap:FairValueInputsLevel2Member2022-09-300001839341us-gaap:EstimateOfFairValueFairValueDisclosureMembercore:ConvertibleNotesIssuedOnSeptember232021Memberus-gaap:FairValueInputsLevel3Member2022-09-300001839341us-gaap:EstimateOfFairValueFairValueDisclosureMembercore:ConvertibleNotesIssuedOnSeptember232021Member2022-09-300001839341core:ConvertibleNotesIssuedOnSeptember242021Memberus-gaap:CarryingReportedAmountFairValueDisclosureMember2022-09-300001839341us-gaap:EstimateOfFairValueFairValueDisclosureMembercore:ConvertibleNotesIssuedOnSeptember242021Memberus-gaap:FairValueInputsLevel1Member2022-09-300001839341us-gaap:EstimateOfFairValueFairValueDisclosureMembercore:ConvertibleNotesIssuedOnSeptember242021Memberus-gaap:FairValueInputsLevel2Member2022-09-300001839341us-gaap:EstimateOfFairValueFairValueDisclosureMembercore:ConvertibleNotesIssuedOnSeptember242021Memberus-gaap:FairValueInputsLevel3Member2022-09-300001839341us-gaap:EstimateOfFairValueFairValueDisclosureMembercore:ConvertibleNotesIssuedOnSeptember242021Member2022-09-300001839341core:ConvertibleNotesIssuedOnSeptember272021Memberus-gaap:CarryingReportedAmountFairValueDisclosureMember2022-09-300001839341us-gaap:EstimateOfFairValueFairValueDisclosureMembercore:ConvertibleNotesIssuedOnSeptember272021Memberus-gaap:FairValueInputsLevel1Member2022-09-300001839341us-gaap:EstimateOfFairValueFairValueDisclosureMembercore:ConvertibleNotesIssuedOnSeptember272021Memberus-gaap:FairValueInputsLevel2Member2022-09-300001839341us-gaap:EstimateOfFairValueFairValueDisclosureMembercore:ConvertibleNotesIssuedOnSeptember272021Memberus-gaap:FairValueInputsLevel3Member2022-09-300001839341us-gaap:EstimateOfFairValueFairValueDisclosureMembercore:ConvertibleNotesIssuedOnSeptember272021Member2022-09-300001839341us-gaap:CarryingReportedAmountFairValueDisclosureMembercore:ConvertibleNotesIssuedOnOctober12021Member2022-09-300001839341us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel1Membercore:ConvertibleNotesIssuedOnOctober12021Member2022-09-300001839341us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel2Membercore:ConvertibleNotesIssuedOnOctober12021Member2022-09-300001839341us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel3Membercore:ConvertibleNotesIssuedOnOctober12021Member2022-09-300001839341us-gaap:EstimateOfFairValueFairValueDisclosureMembercore:ConvertibleNotesIssuedOnOctober12021Member2022-09-300001839341core:ConvertibleNotesIssuedOnNovember102021Memberus-gaap:CarryingReportedAmountFairValueDisclosureMember2022-09-300001839341us-gaap:EstimateOfFairValueFairValueDisclosureMembercore:ConvertibleNotesIssuedOnNovember102021Memberus-gaap:FairValueInputsLevel1Member2022-09-300001839341us-gaap:EstimateOfFairValueFairValueDisclosureMembercore:ConvertibleNotesIssuedOnNovember102021Memberus-gaap:FairValueInputsLevel2Member2022-09-300001839341us-gaap:EstimateOfFairValueFairValueDisclosureMembercore:ConvertibleNotesIssuedOnNovember102021Memberus-gaap:FairValueInputsLevel3Member2022-09-300001839341us-gaap:EstimateOfFairValueFairValueDisclosureMembercore:ConvertibleNotesIssuedOnNovember102021Member2022-09-300001839341us-gaap:CarryingReportedAmountFairValueDisclosureMembercore:ConvertibleNotesMatureInApril2025Member2022-09-300001839341us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel1Membercore:ConvertibleNotesMatureInApril2025Member2022-09-300001839341us-gaap:EstimateOfFairValueFairValueDisclosureMembercore:ConvertibleNotesMatureInApril2025Memberus-gaap:FairValueInputsLevel2Member2022-09-300001839341us-gaap:EstimateOfFairValueFairValueDisclosureMembercore:ConvertibleNotesMatureInApril2025Memberus-gaap:FairValueInputsLevel3Member2022-09-300001839341us-gaap:EstimateOfFairValueFairValueDisclosureMembercore:ConvertibleNotesMatureInApril2025Member2022-09-300001839341core:ConvertibleNotesIssuedOnApril192021Memberus-gaap:CarryingReportedAmountFairValueDisclosureMember2021-12-310001839341us-gaap:EstimateOfFairValueFairValueDisclosureMembercore:ConvertibleNotesIssuedOnApril192021Memberus-gaap:FairValueInputsLevel1Member2021-12-310001839341us-gaap:EstimateOfFairValueFairValueDisclosureMembercore:ConvertibleNotesIssuedOnApril192021Memberus-gaap:FairValueInputsLevel2Member2021-12-310001839341us-gaap:EstimateOfFairValueFairValueDisclosureMembercore:ConvertibleNotesIssuedOnApril192021Memberus-gaap:FairValueInputsLevel3Member2021-12-310001839341us-gaap:EstimateOfFairValueFairValueDisclosureMembercore:ConvertibleNotesIssuedOnApril192021Member2021-12-310001839341us-gaap:CarryingReportedAmountFairValueDisclosureMembercore:ConvertibleNotesIssuedOnApril212021Member2021-12-310001839341us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel1Membercore:ConvertibleNotesIssuedOnApril212021Member2021-12-310001839341us-gaap:EstimateOfFairValueFairValueDisclosureMembercore:ConvertibleNotesIssuedOnApril212021Memberus-gaap:FairValueInputsLevel2Member2021-12-310001839341us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel3Membercore:ConvertibleNotesIssuedOnApril212021Member2021-12-310001839341us-gaap:EstimateOfFairValueFairValueDisclosureMembercore:ConvertibleNotesIssuedOnApril212021Member2021-12-310001839341core:ConvertibleNotesIssuedOnApril232021Memberus-gaap:CarryingReportedAmountFairValueDisclosureMember2021-12-310001839341us-gaap:EstimateOfFairValueFairValueDisclosureMembercore:ConvertibleNotesIssuedOnApril232021Memberus-gaap:FairValueInputsLevel1Member2021-12-310001839341us-gaap:EstimateOfFairValueFairValueDisclosureMembercore:ConvertibleNotesIssuedOnApril232021Memberus-gaap:FairValueInputsLevel2Member2021-12-310001839341us-gaap:EstimateOfFairValueFairValueDisclosureMembercore:ConvertibleNotesIssuedOnApril232021Memberus-gaap:FairValueInputsLevel3Member2021-12-310001839341us-gaap:EstimateOfFairValueFairValueDisclosureMembercore:ConvertibleNotesIssuedOnApril232021Member2021-12-310001839341core:ConvertibleNotesIssuedOnApril262021Memberus-gaap:CarryingReportedAmountFairValueDisclosureMember2021-12-310001839341us-gaap:EstimateOfFairValueFairValueDisclosureMembercore:ConvertibleNotesIssuedOnApril262021Memberus-gaap:FairValueInputsLevel1Member2021-12-310001839341us-gaap:EstimateOfFairValueFairValueDisclosureMembercore:ConvertibleNotesIssuedOnApril262021Memberus-gaap:FairValueInputsLevel2Member2021-12-310001839341us-gaap:EstimateOfFairValueFairValueDisclosureMembercore:ConvertibleNotesIssuedOnApril262021Memberus-gaap:FairValueInputsLevel3Member2021-12-310001839341us-gaap:EstimateOfFairValueFairValueDisclosureMembercore:ConvertibleNotesIssuedOnApril262021Member2021-12-310001839341core:ConvertibleNotesIssuedOnAugust202021Memberus-gaap:CarryingReportedAmountFairValueDisclosureMember2021-12-310001839341us-gaap:EstimateOfFairValueFairValueDisclosureMembercore:ConvertibleNotesIssuedOnAugust202021Memberus-gaap:FairValueInputsLevel1Member2021-12-310001839341us-gaap:EstimateOfFairValueFairValueDisclosureMembercore:ConvertibleNotesIssuedOnAugust202021Memberus-gaap:FairValueInputsLevel2Member2021-12-310001839341us-gaap:EstimateOfFairValueFairValueDisclosureMembercore:ConvertibleNotesIssuedOnAugust202021Memberus-gaap:FairValueInputsLevel3Member2021-12-310001839341us-gaap:EstimateOfFairValueFairValueDisclosureMembercore:ConvertibleNotesIssuedOnAugust202021Member2021-12-310001839341us-gaap:CarryingReportedAmountFairValueDisclosureMembercore:ConvertibleNotesIssuedOnSeptember102021Member2021-12-310001839341us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel1Membercore:ConvertibleNotesIssuedOnSeptember102021Member2021-12-310001839341us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel2Membercore:ConvertibleNotesIssuedOnSeptember102021Member2021-12-310001839341us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel3Membercore:ConvertibleNotesIssuedOnSeptember102021Member2021-12-310001839341us-gaap:EstimateOfFairValueFairValueDisclosureMembercore:ConvertibleNotesIssuedOnSeptember102021Member2021-12-310001839341core:ConvertibleNotesIssuedOnSeptember232021Memberus-gaap:CarryingReportedAmountFairValueDisclosureMember2021-12-310001839341us-gaap:EstimateOfFairValueFairValueDisclosureMembercore:ConvertibleNotesIssuedOnSeptember232021Memberus-gaap:FairValueInputsLevel1Member2021-12-310001839341us-gaap:EstimateOfFairValueFairValueDisclosureMembercore:ConvertibleNotesIssuedOnSeptember232021Memberus-gaap:FairValueInputsLevel2Member2021-12-310001839341us-gaap:EstimateOfFairValueFairValueDisclosureMembercore:ConvertibleNotesIssuedOnSeptember232021Memberus-gaap:FairValueInputsLevel3Member2021-12-310001839341us-gaap:EstimateOfFairValueFairValueDisclosureMembercore:ConvertibleNotesIssuedOnSeptember232021Member2021-12-310001839341core:ConvertibleNotesIssuedOnSeptember242021Memberus-gaap:CarryingReportedAmountFairValueDisclosureMember2021-12-310001839341us-gaap:EstimateOfFairValueFairValueDisclosureMembercore:ConvertibleNotesIssuedOnSeptember242021Memberus-gaap:FairValueInputsLevel1Member2021-12-310001839341us-gaap:EstimateOfFairValueFairValueDisclosureMembercore:ConvertibleNotesIssuedOnSeptember242021Memberus-gaap:FairValueInputsLevel2Member2021-12-310001839341us-gaap:EstimateOfFairValueFairValueDisclosureMembercore:ConvertibleNotesIssuedOnSeptember242021Memberus-gaap:FairValueInputsLevel3Member2021-12-310001839341us-gaap:EstimateOfFairValueFairValueDisclosureMembercore:ConvertibleNotesIssuedOnSeptember242021Member2021-12-310001839341core:ConvertibleNotesIssuedOnSeptember272021Memberus-gaap:CarryingReportedAmountFairValueDisclosureMember2021-12-310001839341us-gaap:EstimateOfFairValueFairValueDisclosureMembercore:ConvertibleNotesIssuedOnSeptember272021Memberus-gaap:FairValueInputsLevel1Member2021-12-310001839341us-gaap:EstimateOfFairValueFairValueDisclosureMembercore:ConvertibleNotesIssuedOnSeptember272021Memberus-gaap:FairValueInputsLevel2Member2021-12-310001839341us-gaap:EstimateOfFairValueFairValueDisclosureMembercore:ConvertibleNotesIssuedOnSeptember272021Memberus-gaap:FairValueInputsLevel3Member2021-12-310001839341us-gaap:EstimateOfFairValueFairValueDisclosureMembercore:ConvertibleNotesIssuedOnSeptember272021Member2021-12-310001839341us-gaap:CarryingReportedAmountFairValueDisclosureMembercore:ConvertibleNotesIssuedOnOctober12021Member2021-12-310001839341us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel1Membercore:ConvertibleNotesIssuedOnOctober12021Member2021-12-310001839341us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel2Membercore:ConvertibleNotesIssuedOnOctober12021Member2021-12-310001839341us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel3Membercore:ConvertibleNotesIssuedOnOctober12021Member2021-12-310001839341us-gaap:EstimateOfFairValueFairValueDisclosureMembercore:ConvertibleNotesIssuedOnOctober12021Member2021-12-310001839341core:ConvertibleNotesIssuedOnNovember102021Memberus-gaap:CarryingReportedAmountFairValueDisclosureMember2021-12-310001839341us-gaap:EstimateOfFairValueFairValueDisclosureMembercore:ConvertibleNotesIssuedOnNovember102021Memberus-gaap:FairValueInputsLevel1Member2021-12-310001839341us-gaap:EstimateOfFairValueFairValueDisclosureMembercore:ConvertibleNotesIssuedOnNovember102021Memberus-gaap:FairValueInputsLevel2Member2021-12-310001839341us-gaap:EstimateOfFairValueFairValueDisclosureMembercore:ConvertibleNotesIssuedOnNovember102021Memberus-gaap:FairValueInputsLevel3Member2021-12-310001839341us-gaap:EstimateOfFairValueFairValueDisclosureMembercore:ConvertibleNotesIssuedOnNovember102021Member2021-12-310001839341us-gaap:CarryingReportedAmountFairValueDisclosureMembercore:ConvertibleNotesMatureInApril2025Member2021-12-310001839341us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel1Membercore:ConvertibleNotesMatureInApril2025Member2021-12-310001839341us-gaap:EstimateOfFairValueFairValueDisclosureMembercore:ConvertibleNotesMatureInApril2025Memberus-gaap:FairValueInputsLevel2Member2021-12-310001839341us-gaap:EstimateOfFairValueFairValueDisclosureMembercore:ConvertibleNotesMatureInApril2025Memberus-gaap:FairValueInputsLevel3Member2021-12-310001839341us-gaap:EstimateOfFairValueFairValueDisclosureMembercore:ConvertibleNotesMatureInApril2025Member2021-12-310001839341us-gaap:ConvertibleDebtMemberus-gaap:FairValueInputsLevel3Member2021-12-310001839341us-gaap:ConvertibleDebtMemberus-gaap:FairValueInputsLevel3Member2022-01-012022-03-310001839341us-gaap:ConvertibleDebtMemberus-gaap:FairValueInputsLevel3Member2022-03-310001839341us-gaap:ConvertibleDebtMemberus-gaap:FairValueInputsLevel3Member2022-04-012022-06-300001839341us-gaap:ConvertibleDebtMemberus-gaap:FairValueInputsLevel3Member2022-06-300001839341us-gaap:ConvertibleDebtMemberus-gaap:FairValueInputsLevel3Member2022-07-012022-09-300001839341us-gaap:ConvertibleDebtMemberus-gaap:FairValueInputsLevel3Member2022-09-300001839341core:MeasurementInputFairValueMemberus-gaap:ConvertibleDebtMember2022-09-300001839341us-gaap:MeasurementInputExpectedTermMemberus-gaap:ConvertibleDebtMembersrt:MinimumMember2022-09-300001839341srt:MaximumMemberus-gaap:MeasurementInputExpectedTermMemberus-gaap:ConvertibleDebtMember2022-09-300001839341us-gaap:MeasurementInputExpectedTermMembersrt:WeightedAverageMemberus-gaap:ConvertibleDebtMember2022-09-300001839341us-gaap:MeasurementInputPriceVolatilityMemberus-gaap:ConvertibleDebtMembersrt:MinimumMember2022-09-300001839341srt:MaximumMemberus-gaap:MeasurementInputPriceVolatilityMemberus-gaap:ConvertibleDebtMember2022-09-300001839341srt:WeightedAverageMemberus-gaap:MeasurementInputPriceVolatilityMemberus-gaap:ConvertibleDebtMember2022-09-300001839341core:BitcoinMember2022-09-300001839341core:BitcoinMember2021-12-310001839341core:EthereumMember2022-09-300001839341core:EthereumMember2021-12-310001839341core:PolygonMember2022-09-300001839341core:PolygonMember2021-12-310001839341core:SiacoinMember2022-09-300001839341core:SiacoinMember2021-12-310001839341core:DaiMember2022-09-300001839341core:DaiMember2021-12-310001839341core:DigitalAssetsOtherMember2022-09-300001839341core:DigitalAssetsOtherMember2021-12-310001839341us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:ValuationTechniqueDiscountedCashFlowMemberus-gaap:FairValueInputsLevel3Member2022-09-300001839341us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:ValuationTechniqueDiscountedCashFlowMemberus-gaap:FairValueInputsLevel3Member2021-12-310001839341us-gaap:ValuationTechniqueDiscountedCashFlowMemberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:FairValueInputsLevel3Member2022-09-300001839341us-gaap:ValuationTechniqueDiscountedCashFlowMemberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:FairValueInputsLevel3Member2021-12-310001839341core:MinnkotaPowerCooperativeMember2021-09-012021-09-30core:megawatt0001839341core:MinnkotaPowerCooperativeMember2021-09-300001839341core:MinnkotaPowerCooperativeMembersrt:MinimumMember2021-09-300001839341srt:MaximumMembercore:MinnkotaPowerCooperativeMember2021-09-30core:option00018393412021-12-012021-12-310001839341core:LibertyCommercialFinanceLLCMember2021-12-310001839341core:LibertyCommercialFinanceLLCMember2021-12-012021-12-310001839341core:MassMutualAssetFinanceLLCMember2021-12-310001839341core:MassMutualAssetFinanceLLCMember2021-12-012021-12-310001839341core:MassMutualAssetFinanceLLCMember2022-08-012022-08-310001839341core:MassMutualAssetFinanceLLCMember2022-08-310001839341core:CelsiusMiningLLCMember2022-09-300001839341core:BreachOfContractForHostingServicesMemberus-gaap:SubsequentEventMember2022-11-012022-11-210001839341us-gaap:RedeemableConvertiblePreferredStockMember2022-01-012022-09-30core:vote0001839341us-gaap:CommonStockMember2022-01-192022-01-190001839341core:BRileyPrincipalCapitalIILLCMembercore:CommonStockEquityLineOfCreditMember2022-07-310001839341core:BRileyPrincipalCapitalIILLCMembercore:CommonStockEquityLineOfCreditMember2022-07-012022-07-310001839341core:CommonStockCommitmentSharesMembercore:BRileyPrincipalCapitalIILLCMembercore:CommonStockEquityLineOfCreditMember2022-07-012022-07-310001839341core:BRileyPrincipalCapitalIILLCMembercore:CommonStockEquityLineOfCreditMember2022-07-012022-09-300001839341core:BRileyPrincipalCapitalIILLCMembercore:CommonStockEquityLineOfCreditMember2022-01-012022-09-300001839341core:BRileyPrincipalCapitalIILLCMembercore:CommonStockEquityLineOfCreditMember2022-09-300001839341us-gaap:CommonStockMember2022-09-300001839341us-gaap:BridgeLoanMembercore:AmendedBRileyBridgeNotesMember2022-09-300001839341core:ExecutiveNotesWarrantsMember2020-03-310001839341core:ExecutiveNotesWarrantsMember2022-02-012022-02-280001839341core:ExecutiveNotesWarrantsMember2022-03-012022-03-310001839341core:ServiceProvidersWarrantsMember2020-03-310001839341core:ServiceProvidersWarrantsMember2022-02-012022-02-2800018393412022-03-012022-03-3100018393412021-07-012021-07-3100018393412021-07-310001839341core:A2018OmnibusIncentivePlanMembersrt:MinimumMember2022-01-012022-09-300001839341srt:MaximumMemberus-gaap:EmployeeStockOptionMembercore:A2018OmnibusIncentivePlanMember2022-01-012022-09-300001839341core:A2021EquityIncentivePlanMembersrt:MinimumMember2022-01-012022-09-300001839341us-gaap:EmployeeStockOptionMembercore:A2021EquityIncentivePlanMember2022-01-012022-09-300001839341core:A2021EquityIncentivePlanMember2022-09-300001839341core:RestrictedStockUnitsAndRestrictedAwardsMember2022-09-300001839341core:AmendmentTo2018OmnibusIncentivePlanMemberus-gaap:RestrictedStockUnitsRSUMember2022-06-080001839341us-gaap:RestrictedStockUnitsRSUMember2022-07-012022-09-300001839341us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-09-300001839341core:CostOfRevenueMember2022-07-012022-09-300001839341core:CostOfRevenueMember2021-07-012021-09-300001839341core:CostOfRevenueMember2022-01-012022-09-300001839341core:CostOfRevenueMember2021-01-012021-09-300001839341us-gaap:ResearchAndDevelopmentExpenseMember2022-07-012022-09-300001839341us-gaap:ResearchAndDevelopmentExpenseMember2021-07-012021-09-300001839341us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-09-300001839341us-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-09-300001839341us-gaap:SellingAndMarketingExpenseMember2022-07-012022-09-300001839341us-gaap:SellingAndMarketingExpenseMember2021-07-012021-09-300001839341us-gaap:SellingAndMarketingExpenseMember2022-01-012022-09-300001839341us-gaap:SellingAndMarketingExpenseMember2021-01-012021-09-300001839341us-gaap:GeneralAndAdministrativeExpenseMember2022-07-012022-09-300001839341us-gaap:GeneralAndAdministrativeExpenseMember2021-07-012021-09-300001839341us-gaap:GeneralAndAdministrativeExpenseMember2022-01-012022-09-300001839341us-gaap:GeneralAndAdministrativeExpenseMember2021-01-012021-09-300001839341us-gaap:EmployeeStockOptionMember2022-01-012022-09-300001839341core:RestrictedStockUnitsAndRestrictedAwardsMember2022-01-012022-09-300001839341us-gaap:EmployeeStockOptionMember2022-07-012022-09-300001839341us-gaap:EmployeeStockOptionMember2021-07-012021-09-300001839341us-gaap:EmployeeStockOptionMember2022-01-012022-09-300001839341us-gaap:EmployeeStockOptionMember2021-01-012021-09-300001839341us-gaap:PreferredStockMember2022-07-012022-09-300001839341us-gaap:PreferredStockMember2021-07-012021-09-300001839341us-gaap:PreferredStockMember2022-01-012022-09-300001839341us-gaap:PreferredStockMember2021-01-012021-09-300001839341us-gaap:WarrantMember2022-07-012022-09-300001839341us-gaap:WarrantMember2021-07-012021-09-300001839341us-gaap:WarrantMember2022-01-012022-09-300001839341us-gaap:WarrantMember2021-01-012021-09-300001839341us-gaap:RestrictedStockMember2022-07-012022-09-300001839341us-gaap:RestrictedStockMember2021-07-012021-09-300001839341us-gaap:RestrictedStockMember2022-01-012022-09-300001839341us-gaap:RestrictedStockMember2021-01-012021-09-300001839341us-gaap:ConvertibleDebtMember2022-07-012022-09-300001839341us-gaap:ConvertibleDebtMember2021-07-012021-09-300001839341us-gaap:ConvertibleDebtMember2022-01-012022-09-300001839341us-gaap:ConvertibleDebtMember2021-01-012021-09-300001839341core:SPACVestingSharesMember2022-07-012022-09-300001839341core:SPACVestingSharesMember2021-07-012021-09-300001839341core:SPACVestingSharesMember2022-01-012022-09-300001839341core:SPACVestingSharesMember2021-01-012021-09-30core:segment0001839341us-gaap:OperatingSegmentsMembercore:HostingServiceMembercore:EquipmentSalesAndHostingSegmentMember2022-07-012022-09-300001839341us-gaap:OperatingSegmentsMembercore:HostingServiceMembercore:EquipmentSalesAndHostingSegmentMember2021-07-012021-09-300001839341us-gaap:OperatingSegmentsMembercore:HostingServiceMembercore:EquipmentSalesAndHostingSegmentMember2022-01-012022-09-300001839341us-gaap:OperatingSegmentsMembercore:HostingServiceMembercore:EquipmentSalesAndHostingSegmentMember2021-01-012021-09-300001839341us-gaap:OperatingSegmentsMembercore:EquipmentSalesAndHostingSegmentMembercore:EquipmentSalesMember2022-07-012022-09-300001839341us-gaap:OperatingSegmentsMembercore:EquipmentSalesAndHostingSegmentMembercore:EquipmentSalesMember2021-07-012021-09-300001839341us-gaap:OperatingSegmentsMembercore:EquipmentSalesAndHostingSegmentMembercore:EquipmentSalesMember2022-01-012022-09-300001839341us-gaap:OperatingSegmentsMembercore:EquipmentSalesAndHostingSegmentMembercore:EquipmentSalesMember2021-01-012021-09-300001839341us-gaap:OperatingSegmentsMembercore:EquipmentSalesAndHostingSegmentMember2022-07-012022-09-300001839341us-gaap:OperatingSegmentsMembercore:EquipmentSalesAndHostingSegmentMember2021-07-012021-09-300001839341us-gaap:OperatingSegmentsMembercore:EquipmentSalesAndHostingSegmentMember2022-01-012022-09-300001839341us-gaap:OperatingSegmentsMembercore:EquipmentSalesAndHostingSegmentMember2021-01-012021-09-300001839341core:MiningSegmentMemberus-gaap:OperatingSegmentsMembercore:DigitalAssetMiningServiceMember2022-07-012022-09-300001839341core:MiningSegmentMemberus-gaap:OperatingSegmentsMembercore:DigitalAssetMiningServiceMember2021-07-012021-09-300001839341core:MiningSegmentMemberus-gaap:OperatingSegmentsMembercore:DigitalAssetMiningServiceMember2022-01-012022-09-300001839341core:MiningSegmentMemberus-gaap:OperatingSegmentsMembercore:DigitalAssetMiningServiceMember2021-01-012021-09-300001839341core:MiningSegmentMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300001839341core:MiningSegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300001839341core:MiningSegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300001839341core:MiningSegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300001839341country:USus-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2022-07-012022-09-300001839341country:USus-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2022-01-012022-09-300001839341core:MiningSegmentMembercore:IndefiniteLivedIntangibleAssetConcentrationRiskMembercore:BitcoinMemberus-gaap:SalesRevenueNetMember2022-07-012022-09-300001839341core:MiningSegmentMembercore:IndefiniteLivedIntangibleAssetConcentrationRiskMembercore:BitcoinMemberus-gaap:SalesRevenueNetMember2022-01-012022-09-300001839341us-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMembercore:CustomerAMember2022-07-012022-09-300001839341us-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMembercore:CustomerAMember2021-07-012021-09-300001839341us-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerSegmentBenchmarkMembercore:CustomerAMember2022-07-012022-09-300001839341us-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerSegmentBenchmarkMembercore:CustomerAMember2021-07-012021-09-300001839341us-gaap:CustomerConcentrationRiskMembercore:CelsiusMiningLLCMemberus-gaap:RevenueFromContractWithCustomerMember2021-07-012021-09-300001839341us-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerSegmentBenchmarkMembercore:CelsiusMiningLLCMember2022-07-012022-09-300001839341us-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerSegmentBenchmarkMembercore:CelsiusMiningLLCMember2021-07-012021-09-300001839341us-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerSegmentBenchmarkMembercore:CustomerBMember2021-07-012021-09-300001839341us-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMembercore:CustomerAMember2022-01-012022-09-300001839341us-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerSegmentBenchmarkMembercore:CustomerAMember2022-01-012022-09-300001839341us-gaap:CustomerConcentrationRiskMembercore:CelsiusMiningLLCMemberus-gaap:RevenueFromContractWithCustomerMember2021-01-012021-09-300001839341us-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerSegmentBenchmarkMembercore:CelsiusMiningLLCMember2022-01-012022-09-300001839341us-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerSegmentBenchmarkMembercore:CelsiusMiningLLCMember2021-01-012021-09-300001839341us-gaap:CustomerConcentrationRiskMembercore:CustomerBMemberus-gaap:RevenueFromContractWithCustomerMember2021-01-012021-09-300001839341us-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerSegmentBenchmarkMembercore:CustomerBMember2021-01-012021-09-300001839341core:BlockcapIncMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2021-01-012021-09-300001839341core:BlockcapIncMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerSegmentBenchmarkMember2021-01-012021-09-300001839341core:DirectorsAndExecutivesMembercore:HostingServiceMembersrt:AffiliatedEntityMember2022-07-012022-09-300001839341core:DirectorsAndExecutivesMembercore:HostingServiceMembersrt:AffiliatedEntityMember2022-01-012022-09-300001839341core:DirectorsAndExecutivesMembercore:HostingServiceMembersrt:AffiliatedEntityMember2021-07-012021-09-300001839341core:DirectorsAndExecutivesMembercore:HostingServiceMembersrt:AffiliatedEntityMember2021-01-012021-09-300001839341core:DirectorsAndExecutivesMembersrt:AffiliatedEntityMembercore:EquipmentSalesMember2022-07-012022-09-300001839341core:DirectorsAndExecutivesMembersrt:AffiliatedEntityMembercore:EquipmentSalesMember2022-01-012022-09-300001839341core:DirectorsAndExecutivesMembersrt:AffiliatedEntityMembercore:EquipmentSalesMember2021-07-012021-09-300001839341core:DirectorsAndExecutivesMembersrt:AffiliatedEntityMembercore:EquipmentSalesMember2021-01-012021-09-300001839341core:DirectorsAndExecutivesMembersrt:AffiliatedEntityMember2022-09-300001839341core:DirectorsAndExecutivesMembersrt:AffiliatedEntityMember2021-12-310001839341srt:AffiliatedEntityMembersrt:ChiefExecutiveOfficerMember2022-07-012022-09-300001839341srt:AffiliatedEntityMembersrt:ChiefExecutiveOfficerMember2022-01-012022-09-300001839341srt:AffiliatedEntityMembersrt:ChiefExecutiveOfficerMember2021-07-012021-09-300001839341srt:AffiliatedEntityMembersrt:ChiefExecutiveOfficerMember2021-01-012021-09-300001839341srt:AffiliatedEntityMembersrt:ChiefExecutiveOfficerMember2022-09-300001839341srt:AffiliatedEntityMembersrt:ChiefExecutiveOfficerMember2021-12-310001839341us-gaap:SubsequentEventMember2022-10-012022-11-21core:customer0001839341us-gaap:SubsequentEventMembersrt:AffiliatedEntityMember2022-10-012022-11-210001839341core:HostingServiceMembercore:CustomersTerminatedMember2022-07-012022-09-300001839341core:CustomersTerminatedMember2022-01-012022-09-300001839341core:HostingServiceMembercore:CustomersTerminatedMembersrt:AffiliatedEntityMember2022-07-012022-09-300001839341core:HostingServiceMembercore:CustomersTerminatedMembersrt:AffiliatedEntityMember2022-01-012022-09-300001839341us-gaap:SubsequentEventMembercore:BRileyPrincipalCapitalIILLCMembercore:CommonStockEquityLineOfCreditMember2022-10-012022-11-210001839341us-gaap:SubsequentEventMemberus-gaap:CommonStockMember2022-11-21
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
|
|
|
|
|
|
☒ |
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
|
|
For the quarterly period ended September 30, 2022
|
OR
|
|
|
|
|
|
☐ |
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
|
|
For the transition period from to |
Commission file number 001-40046
Core Scientific, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Delaware
|
|
86-1243837
|
|
|
(State or other jurisdiction of incorporation or
organization)
|
|
(I.R.S. Employer Identification No.)
|
|
210 Barton Springs Road
Suite 300
Austin, Texas
(Address of Principal Executive Offices)
78704
(Zip Code)
(512) 402-5233
Registrant's telephone number, including area code
Securities registered pursuant to Section 12(b) of the
Act:
|
|
|
|
|
|
|
|
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common stock, par value $0.0001 per share
|
CORZ |
The Nasdaq Global Select Market
|
Warrants, exercisable for shares of common stock
|
CORZW |
The Nasdaq Global Select Market
|
Indicate by check mark whether the registrant: (1) has filed all
reports required to be filed by Section 13 or 15(d) of the
Securities Exchange Act of 1934 during the preceding 12 months (or
for such shorter period that the registrant was required to file
such reports); and (2) has been subject to such filing requirements
for the past 90 days. Yes
☒
No
☐
Indicate by check mark whether the registrant has submitted
electronically and posted on its corporate web site, if any, every
Interactive Data File required to be submitted and posted pursuant
to Rule 405 of Regulation S-T (§232.405 of this chapter) during the
preceding 12 months (or for such shorter period that the registrant
was required to submit and post such files). Yes
☒
No
☐
Indicate by check mark whether the registrant is a large
accelerated filer, an accelerated filer, a non-accelerated filer,
or a smaller reporting company. See the definitions of “large
accelerated filer,” “accelerated filer” and “smaller reporting
company” in Rule 12b-2 of the Exchange Act. (Check
one):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Large accelerated filer
|
☐ |
|
Accelerated filer
|
☐ |
Non-accelerated filer
|
☒ |
|
Smaller reporting company
|
☒ |
|
|
|
Emerging growth company
|
☒ |
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange
Act.
☐
Indicate by check mark whether the registrant is a shell company
(as defined in Rule 12b-2 of the Act). Yes
☐
No
☒
|
|
|
|
|
|
|
|
|
Common Stock, par value $0.0001 per share |
|
Shares Outstanding as of November 14, 2022
|
|
|
374,527,988
|
TABLE OF CONTENTS
Part I - Financial Information
Item 1. Financial Statements
Core Scientific, Inc.
Consolidated Balance Sheets
(in thousands, except par value)
|
|
|
|
|
|
|
|
|
|
|
|
|
September 30,
2022 |
|
December 31,
2021 |
Assets |
(Unaudited) |
|
|
Current Assets: |
|
|
|
Cash and cash equivalents |
$ |
29,546 |
|
|
$ |
117,871 |
|
Restricted cash |
8,098 |
|
|
13,807 |
|
Accounts receivable, net of allowance of $5,943 and $—,
respectively
|
2,176 |
|
|
1,382 |
|
Accounts receivable from related parties |
895 |
|
|
300 |
|
Deposits for equipment |
97,678 |
|
|
358,791 |
|
Digital assets |
19,663 |
|
|
234,298 |
|
Prepaid expenses and other current assets |
55,515 |
|
|
30,111 |
|
Total Current Assets |
213,571 |
|
|
756,560 |
|
Property, plant and equipment, net |
1,156,369 |
|
|
597,304 |
|
|
|
|
|
Goodwill |
— |
|
|
1,055,760 |
|
Intangible assets, net |
1,400 |
|
|
8,195 |
|
Other noncurrent assets |
32,661 |
|
|
21,045 |
|
Total Assets |
$ |
1,404,001 |
|
|
$ |
2,438,864 |
|
Liabilities, Redeemable Preferred Stock and Stockholders’
Equity |
|
|
|
Current Liabilities: |
|
|
|
Accounts payable |
$ |
43,613 |
|
|
$ |
11,617 |
|
Accrued expenses and other |
102,213 |
|
|
67,862 |
|
Deferred revenue |
80,268 |
|
|
63,417 |
|
Deferred revenue from related parties |
6,981 |
|
|
72,945 |
|
Derivative warrant liabilities |
5,287 |
|
|
— |
|
|
|
|
|
Finance lease liabilities, current portion |
73,045 |
|
|
28,452 |
|
Notes payable, current portion (includes $682,831 and $— at fair
value)
|
977,600 |
|
|
75,996 |
|
Total Current Liabilities |
1,289,007 |
|
|
320,289 |
|
|
|
|
|
Finance lease liabilities, net of current portion |
— |
|
|
62,145 |
|
Notes payable, net of current portion (includes $— and $557,007 at
fair value)
|
— |
|
|
652,213 |
|
Other noncurrent liabilities |
41,967 |
|
|
18,531 |
|
Total Liabilities |
1,330,974 |
|
|
1,053,178 |
|
Contingently redeemable convertible preferred stock; $0.0001 par
value; 2,000,000 shares authorized; — and 10,826 shares issued and
outstanding at September 30, 2022 and December 31, 2021,
respectively; $— and $45,164 total liquidation preference at
September 30, 2022 and December 31, 2021,
respectively
|
— |
|
|
44,476 |
|
Commitments and contingencies (Note 10)
|
|
|
|
Stockholders’ Equity: |
|
|
|
Common stock; $0.0001 par value; 10,000,000 shares authorized at
both September 30, 2022 and December 31, 2021; 364,710
and 271,576 shares issued and outstanding at September 30,
2022 and December 31, 2021, respectively
|
36 |
|
|
27 |
|
Additional paid-in capital |
1,739,282 |
|
|
1,379,581 |
|
Accumulated deficit |
(1,738,903) |
|
|
(27,432) |
|
Accumulated other comprehensive income (loss) |
72,612 |
|
|
(10,966) |
|
Total Stockholders’ Equity |
73,027 |
|
|
1,341,210 |
|
Total Liabilities, Redeemable Preferred Stock and Stockholders’
Equity |
$ |
1,404,001 |
|
|
$ |
2,438,864 |
|
See accompanying notes to unaudited consolidated financial
statements.
Core Scientific, Inc.
Consolidated Statements of Operations
(in thousands, except per share amounts)
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended September 30, |
|
Nine Months Ended September 30, |
|
2022 |
|
2021 |
|
2022 |
|
2021 |
Revenue: |
|
|
|
|
|
|
|
Hosting revenue from customers |
$ |
35,731 |
|
|
$ |
17,585 |
|
|
$ |
94,407 |
|
|
$ |
37,836 |
|
Hosting revenue from related parties
|
9,185 |
|
|
2,903 |
|
|
22,659 |
|
|
13,906 |
|
Equipment sales to customers
|
7,468 |
|
|
23,879 |
|
|
11,391 |
|
|
84,378 |
|
Equipment sales to related parties
|
29,693 |
|
|
11,654 |
|
|
67,269 |
|
|
29,057 |
|
Digital asset mining revenue
|
80,495 |
|
|
57,118 |
|
|
323,337 |
|
|
77,511 |
|
Total revenue
|
162,572 |
|
|
113,139 |
|
|
519,063 |
|
|
242,688 |
|
Cost of revenue: |
|
|
|
|
|
|
|
Cost of hosting services |
44,975 |
|
|
19,577 |
|
|
119,850 |
|
|
48,956 |
|
Cost of equipment sales |
27,917 |
|
|
24,997 |
|
|
63,993 |
|
|
82,328 |
|
Cost of digital asset mining |
116,756 |
|
|
10,141 |
|
|
279,576 |
|
|
13,909 |
|
Total cost of revenue
|
189,648 |
|
|
54,715 |
|
|
463,419 |
|
|
145,193 |
|
Gross (loss) profit
|
(27,076) |
|
|
58,424 |
|
|
55,644 |
|
|
97,495 |
|
Loss on legal settlement
|
— |
|
|
(2,603) |
|
|
— |
|
|
(2,603) |
|
Gain from sales of digital assets
|
11,036 |
|
|
391 |
|
|
25,007 |
|
|
405 |
|
Impairment of digital assets |
(7,986) |
|
|
(12,552) |
|
|
(212,184) |
|
|
(12,552) |
|
Impairment of goodwill and other intangibles |
(268,512) |
|
|
— |
|
|
(1,059,265) |
|
|
— |
|
Impairment of property, plant and equipment |
(59,259) |
|
|
— |
|
|
(59,259) |
|
|
— |
|
Losses on exchange or disposal of property, plant and
equipment |
— |
|
|
— |
|
|
(13,057) |
|
|
(17) |
|
Operating expenses:
|
|
|
|
|
|
|
|
Research and development
|
6,192 |
|
|
1,586 |
|
|
24,305 |
|
|
4,231 |
|
Sales and marketing
|
39 |
|
|
932 |
|
|
11,675 |
|
|
2,186 |
|
General and administrative
|
43,346 |
|
|
36,358 |
|
|
174,380 |
|
|
46,975 |
|
Total operating expenses
|
49,577 |
|
|
38,876 |
|
|
210,360 |
|
|
53,392 |
|
Operating (loss) income
|
(401,374) |
|
|
4,784 |
|
|
(1,473,474) |
|
|
29,336 |
|
Non-operating expenses, net:
|
|
|
|
|
|
|
|
Loss on debt extinguishment
|
— |
|
|
— |
|
|
— |
|
|
8,016 |
|
Interest expense, net
|
25,942 |
|
|
13,569 |
|
|
74,734 |
|
|
26,550 |
|
Fair value adjustment on convertible notes |
(4,123) |
|
|
8,663 |
|
|
186,853 |
|
|
8,663 |
|
Fair value adjustment on derivative warrant liabilities |
(521) |
|
|
— |
|
|
(32,985) |
|
|
— |
|
Other non-operating expenses (income), net
|
1,478 |
|
|
(4) |
|
|
4,997 |
|
|
(2) |
|
Total non-operating expenses, net
|
22,776 |
|
|
22,228 |
|
|
233,599 |
|
|
43,227 |
|
Loss before income taxes
|
(424,150) |
|
|
(17,444) |
|
|
(1,707,073) |
|
|
(13,891) |
|
Income tax expense (benefit)
|
10,642 |
|
|
(815) |
|
|
4,398 |
|
|
(697) |
|
Net loss
|
$ |
(434,792) |
|
|
$ |
(16,629) |
|
|
$ |
(1,711,471) |
|
|
$ |
(13,194) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss per share (Note 14):
|
|
|
|
|
|
|
|
Basic
|
$ |
(1.23) |
|
|
$ |
(0.07) |
|
|
$ |
(5.38) |
|
|
$ |
(0.07) |
|
Diluted
|
$ |
(1.23) |
|
|
$ |
(0.07) |
|
|
$ |
(5.38) |
|
|
$ |
(0.07) |
|
Weighted average shares outstanding:
|
|
|
|
|
|
|
|
Basic
|
354,195 |
|
|
236,951 |
|
|
318,169 |
|
|
184,790 |
|
Diluted
|
354,195 |
|
|
236,951 |
|
|
318,169 |
|
|
184,790 |
|
See accompanying notes to unaudited consolidated financial
statements.
Core Scientific, Inc.
Consolidated Statements of Comprehensive Loss
(in thousands, except per share amounts)
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended September 30, |
|
Nine Months Ended September 30, |
|
2022 |
|
2021 |
|
2022 |
|
2021 |
Net loss
|
$ |
(434,792) |
|
|
$ |
(16,629) |
|
|
$ |
(1,711,471) |
|
|
$ |
(13,194) |
|
Other comprehensive income (loss), net of income
taxes:
|
|
|
|
|
|
|
|
Change in fair value attributable to instrument-specific credit
risk of convertible notes measured at fair value under the fair
value option, net of tax effect of $—, $—, $— and $—
|
47,832 |
|
|
(8,552) |
|
|
83,578 |
|
|
(8,552) |
|
Total other comprehensive income (loss), net of income
taxes
|
47,832 |
|
|
(8,552) |
|
|
83,578 |
|
|
(8,552) |
|
Comprehensive loss
|
$ |
(386,960) |
|
|
$ |
(25,181) |
|
|
$ |
(1,627,893) |
|
|
$ |
(21,746) |
|
See accompanying notes to unaudited consolidated financial
statements.
Core Scientific, Inc.
Consolidated Statements of Changes in Contingently Redeemable
Convertible Preferred Stock and Stockholders’ Equity
(in thousands)
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Contingently Redeemable
Convertible Preferred
Stock |
|
|
Common Stock |
|
Additional
Paid-In Capital |
|
Accumulated
Deficit |
|
Accumulated Other Comprehensive Income |
|
Total
Stockholders’
Equity |
|
Shares |
|
Amount |
|
|
Shares |
|
Amount |
|
|
|
|
Balance at June 30, 2022 |
— |
|
|
— |
|
|
|
353,481 |
|
|
35 |
|
|
1,695,748 |
|
|
(1,304,111) |
|
|
24,780 |
|
|
416,452 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss |
— |
|
|
— |
|
|
|
— |
|
|
— |
|
|
— |
|
|
(434,792) |
|
|
— |
|
|
(434,792) |
|
Other comprehensive income |
— |
|
|
— |
|
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
47,832 |
|
|
47,832 |
|
Stock-based compensation |
— |
|
|
— |
|
|
|
— |
|
|
— |
|
|
29,884 |
|
|
— |
|
|
— |
|
|
29,884 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Issuance of common stock - restricted stock and restricted stock
units, net of shares withheld for tax withholding
obligations |
— |
|
|
— |
|
|
|
4,897 |
|
|
— |
|
|
(2,349) |
|
|
— |
|
|
— |
|
|
(2,349) |
|
Restricted stock awards cancelled upon forfeiture |
— |
|
|
— |
|
|
|
(2,268) |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Issuances of common stock - equity line of credit |
— |
|
|
— |
|
|
|
7,315 |
|
|
1 |
|
|
13,039 |
|
|
— |
|
|
— |
|
|
13,040 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Issuances of common stock - financing transaction fees |
— |
|
|
— |
|
|
|
1,285 |
|
|
— |
|
|
2,960 |
|
|
— |
|
|
— |
|
|
2,960 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at September 30, 2022 |
— |
|
|
— |
|
|
|
364,710 |
|
|
36 |
|
|
1,739,282 |
|
|
(1,738,903) |
|
|
72,612 |
|
|
73,027 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at December 31, 2021 |
10,826 |
|
|
44,476 |
|
|
|
271,576 |
|
|
27 |
|
|
1,379,581 |
|
|
(27,432) |
|
|
(10,966) |
|
|
1,341,210 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss |
— |
|
|
— |
|
|
|
— |
|
|
— |
|
|
— |
|
|
(1,711,471) |
|
|
— |
|
|
(1,711,471) |
|
Other comprehensive income |
— |
|
|
— |
|
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
83,578 |
|
|
83,578 |
|
Stock-based compensation |
— |
|
|
— |
|
|
|
— |
|
|
— |
|
|
165,949 |
|
|
— |
|
|
— |
|
|
165,949 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Issuance of common stock - employee stock options |
— |
|
|
— |
|
|
|
1,321 |
|
|
— |
|
|
3,846 |
|
|
— |
|
|
— |
|
|
3,846 |
|
Issuance of common stock - restricted stock and restricted stock
units, net of shares withheld for tax withholding
obligations |
— |
|
|
— |
|
|
|
39,099 |
|
|
4 |
|
|
(31,630) |
|
|
— |
|
|
— |
|
|
(31,626) |
|
Restricted stock awards cancelled upon forfeiture |
— |
|
|
— |
|
|
|
(2,268) |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
Issuance of common stock - exercise of convertible
notes |
— |
|
|
— |
|
|
|
197 |
|
|
— |
|
|
1,574 |
|
|
— |
|
|
— |
|
|
1,574 |
|
Issuance of common stock - exercise of warrants |
— |
|
|
— |
|
|
|
3,001 |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
Issuances of common stock - equity line of credit |
— |
|
|
— |
|
|
|
7,315 |
|
|
1 |
|
|
13,039 |
|
|
— |
|
|
— |
|
|
13,040 |
|
Conversion of contingently redeemable preferred stock to common
stock |
(10,826) |
|
|
(44,476) |
|
|
|
10,826 |
|
|
1 |
|
|
44,475 |
|
|
— |
|
|
— |
|
|
44,476 |
|
Issuances of common stock - Merger with XPDI |
— |
|
|
— |
|
|
|
30,778 |
|
|
3 |
|
|
163,456 |
|
|
— |
|
|
— |
|
|
163,459 |
|
Issuances of common stock - financing transaction fees |
— |
|
|
— |
|
|
|
1,285 |
|
|
— |
|
|
2,960 |
|
|
— |
|
|
— |
|
|
2,960 |
|
Issuances of common stock - vendor settlement |
— |
|
|
— |
|
|
|
1,580 |
|
|
— |
|
|
12,674 |
|
|
— |
|
|
— |
|
|
12,674 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Costs attributable to issuance of common stock and equity
instruments - Merger with XPDI |
— |
|
|
— |
|
|
|
— |
|
|
— |
|
|
(16,642) |
|
|
— |
|
|
— |
|
|
(16,642) |
|
Balance at September 30, 2022 |
— |
|
|
— |
|
|
|
364,710 |
|
|
36 |
|
|
1,739,282 |
|
|
(1,738,903) |
|
|
72,612 |
|
|
73,027 |
|
See accompanying notes to unaudited consolidated financial
statements.
Core Scientific, Inc.
Consolidated Statements of Changes in Contingently Redeemable
Convertible Preferred Stock and Stockholders’ Equity
(in thousands)
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Contingently Redeemable
Convertible Preferred
Stock |
|
|
Common Stock |
|
Additional
Paid-In Capital |
|
Accumulated
Deficit |
|
Accumulated Other Comprehensive Loss |
|
Total
Stockholders’
Equity |
|
Shares |
|
Amount |
|
|
Shares |
|
Amount |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at June 30, 2021 |
10,826 |
|
|
44,476 |
|
|
|
157,826 |
|
|
16 |
|
|
167,172 |
|
|
(71,309) |
|
|
— |
|
|
95,879 |
|
Net loss |
— |
|
|
— |
|
|
|
— |
|
|
— |
|
|
— |
|
|
(16,629) |
|
|
— |
|
|
(16,629) |
|
Other comprehensive loss |
— |
|
|
— |
|
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
(8,552) |
|
|
(8,552) |
|
Stock-based compensation |
— |
|
|
— |
|
|
|
(40) |
|
|
— |
|
|
28,288 |
|
|
— |
|
|
— |
|
|
28,288 |
|
Issuances of common stock - business combination |
— |
|
|
— |
|
|
|
115,508 |
|
|
1 |
|
|
1,189,906 |
|
|
— |
|
|
— |
|
|
1,189,907 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at September 30, 2021
|
10,826 |
|
|
44,476 |
|
|
|
273,334 |
|
|
17 |
|
|
1,385,366 |
|
|
(87,938) |
|
|
(8,552) |
|
|
1,288,893 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at December 31, 2020
|
6,766 |
|
|
$ |
44,476 |
|
|
|
98,607 |
|
|
$ |
1 |
|
|
$ |
163,967 |
|
|
$ |
(74,744) |
|
|
$ |
— |
|
|
$ |
89,224 |
|
Retroactive application of the recapitalization |
4,060 |
|
|
— |
|
|
|
59,179 |
|
|
15 |
|
|
(15) |
|
|
— |
|
|
— |
|
|
— |
|
Balance at December 31, 2020, as adjusted |
10,826 |
|
|
44,476 |
|
|
|
157,786 |
|
|
16 |
|
|
163,952 |
|
|
(74,744) |
|
|
— |
|
|
89,224 |
|
Net loss |
— |
|
|
— |
|
|
|
— |
|
|
— |
|
|
— |
|
|
(13,194) |
|
|
— |
|
|
(13,194) |
|
Other comprehensive loss |
— |
|
|
— |
|
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
(8,552) |
|
|
(8,552) |
|
Stock-based compensation |
— |
|
|
— |
|
|
|
— |
|
|
— |
|
|
31,012 |
|
|
— |
|
|
— |
|
|
31,012 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Issuances of common stock - business combination |
— |
|
|
— |
|
|
|
115,508 |
|
|
1 |
|
|
1,189,906 |
|
|
— |
|
|
— |
|
|
1,189,907 |
|
Issuances of common stock - warrants and options |
— |
|
|
— |
|
|
|
40 |
|
|
— |
|
|
496 |
|
|
— |
|
|
— |
|
|
496 |
|
Balance at September 30, 2021
|
10,826 |
|
|
44,476 |
|
|
|
273,334 |
|
|
17 |
|
|
1,385,366 |
|
|
(87,938) |
|
|
(8,552) |
|
|
1,288,893 |
|
See accompanying notes to unaudited consolidated financial
statements.
Core Scientific, Inc.
Consolidated Statements of Cash Flows
(in thousands)
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
Nine Months Ended September 30,
|
|
2022 |
|
2021 |
Cash flows from Operating Activities: |
|
|
|
Net loss
|
$ |
(1,711,471) |
|
|
$ |
(13,194) |
|
Adjustments to reconcile net loss to net cash provided by (used in)
operating activities:
|
|
|
|
Depreciation and amortization |
156,544 |
|
|
12,886 |
|
Amortization of operating lease right-of-use assets |
424 |
|
|
— |
|
Stock-based compensation |
166,548 |
|
|
31,012 |
|
Digital asset mining revenue |
(323,337) |
|
|
(77,511) |
|
Deferred income taxes |
3,434 |
|
|
3,604 |
|
Loss on legal settlement
|
— |
|
|
2,603 |
|
Gain on sale of intangible assets |
(5,904) |
|
|
— |
|
Loss on debt extinguishment
|
— |
|
|
8,016 |
|
Fair value adjustment on derivative warrant liabilities |
(32,985) |
|
|
— |
|
Fair value adjustment on convertible notes |
210,968 |
|
|
15,937 |
|
Fair value adjustment on other liabilities |
9,498 |
|
|
— |
|
Equity line of credit expenses |
1,431 |
|
|
— |
|
Amortization of debt discount and debt issuance costs |
6,172 |
|
|
1,024 |
|
Losses on exchange or disposal of property, plant and
equipment
|
13,057 |
|
|
17 |
|
|
|
|
|
Impairment of digital assets |
212,184 |
|
|
12,552 |
|
Impairment of goodwill, other intangibles and property, plant and
equipment |
1,118,524 |
|
|
— |
|
Provision for doubtful accounts |
5,943 |
|
|
— |
|
Changes in working capital components: |
|
|
|
Accounts receivable, net |
(6,737) |
|
|
(6,641) |
|
Accounts receivable from related parties |
(595) |
|
|
55 |
|
Digital assets |
325,787 |
|
|
27,316 |
|
Deposits for equipment for sales to customers |
(66,932) |
|
|
(414,771) |
|
Prepaid expenses and other current assets |
53,832 |
|
|
970 |
|
Accounts payable |
2,954 |
|
|
(35,132) |
|
Accrued expenses and other |
(241) |
|
|
17,945 |
|
Deferred revenue |
22,251 |
|
|
36,226 |
|
Deferred revenue from related parties |
(65,954) |
|
|
218,304 |
|
Other noncurrent assets and liabilities, net |
(6,194) |
|
|
(7,692) |
|
Net cash provided by (used in) operating activities |
89,201 |
|
|
(166,474) |
|
Cash flows from Investing Activities: |
|
|
|
Purchases of property, plant and equipment |
(243,755) |
|
|
(116,074) |
|
Cash acquired in acquisition |
— |
|
|
704 |
|
Deposits for self-mining equipment |
(217,677) |
|
|
— |
|
Proceeds from sale of intangibles |
10,850 |
|
|
— |
|
Other |
(719) |
|
|
(154) |
|
Net cash used in investing activities |
(451,301) |
|
|
(115,524) |
|
Cash flows from Financing Activities: |
|
|
|
Proceeds from issuance of common stock, net of transaction
costs |
210,534 |
|
|
496 |
|
Proceeds from debt, net of issuance costs |
216,182 |
|
|
475,301 |
|
Repurchase of common shares to pay employee withholding
taxes |
(31,627) |
|
|
— |
|
Principal repayments of finance leases |
(28,070) |
|
|
— |
|
Principal payments on debt |
(98,953) |
|
|
(42,513) |
|
|
|
|
|
Net cash provided by financing activities |
268,066 |
|
|
433,284 |
|
Net (decrease) increase in cash, cash equivalents and restricted
cash |
(94,034) |
|
|
151,286 |
|
Cash, cash equivalents and restricted cash—beginning of
period |
131,678 |
|
|
8,721 |
|
Cash, cash equivalents and restricted cash—end of
period |
$ |
37,644 |
|
|
$ |
160,007 |
|
See accompanying notes to unaudited consolidated financial
statements.
Core Scientific, Inc.
Notes to Unaudited Consolidated Financial Statements
Notes to Unaudited Consolidated Financial Statements
1. ORGANIZATION AND DESCRIPTION OF BUSINESS
MineCo Holdings, Inc. was incorporated on December 13, 2017 in
the State of Delaware and changed its name to Core Scientific, Inc.
(“Legacy Core Scientific”) pursuant to an amendment to its
Certificate of Incorporation dated June 12, 2018. On
August 17, 2020 Legacy Core Scientific engaged in a holdco
restructuring to facilitate a borrowing arrangement by Legacy Core
Scientific pursuant to which Legacy Core Scientific was merged with
and into a wholly owned subsidiary of Core Scientific Holding Co.
and became a wholly owned subsidiary of Core Scientific Holding Co.
and the stockholders of Legacy Core Scientific became the
stockholders of Core Scientific Holding Co. Following the approval
at the special meeting of the stockholders of XPDI held on January
19, 2022, on January 19, 2022, Core Scientific Holding Co. merged
with Power & Digital Infrastructure Acquisition Corp., a
Delaware corporation (“XPDI”), and XPDI Merger Sub Inc., a Delaware
corporation and wholly owned subsidiary of XPDI (“Merger Sub”),
consummated the transactions contemplated under the merger
agreement. In connection with the closing of the merger, XPDI
changed its name from Power & Digital Infrastructure
Acquisition Corp. to Core Scientific, Inc. (“Core Scientific” or
the “Company”). The Company, headquartered in Austin, Texas, is an
infrastructure, technology and services company that conducts, or
plans to conduct, the following business activities:
•Owning
and operating computer equipment used to process transactions
conducted on one or more blockchain networks in exchange for
digital currency assets and transaction processing fees awarded in
digital currency assets, commonly referred to as
mining;
•Owning
and operating datacenter facilities in the U.S. to provide
colocation and hosting services for distributed ledger technology,
also commonly known as blockchain;
•Developing
blockchain-based platforms and applications, including
infrastructure management, security technologies, mining
optimization, and recordkeeping;
Merger Agreement
In 2021, XPDI entered into that certain Agreement and Plan of
Reorganization and Merger, dated as of July 20, 2021, as amended on
October 1, 2021, and as further amended on December 29, 2021, by
and among Core Scientific Holding Co., XPDI Merger Sub and XPDI
(the “Merger Agreement”). XPDI’s stockholders approved the
transactions (collectively, the “Merger”) contemplated by the
Merger Agreement at a special meeting of stockholders held on
January 19, 2022 (the “Special Meeting”).
Pursuant to the terms of (a) the Merger Agreement and (b) that
certain Agreement and Plan of Merger, dated as of October 1, 2021,
as amended on January 14, 2022, by and among XPDI, Core Scientific
Holding Co., XPDI Merger Sub 3, LLC, a Delaware limited liability
company and wholly owned subsidiary of XPDI (“Merger Sub 3”), and
Blockcap, Inc., a Nevada corporation and wholly owned subsidiary of
Core Scientific (“Blockcap”), the Merger was effected by (i) the
merger of Merger Sub with and into Core Scientific (the “First
Merger”), which occurred on January 19, 2022 (the “Closing Date”),
with Core Scientific surviving the First Merger as a wholly owned
subsidiary of XPDI, (ii) the merger of Core Scientific with and
into XPDI (the “Second Merger”), which occurred on January 20,
2022, with XPDI surviving the Second Merger, and (iii) following
the closing of the Second Merger on January 20, 2022, the merger of
Blockcap with and into Merger Sub 3 (the “Third Merger”), with
Merger Sub 3 surviving the Third Merger as a wholly owned
subsidiary of XPDI under the name “Core Scientific Acquired Mining
LLC.” Immediately prior to the effective time of the First Merger
(such effective time of the First Merger, the “Effective Time”),
XPDI filed a Second Amended and Restated Certificate of
Incorporation (the “Post-Combination Charter”) with the Secretary
of State of the State of Delaware pursuant to which XPDI changed
its name from “Power & Digital Infrastructure Acquisition
Corp.” to “Core Scientific, Inc.” (hereinafter referred to as the
“Company” or “New Core”) and redesignated its Class A common stock,
par value $0.0001 per share (“XPDI Class A Common Stock”), and
Class B common stock, par value $0.0001 per share (“XPDI Class B
Common Stock”), as common stock, par value $0.0001, of the Company
(“New Core Common Stock”). The Exchange Ratio (as defined in the
Merger Agreement) was 1.6001528688 of a share of New Core Common
Stock per fully-diluted share of Core Scientific Common
Stock.
In connection with the Special Meeting and the Merger, holders of
12.3 million of the 34.5 million then-outstanding shares
of Class A common stock of XPDI exercised their right to redeem
their shares for cash at a redemption price of approximately $10.00
per share, for an aggregate redemption amount of
$123.5 million.
Core Scientific, Inc.
Notes to Unaudited Consolidated Financial Statements
The Merger provided gross proceeds of approximately
$221.6 million from the XPDI trust account, resulting in
approximately $195.0 million in net cash proceeds to Core
Scientific, after the payment of transaction expenses, which is
presented within proceeds from issuance of common stock, net of
transaction costs on the consolidated statements of cash flows.
Following the Merger, former Core Scientific stockholders owned
90.7%, former XPDI public stockholders owned 6.7% and XPDI’s
sponsor owned 2.6% of the issued and outstanding shares of common
stock, respectively, of the Company, excluding the impact of
unvested restricted stock units and options. The proceeds from the
Merger were used to fund mining equipment purchases and
infrastructure build-out.
The Merger is accounted for as a reverse recapitalization with the
Company being the accounting acquirer. A reverse recapitalization
does not result in a new basis of accounting. Accordingly, the
reverse recapitalization was treated as the equivalent of Core
Scientific Holding Co. issuing stock for the net assets of XPDI,
accompanied by a recapitalization. The net assets of XPDI are
stated at historical costs, with no goodwill or other intangible
assets recorded. The Company identified $18.6 million of
direct and incremental transaction costs, which consist of legal,
accounting, and other professional services directly related to the
Merger, of which $10.7 million were recorded in other
noncurrent assets on the consolidated balance sheets as of
December 31, 2021 and the remaining $7.9 million were
recognized in the nine months ended September 30, 2022. These
transaction costs have been allocated to all instruments assumed or
issued in the merger on a relative fair value basis as of the date
of the merger. Transaction costs of $16.6 million have been
allocated to equity-classified instruments and recognized as an
adjustment to additional paid-in capital within total stockholders’
equity. The cash outflows related to these costs have been netted
against the proceeds from the issuance of common stock upon the
Merger with XPDI within financing activities on the Company’s
consolidated statement of cash flows. Transaction costs of
$2.0 million have been allocated to liability-classified
instruments that are measured at fair value through earnings and
have been recognized as a charge within general and administrative
expenses in the nine months ended September 30,
2022.
Immediately prior to the Effective Time, each share of Series A
convertible preferred stock, par value $0.00001, of Core Scientific
automatically converted into one share of Core Scientific common
stock, par value $0.00001 per share (“Core Scientific Common
Stock”), and each share of Series B convertible preferred stock,
par value $0.00001, of Core Scientific automatically converted into
one share of Core Scientific Common Stock.
In addition, immediately prior to the Effective Time, each share of
XPDI Class B Common Stock automatically converted into one share of
New Core Common Stock. 1.7 million shares (“SPAC Vesting
Shares”) are subject to vesting conditions, and will vest i) upon
the date on which New Core Common Stock’s volume-weighted average
price is greater than $12.50 per share for any 20 trading days
within any 30 consecutive trading day period within five years of
the Closing Date or ii) upon any Company Sale that is consummated
within five years of the Closing Date that results in the holders
of the Company’s common stock receiving a Company Sale Price equal
to or in excess of $12.50 per share. A Company Sale means any
change in control of the Company, or a sale of substantially all of
the Company’s assets that results in a change in control. Company
Sale Price means the price per share paid to holders of common
stock in a Company Sale.
As a result of the Merger, all of XPDI’s Class A Common Stock and
Class B Common Stock automatically converted into shares of New
Core Common Stock on a one-for-one basis. XPDI’s 8.6 million
public warrants issued in its initial public offering (the “Public
Warrants”) and 6.3 million warrants issued in connection with
private placement at the time of XPDI’s initial public offering
(the “Private Placement Warrants”) became warrants for New Core
Common Stock.
All share-based compensation awards were converted into comparable
equity awards that are settled or exercisable for shares of New
Core Common Stock. As a result, each stock option and warrant was
converted into an option or warrant to purchase shares New Core
Common Stock based on an exchange ratio of 1.6001528688. Each award
of the Company’s restricted stock units (“RSUs”) was converted into
RSUs of New Core based on an exchange ratio of
1.6001528688.
Each convertible note is convertible into New Core Common Stock in
accordance with the terms of such convertible promissory note;
provided, however, that with respect to outstanding convertible
promissory notes for which Core Scientific received a duly executed
exercise of conversion in accordance with such convertible
promissory note, exercising the right of such holder to convert
such convertible promissory note subject to and conditioned upon
the occurrence of the Effective Time, the outstanding principal
amount and accrued interest as of the Effective Time with respect
to such convertible promissory note was converted into shares of
New Core Common Stock, equal to the product (rounded down to the
nearest whole number) of (i) the number of shares of Core
Scientific Common Stock issuable upon the conversion of such
convertible promissory note in accordance with such convertible
promissory note immediately prior to the Effective Time and (ii)
the Exchange Ratio.
Core Scientific, Inc.
Notes to Unaudited Consolidated Financial Statements
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
The accompanying consolidated financial statements reflect the
application of certain significant accounting policies as described
below and elsewhere in these notes to the consolidated financial
statements.
Basis of Presentation
We have prepared the accompanying consolidated financial statements
pursuant to the rules and regulations of the Securities and
Exchange Commission (the “SEC”) for interim financial reporting.
These consolidated financial statements are unaudited and, in our
opinion, include all adjustments, consisting of normal recurring
adjustments and accruals necessary for a fair presentation of our
consolidated cash flows, operating results, and balance sheets for
the periods presented. Operating results for the periods presented
are not necessarily indicative of the results that may be expected
for 2022. Certain information and footnote disclosures normally
included in financial statements prepared in accordance with
accounting principles generally accepted in the United States
(“GAAP”) have been omitted in accordance with the rules and
regulations of the SEC. These consolidated financial statements
should be read in conjunction with the audited consolidated
financial statements and accompanying notes included as an exhibit
to the amendment to the Current Report on Form 8-K/A, which was
filed with the SEC on March 31, 2022.
Going Concern
The consolidated financial statements have been prepared on a going
concern basis. For the three months ended September 30, 2022,
the Company generated a net loss of $434.8 million and used
cash in operating activities of $52.1 million. The Company had
unrestricted cash and cash equivalents of $29.5 million as of
September 30, 2022 compared to $128.5 million as of June
30, 2022. The decrease in cash and cash equivalents for the three
months ended September 30, 2022 primarily reflected
$52.1 million of cash used in operating activities (including
$15.5 million of interest payments on debt), $5.7 million
of cash used in investing activities (including $5.2 million
of purchases of property, plant and equipment) and
$45.1 million of cash used in financing activities (including
$49.5 million of principal payments on debt). The Company has
historically generated cash primarily from the issuance of common
stock and debt, through sales of digital currency assets received
as digital asset mining revenue and from operations through
contracts with customers.
During the three months ended September 30, 2022, the average
price of bitcoin declined to $21,324 compared to $32,502 for the
three months ended June 30, 2022, which reduced digital asset
mining revenue to $80.5 million for the three months ended
September 30, 2022 as compared to $109.8 million for the three
months ended June 30, 2022. At the same time the Company’s power
costs in its Mining Segment increased to $47.1 million for the
three months ended September 30, 2022 as compared to $32.2 million
for the three months ended June 30, 2022, reflecting increases in
both power usage and power rates. These factors contributed to the
Company’s gross loss of $27.1 million for the three months ended
September 30, 2022 as compared to a gross profit of $12.7
million for the three months ended June 30, 2022. Additionally,
during the nine months ended September 30, 2022 the Company had
$217.7 million of deposits paid for blockchain computing equipment
and $243.8 million paid for purchases of property, plant and
equipment used towards construction projects which has contributed
to the Company’s significant indebtedness, including notes payable
with a carrying value of $977.6 million as of September 30,
2022 and finance lease liabilities with a carrying value of $73.0
million as of September 30, 2022. In addition, as discussed in
Note 10, in July 2022, one of the Company’s largest customers filed
for voluntary relief under chapter 11 of the United States
Bankruptcy Code. As a result of these and other factors, the
Company will require additional liquidity to continue its
operations through November 2023. However, the ability to raise
funds through financing and capital market transactions is subject
to many risks and uncertainties and current market conditions have
reduced the availability of these capital and liquidity sources.
The Company anticipates that existing cash resources will be
depleted by the end of 2022 or sooner. Given the uncertainty
regarding the Company’s financial condition, substantial doubt
exists about the Company’s ability to continue as a going concern
through November 2023.
Management has been actively taking steps to decrease operating
costs, eliminate and delay construction expenses, reduce and delay
capital expenditures and increase hosting revenues. In addition, in
October 2022 the Company determined not to make certain payments
with respect to several of its debt facilities, equipment financing
facilities and leases and other financings, including its two
bridge promissory notes. As a result, the creditors under these
debt facilities may exercise remedies following any applicable
grace periods, including electing to accelerate the principal
amount of such debt, suing the Company for nonpayment, increasing
interest rates to default rates, or taking action with respect to
collateral, where applicable. The Company does not believe that it
was in default under any of its debt agreements as of September 30,
2022.
Core Scientific, Inc.
Notes to Unaudited Consolidated Financial Statements
In light of the foregoing, the Company is in the process of
exploring a number of potential strategic alternatives with respect
to the Company’s capital structure, including hiring strategic
advisers, raising additional capital or restructuring its existing
capital structure. Specifically, the Company has engaged Weil,
Gotshal & Manges LLP, as legal advisers, and PJT Partners LP,
as financial advisers, to assist the Company in analyzing and
evaluating potential strategic alternatives and initiatives to
improve liquidity. The Company and its advisers have begun to
engage in discussions with certain of its creditors regarding these
initiatives. The Company expects these activities will continue and
intensify. Among possible alternatives, the Company may explore
liability management transactions, including exchanging its
existing debt for equity or additional debt, which transactions may
be dilutive to holders of the Company’s common stock. These
discussions may not result in any agreement on commercially
acceptable terms or at all. Furthermore, the Company may seek
alternative sources of equity or debt financing, evaluate potential
asset sales, and potentially could seek relief under the applicable
bankruptcy or insolvency laws.
The consolidated financial statements do not include any
adjustments to the carrying amounts and classification of assets,
liabilities, and reported expenses that may be necessary if the
Company were unable to continue as a going concern.
Use of Estimates
The consolidated assets, liabilities and results of operations
prior to the reverse recapitalization are those of Core Scientific
Holding Co. The outstanding shares and corresponding capital
amounts, and losses per share, prior to the reverse
recapitalization, have been retroactively adjusted in accordance
with Accounting Standards Codification (“ASC”) 805,
Business Combinations.
The preparation of the Company’s consolidated financial statements
in conformity with GAAP requires management to make estimates and
assumptions that affect the reported amounts of assets and
liabilities, the disclosure of contingent assets and liabilities at
the date of the financial statements, and the reported amounts of
income and expenses during the reporting period. Some of the more
significant estimates include assumptions used to estimate its
ability to continue as a going concern, the valuation of the
Company’s common shares and the determination of the grant date
fair value of stock-based compensation awards for periods prior to
the Merger, the valuation of goodwill, intangibles and property,
plant and equipment, the fair value of convertible debt,
acquisition purchase price accounting, and income taxes. These
estimates are based on information available as of the date of the
financial statements; therefore, actual results could differ from
management’s estimates.
Cash, Cash Equivalents and Restricted Cash
Cash and cash equivalents include all cash balances and highly
liquid investments with original maturities of three months or less
from the date of acquisition. As of September 30, 2022 and
December 31, 2021, cash equivalents included $2.1 million and
$100.0 million of highly liquid money market funds, respectively,
which are classified as Level 1 within the fair value hierarchy.
Restricted cash consists of cash held in escrow to pay for
construction and development activities.
The following table provides a reconciliation of the amount of
cash, cash equivalents and restricted cash reported on the
Consolidated Balance Sheets to the total of the same amount shown
in the Consolidated Statements of Cash Flows (in
thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
September 30, 2022 |
|
December 31, 2021 |
Cash and cash equivalents
|
$ |
29,546 |
|
|
$ |
117,871 |
|
Restricted cash
|
8,098 |
|
|
13,807 |
|
Total cash, cash equivalents and restricted cash
|
$ |
37,644 |
|
|
$ |
131,678 |
|
Property, Plant and Equipment, Net
Property, plant and equipment includes land, buildings and
improvements for datacenter facilities and leasehold improvements
for the Company’s corporate headquarters. Property and equipment
consists of computer, mining, network, electrical and other
equipment, including right-of-use assets under finance leases.
Property, plant and equipment, net is stated at cost less
accumulated depreciation and amortization. Depreciation and
amortization is computed using the straight-line method over the
estimated useful lives of the assets. Leasehold improvements are
capitalized at cost and amortized over the shorter of their
estimated useful lives or the lease term. Property, plant and
equipment, net included construction in progress of
$161.5 million and $42.6 million as of September 30,
2022 and December 31, 2021, respectively.
Subsequent to January 1, 2022, future obligations related to
finance leases are presented as Finance lease liabilities,
current portion and Finance lease liabilities, net of
current portion in the Company’s Consolidated Balance
Sheets. Finance lease right-of-use
Core Scientific, Inc.
Notes to Unaudited Consolidated Financial Statements
assets are included within Property and equipment, net on our
Consolidated Balance Sheets. Depreciation expense, including
amortization of right-of-use assets held under finance leases, is
primarily included in cost of revenue in the
Company’s Consolidated Statements of Operations and
Comprehensive Loss.
Prior to January 1, 2022, future obligations related to capital
leases accounted for under ASC 840,
Leases,
are presented as Finance lease liabilities, current
portion and Finance lease liabilities, net of current
portion on the Company’s Consolidated Balance Sheets. Capital
lease assets for those periods are included within Property and
equipment, net on our Consolidated Balance Sheets. Amortization of
capital lease assets for periods prior to January 1, 2022 is
primarily included in cost of revenue in the
Company’s Consolidated Statements of Operations and
Comprehensive Loss.
Self-mining computer equipment that is subsequently contracted for
sale to customers is valued at the lower of cost or net realizable
value, with any write-down recognized as cost of equipment sales in
the Company’s Consolidated Statements of Operations.
Long-Lived Asset Impairments
The Company tests long-lived asset groups for recoverability
whenever events or changes in circumstances have occurred that may
affect the recoverability or the estimated useful lives of
long-lived assets. Long-lived assets include property, plant and
equipment and intangible assets subject to amortization. A
long-lived asset may be impaired when the estimated future
undiscounted cash flows are less than the carrying amount of the
asset. If that comparison indicates that the asset’s carrying value
may not be recoverable, the impairment is measured based on the
difference between the carrying amount and the estimated fair value
of the asset. This evaluation is performed at the lowest level for
which separately identifiable cash flows exist, which for the
Company is the hosting and mining gross margins it earns at each of
its data center facility sites. Long-lived assets to be disposed of
are reported at the lower of the carrying amount or estimated fair
value less costs to sell.
During the three months ended September 30, 2022, the
Company’s operating performance and liquidity continued to be
severely impacted by the prolonged decrease in the price of
bitcoin, the increase in electricity costs, the increase in the
global bitcoin network hash rate and an increase in additional
operating costs related to these factors. Additionally, primary and
secondary market prices for ASIC miners of the type used by the
Company in its business operations have decreased significantly
from previous levels, including those acquired earlier in
2022.
Accordingly, the Company evaluated whether the estimated future
undiscounted cash flows from the operation of its data center
facilities would recover the carrying value of the property, plant
and equipment located at the sites and used in site operations,
including the Company’s deployed mining equipment. Based on this
evaluation, the Company determined that the carrying value of the
property, plant and equipment at the Cedarvale, TX facility site
may no longer be fully recoverable by the cash flows of the site.
The Company measured the amount of impairment at the Cedarvale, TX
facility site as the difference between the carrying amount of the
site asset group of $119.8 million and the estimated fair value of
the site asset group of $60.5 million, resulting in an impairment
of the facility site’s property, plant and equipment of $59.3
million for both the three and nine months ended September 30,
2022.
The Company’s analysis involved the use of a combination and
corroboration of cost and market approaches. The cost approach has
been used to estimate the fair value of buildings, improvements,
electrical equipment and other tangible assets used in combination
with other assets. Significant assumptions used in the cost
approach include reproduction and replacement costs, useful service
live, and orderly liquidation values. The cost approach utilizes
useful service life and other estimates developed by the Company to
determine fair value, which are unobservable Level 3 inputs. The
market approach has been used to estimate the fair value of the
Company’s ASIC miners, network equipment, and real estate, and to
corroborate certain estimates using the cost approach. Valuations
using the market approach are derived from manufacturer and
secondary market pricing sources and, when available, comparable
secondary market transactions. Significant judgment in using the
market approach includes the selection of comparable assets based
on ASIC model efficiency and hash rate, a selection of and
modifications to transactions according to comparable use, size,
geography and other traits, and the use of broker indications of
relative market price metrics. The market approach utilizes
comparable use, relative efficiency and other estimates developed
by the Company to determine fair value, which are unobservable
Level 3 inputs. Unobservable Level 3 inputs are used to measure
fair value to the extent that relevant observable inputs are not
available. The Company developed its estimates using the best
information available at the time. Changes in management’s
estimates or any of its other assumptions used in its analysis
could result in a different conclusion. Continued elevated power
costs, continued increases in the bitcoin network hash rate and a
continuing depression or further decrease of bitcoin’s value in the
market could result in further impairment of the Company’s
property, plant and equipment.
Subsequent to September 30, 2022, the Company relocated its
approximately 7,600 self-miners from Cedarvale, TX to other of the
Company’s data center facilities. There were no hosting customer
miners at Cedarvale, TX as of September 30, 2022.
Core Scientific, Inc.
Notes to Unaudited Consolidated Financial Statements
Derivative Warrant Liabilities
The Company does not use derivative instruments to hedge exposures
to cash flow, market, or foreign currency risks. The Company
evaluates all of its financial instruments, including issued stock
purchase warrants, to determine if such instruments are derivatives
or contain features that qualify as embedded derivatives. The
classification of derivative instruments, including whether such
instruments should be classified as liabilities or as equity, is
re-assessed at the end of each reporting period.
The Public Warrants and the Private Placement Warrants are
recognized as derivative liabilities. Accordingly, the Company
recognizes the warrant instruments as liabilities at fair value and
adjusts the instruments to fair value at each reporting period. The
liabilities are subject to re-measurement at each balance sheet
date until exercised, and any change in fair value is recognized in
the Company’s Consolidated Statements of Operations and presented
as fair value adjustment on derivative warrant liabilities. The
initial and subsequent estimated fair value of both the Public
Warrants and Private Placement Warrants was based on the listed
price in an active market for the Public Warrants.
Recently Adopted Accounting Standards
Simplifying Income Taxes
In December
2019, the
Financial Accounting Standards Board (“FASB”) issued Accounting
Standards Update (“ASU”) 2019-12, Income
Taxes (Topic 740): Simplifying the Accounting for Income
Taxes, which
simplifies the accounting for income taxes by removing the
exceptions to the incremental approach for intra-period tax
allocation in certain situations, the requirement to recognize a
deferred tax liability for a change in the status of a foreign
investment, and the general methodology for computing income taxes
in an interim period when year-to date loss exceeds the
anticipated loss for the year. The amendments also simplify
the accounting for income taxes with regard to franchise tax, the
evaluation of step up in the tax basis goodwill in certain business
combinations, allocating current and deferred tax expense to legal
entities that are not subject
to tax and enacted change in tax laws or rates. The standard was
applied on a prospective basis beginning January 1, 2022 and
the adoption of this standard did not have a material effect
on the Company’s consolidated financial statements.
Leases
In February 2016, the FASB issued ASU No. 2016-02,
Leases-(Topic 842).
Under this new guidance, lessees are required to recognize for all
leases (with the exception of short-term leases): 1) a lease
liability equal to the lessee’s obligation to make lease payments
arising from a lease, measured on a discounted basis and 2) a
right-of-use asset which will represent the lessee’s right to use,
or control the use of, a specified asset for the lease term (“ROU
asset”). The Company adopted Topic 842 effective for the Company’s
annual and interim reporting periods beginning January 1, 2022. The
adoption of Topic 842 required the Company to recognize non-current
assets and liabilities for right-of-use assets and operating lease
liabilities on its Consolidated Balance Sheet, but it did not have
a material effect on the Company’s results of operations or cash
flows. Topic 842 also requires additional footnote disclosures to
the Company’s consolidated financial statements.
A modified retrospective transition approach is required, applying
the new standard to all leases existing at the date of initial
application. The Company adopted the new standard on January 1,
2022 and used the effective date as the date of initial
application. Consequently, financial information has not been
updated, and the disclosures required under the new standard will
not be provided for dates and periods before January 1,
2022.
The new standard provides a number of optional practical expedients
in transition. The Company has elected the ‘package of practical
expedients’, which permits the Company not to reassess prior
conclusions about lease identification, lease classification and
initial direct costs under the new standard. The Company has not
elected the use-of-hindsight or the practical expedient pertaining
to land easements; the latter not being applicable to the
Company.
The new standard also provides practical expedients for the
Company’s ongoing accounting. The Company has elected the
short-term lease recognition exemption for all leases that qualify.
This means, for those leases that qualify, the Company does not
recognize ROU assets or lease liabilities, and this includes not
recognizing ROU assets or lease liabilities for existing short-term
leases of those assets in transition. The Company has not elected
to apply the practical expedient to not separate lease and
non-lease components for the Company’s leases as of the transition
date of January 1, 2022 but may apply the practical expedient
prospectively to certain asset classes.
Core Scientific, Inc.
Notes to Unaudited Consolidated Financial Statements
The cumulative effect of initially applying the new lease standard
on January 1, 2022 is as follows (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
January 1, 2022 |
|
Beginning Balance |
|
Cumulative Effect Adjustment |
|
Beginning Balance, As Adjusted |
Assets |
|
|
|
|
|
Prepaid expenses and other current assets |
$ |
30,111 |
|
|
$ |
(453) |
|
|
$ |
29,658 |
|
Other noncurrent assets |
$ |
21,045 |
|
|
$ |
1,814 |
|
|
$ |
22,859 |
|
Liabilities |
|
|
|
|
|
Accrued expenses and other |
$ |
67,862 |
|
|
$ |
188 |
|
|
$ |
68,050 |
|
Other noncurrent liabilities |
$ |
18,531 |
|
|
$ |
1,173 |
|
|
$ |
19,704 |
|
The most significant judgments and impacts upon adoption of the
standard include the following:
•We
recognized right-of-use assets and operating lease liabilities for
operating leases that have not previously been recorded. The lease
liability for operating leases is based on the net present value of
future minimum lease payments. The right-of-use asset for operating
leases is based on the lease liability adjusted for the
reclassification of certain balance sheet amounts such as prepaid
rent. Deferred and prepaid rent are no longer presented separately
but are included in the balance of operating lease right-of-use
assets.
•In
determining the discount rate used to measure the right-of-use
asset and lease liability, rates implicit in the leases were not
readily available and therefore we used an estimate of our
incremental borrowing rate. Our incremental borrowing rate was
based on an estimated secured rate with reference to recent
borrowings of similar collateral and tenure.
•Certain
line items in the Consolidated Balance Sheets have been renamed to
align with the new terminology presented in the new lease standard;
“Capital lease obligations, current portion” and “Capital lease
obligations, net of current portion” are now presented as “Finance
lease liabilities, current portion” and “Finance lease liabilities,
net of current portion” on the Consolidated Balance Sheets,
respectively.
•Upon
adoption on January 1, 2022, Operating lease right-of-use assets of
$6.7 million were recorded in
Other noncurrent assets, which included $0.5 million
related to prepaid rent that was reclassified from Prepaid expenses
and other current assets and $4.8 million related to prepaid
rent and other that had already previously been presented as Other
noncurrent assets on the Consolidated Balance Sheets.
In addition, upon adoption on January 1, 2022, the current portion
of operating lease liabilities of $0.2 million were recorded
in Accrued expenses and other and the noncurrent portion of
operating lease liabilities of $1.2 million were recorded
within Other noncurrent liabilities on the Consolidated Balance
Sheets.
Accounting Standards not yet adopted
In June 2016, the FASB issued ASU 2016-13,
Financial Instruments—Measurement of Credit Losses on Financial
Instruments,
which will require an entity to measure credit losses for certain
financial instruments and financial assets, including trade
receivables. Under this update, on initial recognition and at each
reporting period, an entity will be required to recognize an
allowance that reflects the entity’s current estimate of credit
losses expected to be incurred over the life of the financial
instrument. This update will be effective for the Company with the
annual reporting period beginning January 1, 2023, including
interim periods within that reporting period. Should the company
lose its status as an “emerging growth company” as defined in the
Jumpstart Our Business Startups Act of 2012 and its status as a
“smaller reporting company” as defined in the Securities Exchange
Act of 1934, as amended, prior to this adoption date, the standard
would be applicable in the Company's Annual Report on Form 10-K for
the year ended December 31, 2022. Early adoption is permitted. The
Company is currently evaluating the impacts the adoption of this
standard will have on the consolidated financial
statements.
There are no other new accounting pronouncements that are expected
to have a significant impact on the Company’s consolidated
financial statements.
Core Scientific, Inc.
Notes to Unaudited Consolidated Financial Statements
3. ACQUISITIONS, DISPOSITIONS AND RESTRUCTURING
Blockcap Acquisition
On July 30, 2021, the Company acquired 100% of the equity interest
in Blockcap, one of its largest hosting customers. Blockcap is a
blockchain technology company with industrial scale digital asset
mining operations. Blockcap’s primary historical business was the
mining of digital asset coins and tokens, primarily Bitcoin and, to
a lesser extent, Siacoin and Ethereum. While Blockcap did sell or
exchange the digital assets it mined to fund its growth strategies
or for general corporate purposes from time to time, it generally
retained its digital assets as investments in anticipation of
continued adoption of digital assets as a “store of value” and a
more accessible and efficient medium of exchange than traditional
fiat currencies. In addition to mining, holding and exchanging
digital assets, Blockcap also evaluated and completed investments
in related technologies and ancillary businesses, including Radar
Relay, Inc. (“RADAR”), an early stage company focused on technology
enhancement and development in the digital asset industry that it
acquired on July 1, 2021. The acquisition of Blockcap significantly
expanded the Company’s self-mining operations and increased the
number of miners it owns.
Consideration consisted of the issuance of 113.9 million shares of
the Company’s common stock, approximately 6.8 million shares
of the Company’s restricted stock and approximately
7.3 million options to purchase shares of the Company’s common
stock. The acquisition has been accounted for as a business
combination using the acquisition method of accounting, whereby the
net assets acquired and the liabilities assumed were recorded at
fair value. The Company and Blockcap had preexisting relationships
which were settled on the acquisition date. Using the estimated
purchase price for the transaction, the Company has allocated the
purchase price to identifiable assets and liabilities based upon
fair value estimates. The excess of the purchase price over the
fair value of the net identifiable assets acquired was allocated to
goodwill.
In a business combination, the initial allocation of the purchase
price is considered preliminary and therefore subject to change
until the end of the measurement period (not to exceed one year
from the acquisition date). During the three months ended June 30,
2022, we determined that a measurement period adjustment to the
accounting for the Blockcap acquisition was necessary based upon
obtaining updated information about property, plant and equipment,
net acquired, resulting in an increase in fair value of property,
plant and equipment, net of $0.7 million, a decrease in
goodwill of $1.0 million and additional depreciation expense
of $0.3 million recognized in the three months ended June 30,
2022. The measurement period for the Blockcap acquisition closed
during the three months ended June 30, 2022.
The following table summarizes the fair values for each major class
of assets acquired and liabilities assumed at the acquisition date.
The Company retained the services of certified valuation
specialists to assist with assigning estimated values to certain
acquired assets and assumed liabilities. Amounts initially
disclosed for the estimated values of certain acquired assets and
liabilities assumed were adjusted through September 30, 2022
based on information arising after the initial preliminary
valuation.
Core Scientific, Inc.
Notes to Unaudited Consolidated Financial Statements
Purchase Price Allocation
|
|
|
|
|
|
Consideration: |
(in thousands) |
113.9 million common shares valued at $10.11 per
share1,2
|
$ |
1,151,985 |
|
Fair value of replaced Blockcap share-based payments attributable
to pre-combination service3
|
21,768 |
|
Settlement of Blockcap debt4
|
25,607 |
|
Settlement of preexisting contracts5
|
(60,522) |
|
|
|
Total Consideration |
$ |
1,138,838 |
|
Fair value of assets acquired, and liabilities assumed: |
|
Cash and cash equivalents |
$ |
704 |
|
|
|
Digital assets-Bitcoin |
73,304 |
|
Digital assets-Ethereum |
365 |
|
Digital assets-Bitcoin cash |
8 |
|
Digital assets-Siacoin |
554 |
|
Digital assets-Other |
3,329 |
|
Other current assets |
633 |
|
Intangible assets, net |
2,925 |
|
Property, plant and equipment, net |
98,965 |
|
Other noncurrent assets |
1,293 |
|
Total assets acquired |
$ |
182,080 |
|
Accounts payable |
492 |
|
Accrued expenses and other |
22,647 |
|
Deferred revenue |
414 |
|
Other current liabilities |
7,204 |
|
|
|
Deferred tax liability |
9,003 |
|
Total liabilities assumed |
$ |
39,760 |
|
Total identifiable net assets |
$ |
142,320 |
|
Goodwill on acquisition |
$ |
996,518 |
|
1
113.9 million common shares represent the equivalent Core
Scientific common shares issued to Blockcap shareholders as
consideration for the purchase.
2
The price per share of our common shares was estimated to be
$10.11. As the Core Scientific common shares were not listed on a
public marketplace, the calculation of the fair value of the common
shares was subject to a greater degree of estimation. Given the
absence of a public market, an estimate of the fair value of the
common shares was required at the time of the Blockcap acquisition.
Objective and subjective factors were considered in determining the
estimated fair value and because there was no active trading of the
Core Scientific equity shares on an established securities market,
an independent valuation specialist was engaged. The valuation was
determined by weighting the outcomes of scenarios estimating share
value based on both public company valuations and private company
valuations. Both a market approach and common stock equivalency
model were used to determine a range of outcomes, which were
weighted based on probability to determine the result.
3
Reflects the estimated fair value of replaced Blockcap share-based
payments allocated to purchase price based on the proportion of
service related to the pre-combination period
4
Reflects the fair value of loans issued by the Company in July 2021
that were effectively used to settle debt that had previously been
held by Blockcap. Refer to Note 6 for further discussion of the
debt issuance.
5
Blockcap had preexisting hosting and equipment contracts with the
Company that were effectively settled by the Company’s acquisition
of Blockcap. As a result, the consideration transferred to Blockcap
has been adjusted by the deferred revenue balances that were
settled at the time of acquisition.
For a reconciliation of the carrying amount of goodwill at the
beginning and end of the reporting period see Note 4.
Core Scientific, Inc.
Notes to Unaudited Consolidated Financial Statements
Intangible Assets and Liabilities
Goodwill with an assigned value of $1.00 billion represents the
excess of the consideration transferred over the estimated fair
values of assets acquired and liabilities assumed in the Blockcap
acquisition. The goodwill recognized includes the assembled
workforce of Blockcap and intangible assets that do not qualify for
separate recognition. None of the goodwill resulting from the
acquisition is deductible for income tax purposes. All of the
goodwill acquired was allocated to the Mining segment. Management
believes the acquisition of Blockcap strengthens its presence in
the digital asset mining market due to the scale of its operations.
These factors are the basis for the excess purchase price paid over
the value of the assets acquired and liabilities assumed, resulting
in goodwill.
Other intangible assets acquired in the Blockcap acquisition
consisted of $2.8 million of developed technology intangibles
and $0.1 million of customer relationships with a weighted
average useful life of 3 years.
Restructuring Activities
During the second quarter of 2022 market conditions led management
to evaluate its operations and refocus its efforts and resources on
the core activities of its hosting and mining segments. Management
initiated a plan to exit certain activities, technologies and
ancillary businesses, and to reduce portions of the Company’s
workforce including those acquired through Blockcap’s acquisition
of RADAR. Management completed the restructuring plan in October
2022 and all expected costs of the restructuring plan have been
recognized as of September 30, 2022.
At June 30, 2022 Core had accrued and expensed estimated cash
restructuring charges of $1.4 million relating to this
restructuring plan. Cash severance and related payments under the
Company’s ongoing severance policy of $0.9 million were paid
as compensation for the three months ended September 30, 2022.
At September 30, 2022 the remaining estimated cash
restructuring charges were reduced by $0.1 million for an
ending balance of $0.4 million to be paid in October 2022. In
addition to the cash restructuring charges, $1.0 million of
stock based compensation was paid in severance during the three
months ended September 30, 2022. Total cash and stock based
restructuring charges of $0.9 million and $2.3 million
were recognized in general and administrative expenses for the
three and nine months ended September 30, 2022,
respectively.
As a result of exiting Blockchain Technologies during the second
quarter of 2022, $2.0 million of intangible assets will cease
to be used. Additionally, in the third quarter of 2022, the Company
determined that $2.5 million of software intangible assets
that were previously acquired from Stax Digital LLC would no longer
be used as a result of current and planned software upgrades.
Consequently, the Company recorded an impairment of other
intangible assets of $2.5 million and $4.5 million for
three and nine months ended September 30, 2022, respectively,
which is presented within impairment of goodwill and other
intangibles on the Company’s Consolidated Statements of Operations.
Goodwill associated with these activities was included in the
goodwill impairment charge of $266.0 million and
$1.05 billion for three and nine months ended
September 30, 2022, respectively, of which $207.8 million
and $996.5 million was related to the Mining reporting unit
for the three and nine months ended September 30, 2022,
respectively, and $58.2 million was related to the Equipment
Sales and Hosting reporting unit for both the three and nine months
ended September 30, 2022.
Sale of Intangible Assets
In March 2022, the Company reclassified $2.2 million of
intangible assets that were previously acquired from Atrio Inc. and
RStor, Inc. to be held for sale as a result of the expected sale of
the software and related patents. The intangible assets were sold
in June 2022 for proceeds of $10.9 million, resulting in a gain on
sale of intangible assets of $5.9 million. The resulting gain is
reflected within other non-operating expenses, net in the Statement
of Operations.
Core Scientific, Inc.
Notes to Unaudited Consolidated Financial Statements
4. GOODWILL
The following table provides the reconciliation of the carrying
amount of goodwill by segment at the beginning and end of the
reporting period (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Equipment Sales and Hosting Segment |
|
Mining Segment |
|
Total Goodwill |
Balance as of December 31, 2021 |
$ |
58,241 |
|
|
$ |
997,519 |
|
|
$ |
1,055,760 |
|
|
|
|
|
|
|
Subsequent measurement period adjustment |
— |
|
|
(1,000) |
|
|
(1,000) |
|
Impairment of goodwill |
(58,241) |
|
|
(996,519) |
|
|
(1,054,760) |
|
Balance as of September 30, 2022 |
$ |
— |
|
|
$ |
— |
|
|
$ |
— |
|
As of September 30, 2022, after impairment, the Company had no
remaining goodwill. At December 31, 2021, the carrying amount of
goodwill was $1.06 billion. For the nine months ended
September 30, 2022 there was a measurement period adjustment
reducing goodwill by $1.0 million and accumulated impairment
losses of $1.05 billion. There were no goodwill adjustments or
impairment losses for the nine months ended September 30,
2021.
The Company does not amortize goodwill, but tests it for impairment
annually as of October 31, or more frequently if events or changes
in circumstances indicate that the carrying amount of goodwill may
not be recoverable. The Company has the option to first assess
qualitative factors to determine whether it is more likely than not
that the fair values of the reporting units are less than their
carrying amounts as a basis for determining whether it is necessary
to perform the quantitative goodwill impairment test. If management
determines that it is more likely than not that the fair value of a
reporting unit is less than the reporting unit’s carrying amount,
or management chooses not to perform a qualitative assessment, then
the quantitative goodwill impairment test will be performed. The
quantitative test compares the fair value of the reporting unit
with the reporting unit’s carrying amount. If the carrying amount
exceeds its fair value, the excess of the carrying amount over the
fair value is recognized as an impairment loss, and the resulting
measurement of goodwill becomes its new cost basis. The Company’s
reporting units are the same as its reportable and operating
segments.
The Company identified goodwill impairment triggering events as of
June 30, 2022 and additional triggering events as of
September 30, 2022. These events included declines in the
market price of bitcoin, the market price of the Company’s stock
and the Company’s market capitalization. As a result, the Company
performed the quantitative test to compare the fair value to the
carrying amount for each reporting unit at June 30, 2022. Sustained
and further deterioration in market prices and in the Company’s
financial position resulted in additional quantitative testing at
September 30, 2022. The Company concluded that the carrying value
of the Mining reporting unit exceeded its fair value and, as such,
recorded a $788.7 million and a $207.8 million impairment
of goodwill in its Mining reporting unit for the three months ended
June 30, 2022 and September 30, 2022, respectively. At
June 30, 2022, the Company concluded that the fair value of
the Equipment Sales and Hosting reporting unit exceeded its
carrying amount, with an excess of fair value over carrying amount
of approximately 136% of the carrying amount, and as such, did not
record an impairment in its Equipment Sales and Hosting reporting
unit at June 30, 2022. At September 30, 2022, the Company
concluded the carrying amount of the Equipment Sales and Hosting
reporting unit exceeded its fair value and, as such, recorded a
$58.2 million impairment of goodwill in its Equipment Sales
and Hosting reporting unit for the three and nine months ended
September 30, 2022. These impairments are presented within
impairment of goodwill and other intangibles on the Company’s
Consolidated Statements of Operations.
The Company’s analysis as of September 30, 2022 involved the use of
a market approach. Valuations using the market approach are derived
from metrics of market transactions. Significant judgments and
assumptions used in the market approach includes the selection of
comparable businesses based on the characteristics of each
reporting unit, the consideration and application of relevant
relative metrics and a reconciliation to the Company’s market
capitalization to the fair value measured. Sustained depressed
bitcoin market value, increased power costs, decreased liquidity,
and increased cost of financing, along with other factors have
contributed to significant and sustained deterioration in the
Company’s market capitalization. The Company concluded that the
fair value of its reporting units would no longer support the
remaining acquired goodwill carrying values. The Company developed
its estimates using the best information available at the time.
Changes in management’s estimates or any of its other assumptions
used in its analysis could result in a different
conclusion.
Core Scientific, Inc.
Notes to Unaudited Consolidated Financial Statements
5. DERIVATIVE WARRANT LIABILITIES
As of September 30, 2022, the Company
had 14.9 million warrants outstanding including: (a)
8.6 million
Public Warrants and (b)
6.3 million
Private Placement Warrants issued to
XPDI Sponsor LLC (“Sponsor”) and certain institutional investors
(“Anchor Investors”).
Each Public Warrant and Private Placement Warrant became
exercisable 30 days following the Closing Date of the XPDI Merger
and may be exercised for one share of common stock at an exercise
price of
$11.50
per share. The Public Warrants and Private Placement Warrants
expire January 19, 2027, which is five years after the Closing
Date.
Redemption of Public Warrants when the price per share of common
stock equals or exceeds
$18.00
Once the warrants become exercisable, the Company may redeem the
outstanding Public Warrants:
•in
whole and not in part;
•at
a price of $0.01 per warrant;
•upon
a minimum of 30 days’ prior written notice of redemption to each
warrant holder; and
•if,
and only if, the last reported sale price of common stock for any
20 trading days within a 30-trading day period ending on the third
trading day prior to the date on which the Company sends the notice
of redemption to the warrant holders equals or exceeds
$18.00
per share (as adjusted).
The Company will not redeem the warrants as described above unless
a registration statement under the Securities Act covering the
issuance of the shares of common stock issuable upon exercise of
the warrants is then effective and a current prospectus relating to
those shares of common stock is available throughout the 30-day
redemption period. If and when the warrants become redeemable by
the Company, the Company may exercise its redemption right even if
it is unable to register or qualify the underlying securities for
sale under all applicable state securities laws.
Redemption of Public Warrants when the price per share of common
stock equals or exceeds $10.00
Once the warrants become exercisable, the Company may redeem the
outstanding Public Warrants:
•in
whole and not in part;
•at
$0.10 per warrant upon a minimum of 30 days’ prior written notice
of redemption provided that holders will be able to exercise their
warrants on a cashless basis prior to redemption and receive that
number of shares determined by reference to an agreed table based
on the redemption date and the “fair market value” (as defined
below) of common stock;
•if,
and only if, the last reported sales price of the Company’s common
stock for any twenty (20) trading days within the thirty (30)
trading-day period ending on the third trading day prior to the
date on which notice of the redemption is given (the “Reference
Value”) equals or exceeds $10.00 per share (as adjusted for
adjustments to the number of shares issuable upon exercise or the
exercise price of a warrant); and
•if
the Reference Value is less than $18.00 per share (as adjusted for
adjustments to the number of shares issuable upon exercise or the
exercise price of a warrant), the Private Placement Warrants must
also concurrently be called for redemption on the same terms as the
outstanding Public Warrants, as described above.
•The
“fair market value” of common stock shall mean the volume-weighted
average price of common stock during the 10 trading days
immediately following the date on which the notice of redemption is
sent to the holders of warrants. In no event will the warrants be
exercisable in connection with this redemption feature for more
than 0.361 shares of Class A common stock per warrant (subject to
adjustment).
Redemption of Private Placement Warrants
The terms of redemption of Private Placement Warrants are identical
in all respects to those for the Public Warrants except that, so
long as they are held by the Sponsor, Anchor Investors or their
permitted transferees they will not be redeemable, except as
described above in Redemption of Public Warrants when the price per
share of common stock equals or exceeds $10.00. If the Private
Placement Warrants are held by someone other than the Sponsor, the
Anchor Investors or their respective permitted transferees, the
Private Placement Warrants will be redeemable by the Company and
exercisable by such holders on the same basis as the Public
Warrants.
Core Scientific, Inc.
Notes to Unaudited Consolidated Financial Statements
Registration
If the Company fails to maintain a registration statement for the
underlying common shares at any time, the holders of the Private
Placement Warrants and Public Warrants may exercise such warrants
on a cashless basis by exchanging the warrants for that number of
shares of common stock equal to the lesser of (A) the quotient
obtained by dividing (x) the product of the number of shares of
common stock underlying the Warrants, multiplied by the excess of
the “Fair Market Value” (as defined below) less the Warrant Price
by (y) the Fair Market Value and (B) the product of the number of
Warrants surrendered and 0.361, subject to adjustment. “Fair Market
Value” shall mean the volume-weighted average price of the shares
of common stock as reported during the ten (10) trading day period
ending on the trading day prior to the date that notice of exercise
is received.
Classification
Both the Public Warrants and Private Placement Warrants are
classified as a liability
on the Company’s Consolidated Balance Sheet because their
settlement amount is subject to change based on the existence of an
effective registration statement for the underlying shares and the
holder of the warrant (for Private Placement Warrants only). As of
September 30, 2022, the liability balance was
$5.3 million.
For the three months ended September 30, 2022, the Company
recorded a mark to market gain of $0.3 million and
$0.2 million within the Consolidated Statement of Operations
for the Public Warrants and Private Placement Warrants,
respectively. For the nine months ended September 30, 2022,
the Company recorded a mark to market gain of $19.1 million
and $13.9 million within the Consolidated Statement of
Operations for the Public Warrants and Private Placement Warrants,
respectively. Refer to Note 8 for further information about the
fair value measurement of the warrants.
Core Scientific, Inc.
Notes to Unaudited Consolidated Financial Statements
6. NOTES PAYABLE
Notes payable as of September 30, 2022 and December 31,
2021 consist of the following (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
September 30
2022 |
|
December 31
2021 |
Kentucky note |
$ |
657 |
|
|
$ |
1,032 |
|
|
|
|
|
|
|
|
|
Genesis loan |
— |
|
|
552 |
|
|
|
|
|
NYDIG loan |
38,781 |
|
|
67,435 |
|
Stockholder loan |
10,000 |
|
|
10,000 |
|
Trinity loan |
24,067 |
|
|
19,641 |
|
Bremer loan |
19,232 |
|
|
15,066 |
|
Blockfi loan |
53,913 |
|
|
60,000 |
|
Anchor Labs loan |
26,500 |
|
|
— |
|
Mass Mutual Barings loans |
63,845 |
|
|
— |
|
B. Riley Bridge Notes |
52,125 |
|
|
— |
|
Liberty loan |
7,401 |
|
|
— |
|
Secured Convertible Notes1
|
230,931 |
|
|
220,871 |
|
Other Convertible Notes2
|
313,381 |
|
|
301,226 |
|
Other |
1,866 |
|
|
663 |
|
Total |
842,699 |
|
|
696,486 |
|
Unamortized discount and debt issuance costs |
(3,618) |
|
|
(3,187) |
|
Fair value adjustment on convertible notes |
138,519 |
|
|
34,910 |
|
Total notes payable, net |
$ |
977,600 |
|
|
$ |
728,209 |
|
1
Secured Convertible Notes (includes principal balance at issuance
and PIK interest) which considers the minimum payoff at maturity of
two times the face value of the note plus accrued interest. The
minimum payoff at maturity related to the principal balance was
$461.9 million on September 30, 2022. The minimum payoff at
maturity related to the principal balance was $441.7 million
on December 31, 2021.
2
Other Convertible Notes which considers the minimum payoff at
maturity of one times the face value of the note plus accrued
interest.
Balance Sheet Classification
In October 2022 the Company determined not to make certain payments
with respect to several of its debt facilities, equipment financing
facilities and leases and other financings, including its two
bridge promissory notes. As a result, the creditors under these
debt facilities may exercise remedies following any applicable
grace periods, including electing to accelerate the principal
amount of such debt, suing the Company for nonpayment, increasing
interest rates to default rates, or taking action with respect to
collateral, where applicable. The Company does not believe that it
was in default under any of its debt agreements as of September 30,
2022. In the event of a default, the Company may become subject to
certain additional provisions in its debt agreements such as higher
default interest rates. As a result of these factors, the Company
has determined that it is probable that its notes payable will
become due within one year and has therefore classified all of its
notes payable as current liabilities as of September 30,
2022.
Kentucky Note—In
December 2018, the Company entered into a
five-year
secured promissory note agreement for $2.4 million in connection
with the acquisition of property in Kentucky for datacenter
development (“Kentucky note”). The note bears interest at a rate
per annum of
5%
and the Company is required to make monthly payments of principal
and interest. Interest expense on the note has been recognized
based on an effective interest rate of
5%.
The loan is secured by the underlying property
purchased.
Genesis Loan—In
July 2020, the Company entered into a credit facility with Genesis
Global Capital, LLC that provides capacity of up to
$13.0 million
to finance the Company’s acquisition of blockchain computing
equipment (“Genesis loan”). The Company borrowed
$5.3 million
in three installments and the borrowing capacity of the facility
was reduced via an amendment in September 2020 to equal the actual
amounts borrowed. The loans under the credit facility are secured
by the blockchain computing equipment and the Company is required
to comply with an approved mining strategy and other restrictions
on use of the collateral. Loans under the credit facility have
terms of 20 months, bear interest at a rate per annum of 16% plus a
fixed risk premium, and require monthly payments. Interest expense
on the loans has been recognized based on an effective interest
rate of 28%, which includes the amortization of a debt discount.
The loan is secured by blockchain computing equipment financed by
the loans. The loan was paid off in April 2022.
Core Scientific, Inc.
Notes to Unaudited Consolidated Financial Statements
NYDIG Loan—In
October 2020, the Company entered into a master equipment finance
agreement with NYDIG and received a loan of
$0.8 million
to finance the Company’s acquisition of blockchain computing
equipment. In March 2021, the Company received $3.8 million of
additional loans under the master equipment finance agreement with
NYDIG to finance the Company’s acquisition of blockchain computing
equipment. The loans bear an interest rate of 15% and have a term
of 24 months from issuance. Interest expense on the loans has been
recognized based on an effective interest rate of 16%. The loans
are secured by the blockchain computing equipment financed by the
loans.
In May 2021, the Company received $13.4 million of additional
loans under the master equipment finance agreement with NYDIG to
finance the Company’s acquisition of blockchain computing equipment
that bear an interest rate of 14.25% and have a term of 24 months
from issuance. Interest expense on the loans issued in May 2021 has
been recognized based on an effective interest rate of
17%.
In July 2021, the Company received blockchain computing equipment
from NYDIG (which had been concurrently acquired by NYDIG from
Blockcap in exchange for settlement of Blockcap’s debt with NYDIG)
in exchange for $26.1 million of additional loans under the
master equipment finance agreement with NYDIG that bear an interest
rate of 14.25% and have a term of 24 months from issuance. Interest
expense on the loans issued in July 2021 has been recognized based
on an effective interest rate of 16%.
In November 2021, the Company received blockchain computing
equipment from NYDIG in exchange for $33.4 million of
additional loans under the master equipment finance agreement with
NYDIG that bear an interest rate of 11% and have a term of 24
months from issuance. Interest expense on the loans issued in
November 2021 has been recognized based on an effective interest
rate of 11%.
Stockholder Loan—In
January 2021, the Company borrowed $10.0 million from a
stockholder for the purchase of blockchain computing equipment. The
loan bears interest at 10% per annum over
a two-year term. The loan was issued with a warrant to
purchase 0.2 million shares of common stock at an exercise
price of $4.21 per share. The warrant has
a two-year term. The Company allocated proceeds of
$9.5 million to the notes and $0.5 million to the
warrants on a relative fair value basis. Interest expense on the
loan has been recognized based on an effective interest rate of
20%. The loan is secured by the blockchain computing equipment
financed by the loan.
Trinity Loan—In
August 2021, the Company entered into a $30.0 million master
equipment finance facility agreement with Trinity Capital Inc.
(“Trinity”) to finance the Company’s acquisition of blockchain
computing equipment and received a loan of $1.0 million at
close. The loan has a term of 36 months from issuance. Interest
expense on the loan has been recognized based on an effective
interest rate of 11.0%. In November and December 2021, the Company
borrowed $14.0 million and $5.0 million, respectively.
The remaining balance of $10.0 million was drawn in February
2022. The loan is secured by the blockchain computing equipment
financed by the loan.
Bremer Loan—In
October 2021, the Company entered into a lending agreement with
Bremer Bank, National Association to borrow up to
$16.2 million in two tranches through May 22, 2022 for
the purchase of blockchain mining equipment and for improvements to
data center and infrastructure. In December 2021, the Company
entered into an additional term loan to borrow up to
$9.6 million. The Company borrowed $15.2 million in
October through December 2021. The Company borrowed an additional
$4.8 million in January through March 2022. In April 2022, the
Company borrowed an additional $0.7 million from Bremer to
finance the construction of our North Dakota facility. The loans
bear interest at 5.5% annually and are due at the earlier of the
date of sale of the underlying mining equipment or 60 months from
issuance. Interest expense on the loans has been recognized based
on an effective interest rate of 5.6%. The loans require the
Company to maintain the following financial covenants: (1) a
minimum debt service coverage ratio (defined in the agreement as
EBITDA divided by scheduled principal and interest payments) of not
less than 1.2:1, measured annually beginning December 31, 2022; and
(2) a fixed charge coverage ratio (defined in the agreement as
EBITDA minus net distributions divided by scheduled principal and
interest payments) of 1:1, measured annually beginning December 31,
2022. The loans are secured by a first priority security interest
in certain of the assets financed by the loans.
Core Scientific, Inc.
Notes to Unaudited Consolidated Financial Statements
Additionally, an interest buydown agreement was made between Grand
Forks Growth Fund and the Bank of North Dakota acting on behalf of
the PACE Program for the purpose of a buydown on the interest for
certain of the Company’s loans financed through Bremer Bank. The
total amount of interest buydown over the term of the loan is
$0.8 million. In order to receive the interest buydown
incentive, the Company must (a) continue operation in the
jurisdiction for a minimum of five years from the benefit date, (b)
employ 13 new full-time employees within two years of receiving the
incentive and continue to keep them employed for the duration of
the agreement and (c) continue to make debt payments and no event
of default should occur. If the Company discontinues operation in
the jurisdiction within the next five years, it is obligated to
repay the incentive back to the Bank of North Dakota. If after two
years, the Company does not employ 13 new full-time employees, the
interest buydown will be prorated to reflect any partial
fulfillment and the Company, at a minimum, is required to pay back
the value of the incentive to the Bank of North Dakota. For the
nine months ended September 30, 2022 and 2021, there was no
interest buydown.
Blockfi Loan—In
December 2021, the Company entered into two lending agreements with
Blockfi Lending, LLC to borrow up to $110.0 million for the
purchase of blockchain mining equipment. The first agreement
consists of $10.0 million and bears interest at 9.7% with a
term of 24 months from issuance. Interest expense on the loans
issued in December 2021 has been recognized based on an effective
interest rate of 10.1%. The second agreement consists of
$100.0 million and bears interest at 13.1% with a term of 24
months from issuance. The Company borrowed the first tranche
totaling $60.0 million across the two loans in December 2021
and borrowed the second tranche of $20.0 million in January
2022. The remaining $30.0 million expired unused in March
2022. Interest expense on the loans issued in December 2021 has
been recognized based on an effective interest rate of 13.1%. The
loans are secured by a first priority security interest in certain
of the assets financed by the loans.
Anchor Labs Loan—In
March 2022, the Company entered into a $20.0 million equipment
loan and security agreement with Anchorage Lending CA, LLC.
(“Anchor Labs”) to finance the Company’s purchase of blockchain
computing equipment. The Company borrowed $20.0 million in
March 2022. The loan has a term of 24 months from issuance.
Interest expense on the loan has been recognized based on an
effective interest rate of 12.5%. In May 2022, the Company entered
into a $11.7 million equipment loan and security agreement
with Anchor Labs to finance the Company’s purchase of blockchain
computing equipment. The Company borrowed $11.7 million in May
2022. The loan has a term of 24 months from issuance. Interest
expense on the loan has been recognized based on an effective
interest rate of 12.5%. The loans are secured by a first priority
security interest in certain of the assets financed by the
loans.
Mass Mutual Barings Loans—In
March 2022, the Company entered into a $100.0 million
equipment loan and security agreement with Barings BDC, Inc.,
Barings Capital Investment Corporation and Barings Private Credit
Corp. (“Mass Mutual Barings”) to finance the Company’s purchase of
blockchain computing equipment. The Company borrowed the first
tranche of $30.0 million in March 2022 and borrowed the second
tranche of $39.6 million in April 2022. On June 30, 2022 the
remaining $30.4 million funding commitment expired unused. The
loans under the agreement have a term of 36 months from issuance.
Interest expense on the loans have been recognized based on an
effective interest rate of 9.8%. The loans are secured by certain
blockchain computing equipment.
In August 2022, the Company amended the Mass Mutual Barings loans
to defer principal payments for a period of six months beginning
with payments due in August 2022. The amendments result in no
change to the term of the loans and the remaining principal will
amortize over the remaining life of the loans beginning in February
2023. The amendments also require an additional amount of
blockchain computing equipment to be provided as collateral.
Interest expense on the amended loans has been recognized based on
an effective interest rate of 13.0%. In August 2022, the Company
issued 0.3 million shares of Common Stock to Mass Mutual
Barings as an amendment fee.
Core Scientific, Inc.
Notes to Unaudited Consolidated Financial Statements
B. Riley Bridge Notes—In
April 2022, the Company entered into a $60.0 million bridge
promissory note with B. Riley Commercial Capital, LLC and a
$15.0 million bridge promissory note with an affiliate of B.
Riley Commercial Capital, LLC (the “Bridge Notes”) maturing in
December 2022. Interest expense on the Bridge Notes has been
recognized based on an effective interest rate of
7.0%.
In August 2022, the Company amended the Bridge Notes to, among
other things, extend the maturity date to June 2023 (the “Amended
Bridge Notes”). Under the terms of the modified agreement,
$37.5 million of principal payments previously due in the
second half of 2022 are now due in the first half of 2023. The
Amended Bridge Notes require the proceeds of (i) any equity
issuances (other than issuances consummated for purposes of making
tax payments in connection with the vesting of restricted stock and
restricted stock units and equity line of credit under the Equity
Line of Credit discussed in Note 12 (“ELOC”) sales), (ii) any
secured debt incurred on or after April 7, 2022 (other than
purchase money debt) in excess of $500 million and (iii) any
ELOC sales in an amount equal to 25% of the net cash proceeds
received from any such ELOC sale, in each case, to be applied by us
to repay the outstanding principal amount of the Amended Bridge
Notes. On August 1, 2022, the Company issued a total of
0.4 million shares of Common Stock to B. Riley Securities,
Inc., an affiliate of B. Riley Commercial Capital, in satisfaction
of an advisory fee for providing advisory services to the Company
in connection with entering into the Amended Bridge
Notes.
Liberty Loan—In
April 2022, the Company entered into an $11.0 million
equipment finance agreement with Liberty Commercial Finance LLC
(“Liberty”) to finance the Company’s purchase of blockchain
computing equipment. The Company borrowed $11.0 million in
April 2022. The loan has a term of 24 months from issuance.
Interest expense on the loan has been recognized based on an
effective interest rate of 10.6%. The loans are secured by a first
priority security interest in the equipment purchased.
Convertible Notes—In
April 2021, the Company entered into a secured convertible note
purchase agreement and issued $215.0 million of secured
convertible notes to new and existing lenders (the “Secured
Convertible Notes”). In addition, in August 2021 the Company
entered into a convertible note purchase agreement and issued
$299.8 million of convertible notes in August through November
2021 under substantially the same terms and conditions as the
original April 2021 notes except that the August through November
2021 notes have a minimum payoff based on the face value plus
accrued interest rather than two times the outstanding face amount
plus accrued interest. In addition, the August through November
2021 notes were unsecured until an IPO or SPAC merger and then
became secured by a lien on the same collateral securing the
Secured Convertible Notes in January 2022 upon the closing of the
Merger Agreement with XPDI (together with the Secured Convertible
Notes, the “Convertible Notes”). In addition, the Company also
issued $31.0 million from issuance through September 30,
2022 as payment-in-kind interest on convertible notes outstanding
at the end of the period. The Convertible Notes have a maturity
date of April 2025 and bear interest at a rate of 10% per annum, of
which 4% is payable in cash and 6% is payable in kind. Upon the
closing of the Merger Agreement with XPDI in January 2022, the
Convertible Notes became convertible into common shares at the
option of the holder at a conversion price equal to $8.00 per
share. The proceeds from the Convertible Notes were used, in part,
to repay $30.0 million of senior secured loans to Silverpeak
Credit Partners LP. During the nine months ended September 30,
2022, $1.6 million of Convertible Notes were exercised
resulting in 0.2 million shares issued to the holders of the
Convertible Notes that were exercised.
As discussed in Note 8, the Company has elected to measure its
Convertible Notes at fair value and accordingly recognized
$13.1 million of debt issuance costs as incurred at the time
of issuance within interest expense, net in the Company’s
Consolidated Statements of Operations and Comprehensive loss. The
Convertible Notes had a fair value of $682.8 million compared
to a principal amount of $544.3 million at September 30,
2022. The Company presents changes in fair value of the Convertible
Notes during the period as follows: (1) the 10% contractual rate of
interest on the convertible notes (consisting of 4% cash interest
and 6% PIK interest) is presented as interest expense, net on the
Consolidated Statements of Operations; (2) changes in fair value
attributable to the Company’s own credit risk are presented within
Accumulated other comprehensive loss on the Consolidated Balance
Sheets and as a component of Other comprehensive income (loss) on
the Consolidated Statements of Comprehensive Loss; and (3) other
fair value changes are presented within Non-operating expenses, net
on the Consolidated Statements of Operations.
The fair value of the Company’s convertible notes as of December
31, 2021 included the effect of a negotiation discount, which is a
calibration adjustment that reflects the illiquidity of the
instruments and the Company's negotiating position. Since the
transaction was an orderly transaction, the Company deemed that the
fair value equaled the transaction price at initial recognition.
However, the closing of the merger of XPDI (which represents the
occurrence of a qualified financing event as defined by the terms
of the notes) in January 2022 resulted in the elimination of the
negotiation discount along with other changes in fair value
resulted in a significant increase in the fair value of the
convertible notes (excluding interest expense and
instrument-specific credit risk) for the nine months ended
September 30, 2022.
Core Scientific, Inc.
Notes to Unaudited Consolidated Financial Statements
The following summarizes the fair value adjustments and debt
issuance costs recognized on the convertible notes (in
thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Financial statement line item |
|
Three Months Ended
September 30, 2022 |
|
Nine Months Ended
September 30, 2022 |
Cash interest payments |
|
Interest expense, net |
|
$ |
5,488 |
|
|
$ |
16,070 |
|
Payment-in-kind (PIK) interest |
|
Interest expense, net |
|
8,232 |
|
|
24,115 |
|
Instrument-specific credit risk |
|
Other comprehensive income, net of income taxes |
|
(47,832) |
|
|
(83,578) |
|
Other fair value adjustments |
|
Fair value adjustment on convertible notes |
|
(4,123) |
|
|
186,853 |
|
Total fair value adjustments |
|
|
|
$ |
(38,235) |
|
|
$ |
143,460 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Financial statement line item |
|
Three Months Ended
September 30, 2021 |
|
Nine Months Ended
September 30, 2021 |
Cash interest payments |
|
Interest expense, net |
|
$ |
3,130 |
|
|
$ |
4,850 |
|
Payment-in-kind (PIK) interest |
|
Interest expense, net |
|
4,694 |
|
|
7,274 |
|
Instrument-specific credit risk |
|
Other comprehensive loss, net of income taxes |
|
8,552 |
|
|
8,552 |
|
Other fair value adjustments |
|
Fair value adjustment on convertible notes |
|
8,663 |
|
|
8,663 |
|
Total fair value adjustments |
|
|
|
$ |
25,039 |
|
|
$ |
29,339 |
|
Debt issuance costs |
|
Interest expense, net |
|
$ |
5,083 |
|
|
$ |
10,664 |
|
The principal amount of the Convertible Notes as of
September 30, 2022 reflects the proceeds received plus any PIK
interest added to the principal balance of the notes. Upon the
closing of the Merger Agreement with XPDI in January 2022, the
conversion price for the Convertible Notes became fixed at 80% of
the financing price ($8.00 per share of common stock) and the
holders now have the right to convert at any time until maturity.
At maturity, any Secured Convertible Notes not converted will be
owed two times the original face value plus accrued interest; any
other Convertible Notes (other than the Secured Convertible Notes)
not converted will be owed the original face value plus accrued
interest. In addition, at any time (both before and after the
merger with XPDI), the Company has the right to prepay the Secured
Convertible Notes at the minimum payoff of two times the
outstanding face value plus accrued interest and for other
Convertible Notes the outstanding face value plus accrued interest.
All of the Convertible Notes, totaling $544.3 million as of
September 30, 2022, are scheduled to mature on April 19, 2025,
which includes $230.9 million for the face value of the Secured
Convertible Notes which have payoff at maturity of two times the
face value of the note plus accrued interest. The total amount that
would be owed on the Secured Convertible Notes outstanding as of
September 30, 2022 if held to maturity was $461.9 million. The
total amount that would be owed on the Convertible Notes if prepaid
as of September 30, 2022 was $789.0 million. See Note 8 for
further information on fair value measurement of the Convertible
Notes.
Core Scientific, Inc.
Notes to Unaudited Consolidated Financial Statements
7. REVENUE
The Company primarily generates revenue from hosting services,
sales of computer equipment and digital asset mining activities.
The Company generally recognizes revenue when the promised service
is performed, or control of the promised equipment is transferred
to customers. Revenue excludes any amounts collected on behalf of
third parties, including sales and indirect taxes.
Deferred Revenue
The Company records contract liabilities in deferred revenue on the
Consolidated Balance Sheets when cash payments are received in
advance of performance and recognizes them as revenue when the
performance obligations are satisfied. The Company’s deferred
revenue balance as of September 30, 2022 and December 31,
2021 was $87.2 million and $136.4 million, respectively, all from
advance payments received during the periods then
ended.
For the three and nine months ended September 30, 2022, the
Company recognized $30.9 million and $79.6 million of revenue,
respectively, that was included in the deferred revenue balance as
of the beginning of the year, primarily due to the deployment of
equipment for related parties for which advanced payments had been
received prior to January 1, 2022. For the three and nine months
ended September 30, 2021, the Company recognized $5.2 million
and $44.2 million of revenue, respectively, that was included in
the deferred revenue balance as of the beginning of the year,
primarily due to deployment of customer equipment for which advance
payments had been received from customers prior to January 1, 2021.
Advanced payments received for hosting services are typically
recognized as revenue within six months after miner deployment.
Advanced payments received for equipment sales are generally
recognized as revenue within one year.
Performance Obligations
The Company’s performance obligations primarily relate to hosting
services and equipment sales. The Company has performance
obligations associated with commitments in customer hosting
contracts for future services and commitments to acquire and deploy
customer equipment that have not yet been recognized in the
financial statements. For contracts with original terms that exceed
one year (typically ranging from 18 to 48 months), those
commitments not yet recognized as of September 30, 2022 and
2021 were $440.7 million and $718.8 million,
respectively.
Core Scientific, Inc.
Notes to Unaudited Consolidated Financial Statements
8. FAIR VALUE MEASUREMENTS
The Company measures certain assets and liabilities at fair value
on a recurring or non-recurring basis in certain
circumstances. Fair value is defined as the price that would be
received to sell an asset or paid to transfer a liability in an
orderly transaction between market participants at the measurement
date. To increase the comparability of fair value measures, the
following hierarchy prioritizes the inputs to valuation
methodologies used to measure fair value:
Level 1 — Valuations based on quoted prices for identical
assets and liabilities in active markets.
Level 2 — Valuations based on observable inputs other than
quoted prices included in Level 1, such as quoted prices for
similar assets and liabilities in active markets, quoted prices for
identical or similar assets and liabilities in markets that are not
active, or other inputs that are observable or can be corroborated
by observable market data.
Level 3 — Valuations based on unobservable inputs reflecting
the Company’s own assumptions, consistent with reasonably available
assumptions made by other market participants. These valuations
require significant judgment.
The Company uses observable market data when determining fair value
whenever possible and relies on unobservable inputs only when
observable market data is not available.
Recurring fair value measurements
The Public Warrants and the Private Placement Warrants are
recognized as derivative liabilities in accordance with ASC
815,
Derivatives and Hedging.
Accordingly, the Company recognizes the warrant instruments as
liabilities at fair value and adjusts the instruments to fair value
at each reporting period. The liabilities are subject to
remeasurement at each balance sheet date until exercised, and any
change in fair value is recognized in the Company’s Consolidated
Statements of Operations. The initial and subsequent fair value
estimates of the Public Warrants and Private Placement Warrants are
based on the listed price in an active market for such
warrants.
The Company has elected to measure its Convertible Notes at fair
value on a recurring basis because the Company believes it better
reflects the underlying economics of the Convertible Notes, which
contain multiple embedded derivative features. The fair value of
the Company’s convertible notes payable is determined using a
market approach based on observable market prices for similar
securities when available.
Prior to the three months ended June 30, 2022, when observable
market data was not available, the Company used an as-converted
value plus risk put option model that included certain unobservable
inputs that were significant to the fair value measurement such as
probability of a financing event occurring (e.g., a SPAC merger or
qualified financing), expected term, volatility and the negotiation
discount. The fair value of the Secured Convertible Notes
considered the minimum payoff at maturity of two times the face
value of the note plus accrued interest, as well as the opportunity
for appreciation if the value of the Company's stock increased 60%
or more relative to the pricing at the financing event (since the
conversion price is set at 80% of the stock price at the financing
event, a stock price appreciation of 60% would match the minimum
payoff of two times the face value plus accrued interest). The fair
value of the other Convertible Notes considered the minimum payoff
at maturity of one times the face value of the note plus accrued
interest, as well as the opportunity for appreciation if the value
of the Company's stock were to fall no more than 20% relative to
the pricing at the financing event (since the conversion price is
set at 80% of the stock price at the financing event, a stock price
decline of 20% would match the minimum payoff of one times the face
value plus accrued interest). Upon the closing of the Merger
Agreement with XPDI in January 2022, the conversion price for the
Convertible Notes became fixed at 80% of the financing price ($8.00
per share of common stock) and the holders now have the right to
convert at any time until maturity.
Due to the occurrence of the SPAC merger and the subsequent
significant decline in the Company’s stock price below the
conversion price, the fair value of the Company’s convertible notes
beginning with the three months ended June 30, 2022 was determined
using a discounted cash flow model that considers the principal and
interest payments, including the minimum payoff at maturity of two
times the face value of the note plus accrued interest for the
Secured Convertible Notes and the value of the call option that
includes certain unobservable inputs that may be significant to the
fair value measurement such as expected term and volatility of the
call option.
The following presents the levels of the fair value hierarchy for
the Company's derivative warrant liabilities and the Convertible
Notes by issuance date measured at fair value on a recurring basis
as of September 30, 2022 and December 31, 2021 (in
thousands):
Core Scientific, Inc.
Notes to Unaudited Consolidated Financial Statements
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
September 30, 2022 |
|
|
|
Fair value hierarchy |
|
|
|
Principal |
|
Level 1 |
|
Level 2 |
|
Level 3 |
|
Fair value |
Derivative warrant liabilities: |
|
|
|
|
|
|
|
|
|
Public Warrants |
$ |
— |
|
|
$ |
3,062 |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
3,062 |
|
Private Placement Warrants |
— |
|
|
— |
|
|
2,225 |
|
|
— |
|
|
2,225 |
|
Total derivative warrant liabilities |
— |
|
|
3,062 |
|
|
2,225 |
|
|
— |
|
|
5,287 |
|
Convertible notes: |
|
|
|
|
|
|
|
|
|
April 19, 20211
|
$ |
95,595 |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
162,797 |
|
|
$ |
162,797 |
|
April 21, 20211
|
5,370 |
|
|
— |
|
|
— |
|
|
9,146 |
|
|
9,146 |
|
April 23, 20211
|
48,334 |
|
|
— |
|
|
— |
|
|
82,313 |
|
|
82,313 |
|
April 26, 20211
|
81,632 |
|
|
— |
|
|
— |
|
|
139,017 |
|
|
139,017 |
|
August 20, 20212
|
52,902 |
|
|
— |
|
|
— |
|
|
46,306 |
|
|
46,306 |
|
September 10, 20212
|
15,792 |
|
|
— |
|
|
— |
|
|
14,248 |
|
|
14,248 |
|
September 23, 20212
|
78,989 |
|
|
— |
|
|
— |
|
|
71,269 |
|
|
71,269 |
|
September 24, 20212
|
62,749 |
|
|
— |
|
|
— |
|
|
56,616 |
|
|
56,616 |
|
September 27, 20212
|
2,064 |
|
|
— |
|
|
— |
|
|
1,863 |
|
|
1,863 |
|
October 1, 20212
|
90,615 |
|
|
— |
|
|
— |
|
|
81,758 |
|
|
81,758 |
|
November 10, 20212
|
10,270 |
|
|
— |
|
|
— |
|
|
9,266 |
|
|
9,266 |
|
Accrued PIK interest1,2,3
|
— |
|
|
— |
|
|
— |
|
|
8,232 |
|
|
8,232 |
|
Total convertible notes |
544,312 |
|
|
— |
|
|
— |
|
|
682,831 |
|
|
682,831 |
|
Total liabilities measured at fair value on a recurring
basis |
$ |
544,312 |
|
|
$ |
3,062 |
|
|
$ |
2,225 |
|
|
$ |
682,831 |
|
|
$ |
688,118 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31, 2021 |
|
|
|
Fair value hierarchy |
|
|
|
Principal |
|
Level 1 |
|
Level 2 |
|
Level 3 |
|
Fair value |
Convertible notes: |
|
|
|
|
|
|
|
|
|
April 19, 20211
|
$ |
91,430 |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
101,078 |
|
|
$ |
101,078 |
|
April 21, 20211
|
5,137 |
|
|
— |
|
|
— |
|
|
5,674 |
|
|
5,674 |
|
April 23, 20211
|
46,229 |
|
|
— |
|
|
— |
|
|
51,062 |
|
|
51,062 |
|
April 26, 20211
|
78,075 |
|
|
— |
|
|
— |
|
|
86,165 |
|
|
86,165 |
|
August 20, 20212
|
50,597 |
|
|
— |
|
|
— |
|
|
50,941 |
|
|
50,941 |
|
September 10, 20212
|
16,110 |
|
|
— |
|
|
— |
|
|
16,472 |
|
|
16,472 |
|
September 23, 20212
|
76,051 |
|
|
— |
|
|
— |
|
|
77,559 |
|
|
77,559 |
|
September 24, 20212
|
60,016 |
|
|
— |
|
|
— |
|
|
61,179 |
|
|
61,179 |
|
September 27, 20212
|
1,974 |
|
|
— |
|
|
— |
|
|
2,012 |
|
|
2,012 |
|
October 1, 20212
|
86,655 |
|
|
— |
|
|
— |
|
|
87,150 |
|
|
87,150 |
|
November 10, 20212
|
9,823 |
|
|
— |
|
|
— |
|
|
9,819 |
|
|
9,819 |
|
Accrued PIK interest1,2,4
|
— |
|
|
— |
|
|
— |
|
|
7,896 |
|
|
7,896 |
|
Total convertible notes |
$ |
522,097 |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
557,007 |
|
|
$ |
557,007 |
|
Core Scientific, Inc.
Notes to Unaudited Consolidated Financial Statements
1
Secured Convertible Notes (includes principal balance at issuance
and PIK interest) which considers the minimum payoff at maturity of
two times the face value of the note plus accrued
interest.
2
Other Convertible Notes (other than the Secured Convertible notes)
which considers the minimum payoff at maturity of one times the
face value of the note plus accrued interest.
3
Represents PIK interest accrued as of September 30, 2022 which
will be recorded as additional principal for each respective
convertible note on October 1, 2022.
4
Represents PIK interest accrued as of December 31, 2021 which
will be recorded as additional principal for each respective
convertible note on January 1, 2022.
Level 3 Recurring Fair Value Measurements
The following presents a rollforward of the activity for the
Convertible Notes measured at fair value on a recurring basis using
level 3 inputs as of September 30, 2022 (in
thousands):
|
|
|
|
|
|
|
Convertible Notes
(Level 3) |
Balance at December 31, 2021 |
$ |
557,007 |
|
Issuances (including PIK principal recorded) |
7,896 |
|
Settlements (including interest payments, PIK principal recorded
and conversions) |
(13,123) |
|
|
|
Unrealized losses |
371,951 |
|
Balance at March 31, 2022 |
923,731 |
|
Issuances (including PIK principal recorded) |
7,851 |
|
Settlements (including interest payments, PIK principal recorded
and conversions) |
(14,772) |
|
|
|
Unrealized gains |
(190,256) |
|
Balance at June 30, 2022 |
726,554 |
|
Issuances (including PIK principal recorded) |
8,031 |
|
Settlements (including interest payments, PIK principal recorded
and conversions) |
(13,519) |
|
|
|
Unrealized gains |
(38,235) |
|
Balance at September 30, 2022 |
$ |
682,831 |
|
Securities are transferred from level 2 to level 3 when observable
market prices for similar securities are no longer available and
unobservable inputs become significant to the fair value
measurement. All transfers into and out of level 3 are assumed to
occur at the beginning of the quarterly reporting period in which
they occur. As of September 30, 2022, level 3 financial
instruments included all the Convertible Notes as the effect of
unobservable inputs are significant to the fair value measurement.
There were no transfers of securities into or out of level 3 for
the three and nine months ended September 30, 2022 and
2021.
The following presents significant Level 3 unobservable inputs used
to measure the fair value of certain convertible notes as of
September 30, 2022 (dollars in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fair value |
|
Unobservable Input |
|
Low |
|
High |
|
Weighted Average1
|
|
|
|
|
|
|
|
|
|
|
Convertible Notes |
$ |
682,831 |
|
|
Expected term (years) |
|
2.55 |
|
2.55 |
|
2.55 |
|
|
|
Volatility |
|
69.5 |
% |
|
69.5 |
% |
|
69.5 |
% |
|
|
|
|
|
|
|
|
|
|
1
Weighted average based on the fair value of convertible
notes.
Expected term is an input into the call option model that measures
the length of time the instrument is expected to be outstanding
before it is exercised or terminated. An increase in expected term,
in isolation, would generally result in an increase in the fair
value measurement of the convertible notes.
Core Scientific, Inc.
Notes to Unaudited Consolidated Financial Statements
Volatility is an input into the call option model that measures the
variability in possible returns for the convertible notes based on
how much the price of underlying shares change in value over time.
An increase in volatility, in isolation, would generally result in
an increase in the fair value measurement of the convertible
notes.
The increase or decrease in the fair value of the convertible notes
resulting from changes to the expected term or volatility
assumptions are not interrelated.
The Company presents separately in other comprehensive income
(loss) the portion of the total change in the fair value of the
convertible notes that resulted from a change in the
instrument-specific credit risk on the convertible notes. The
amount of change in the fair value attributable to
instrument-specific credit risk is determined by comparing the
amount of the total change in fair value to the amount of change in
fair value that would have occurred if the Company’s credit risk
had not changed during the period as reflected in the discount
rates applied to the debt and risk put option.
Nonrecurring fair value measurements
The Company’s non-financial assets, including digital
assets, property, plant and equipment, goodwill and intangible
assets are measured at estimated fair value on a nonrecurring
basis. These assets are adjusted to fair value only when an
impairment is recognized, or the underlying asset is held for sale.
Refer to the discussion of digital assets below for more
information regarding fair value considerations when measuring the
impairment of digital assets held.
Digital assets
The Company classifies digital assets primarily as level 1. The
Company’s digital assets are accounted for as intangible assets
with indefinite useful lives. The Company initially recognizes
digital assets that are received as digital asset mining revenue
based on the fair value of the digital assets. Digital assets that
are purchased in an exchange of one digital asset for another
digital asset are recognized at the fair value of the asset
surrendered or at the fair value of the asset received if more
readily apparent. Impairment exists when the carrying amount
exceeds its fair value, which is measured using the quoted price of
the digital asset at the time its fair value is being measured,
which is measured once a day at 00:00 Coordinated Universal Time
(“UTC”). To the extent that an impairment loss is recognized, the
loss establishes the new cost basis of the digital asset. During
the three and nine months ended September 30, 2022, the
Company recognized impairment of digital assets of
$8.0 million and $212.2 million, respectively. During
both the three and nine months ended September 30, 2021, the
Company recognized impairment of digital assets of
$12.6 million. For the three and nine months ended
September 30, 2022, the Company recognized net gains of $11.0
million and $25.0 million, respectively, from sales of digital
assets. For both the three and nine months ended September 30,
2021, the Company recognized net gains of $0.4 million from sales
of digital assets. Digital assets are available for use, if needed,
for current operations and are classified as current assets on the
Consolidated Balance Sheets, the details of which are presented
below (in thousands).
|
|
|
|
|
|
|
|
|
|
|
|
|
September 30
2022 |
|
December 31
2021 |
Bitcoin (BTC) |
$ |
19,619 |
|
|
$ |
224,843 |
|
Ethereum (ETH) |
22 |
|
|
4,665 |
|
Polygon (MATIC) |
— |
|
|
1,085 |
|
Siacoin (SC) |
— |
|
|
803 |
|
Dai (DAI) |
— |
|
|
1,353 |
|
Other |
22 |
|
|
1,549 |
|
Total digital assets |
$ |
19,663 |
|
|
$ |
234,298 |
|
The Company does not have any off-balance sheet holdings of digital
assets.
Property, plant and equipment
On March 10, 2022, the Company entered into an agreement to sell
mining equipment on order with a 3rd party supplier to a hosting
customer in exchange for the Company receiving ownership of the
customer’s mining equipment that had been hosted by the Company on
its premises (the “Installed Miners”). The primary purpose of the
exchange was to allow for the mutual termination of the hosting
agreements in a manner that avoids the logistical costs and loss of
revenue from downtime associated with relocating and installing the
mining equipment. The exchange began during the three months ended
June 30, 2022 and was completed in July 2022 as ordered mining
equipment was received and exchanged for the Installed Miners. The
agreement also includes the termination of the hosting agreement
between the Company and the customer as ownership of the Installed
Miners is transferred to the Company.
Core Scientific, Inc.
Notes to Unaudited Consolidated Financial Statements
The Company recognized losses of $13.1 million on the exchanges
during the nine months ended September 30, 2022, which are
presented within losses on exchange or disposal of property, plant
and equipment on the Consolidated Statements of Operations. The
amount of the losses was measured as the difference between the
fair value of the installed miners and the carrying value of the
deposits for mining equipment to be exchanged. The fair value of
the installed miners is classified as a Level 2 fair value
measurement and was determined as of contract inception (March 10,
2022) using a cost approach. The replacement cost of the installed
miners was estimated through a review of vendor equipment pricing
of similar equipment. Physical deterioration was also considered
and estimated based on an age/life analysis indicative of a market
participant’s anticipated economic useful life for the
assets.
During the three months ended September 30, 2022, the
Company’s operating performance and liquidity continued to be
severely impacted by the prolonged decrease in the price of
bitcoin, the increase in electricity costs, the increase in the
global bitcoin network hash rate and an increase in additional
operating costs related to these factors. Additionally, primary and
secondary market prices for ASIC miners of the type used by the
Company in its business operations have decreased significantly
from previous levels, including those acquired earlier in 2022.
Accordingly, the Company evaluated whether the estimated future
undiscounted cash flows from the operation of its data center
facilities would recover the carrying value of the property, plant
and equipment located at the sites and used in site operations,
including the Company’s deployed mining equipment. Based on this
evaluation, the Company determined that the carrying value of the
property, plant and equipment at the Cedarvale, TX facility site
may no longer be fully recoverable by the cash flows of the site.
The Company measured the amount of impairment at the Cedarvale, TX
facility site as the difference between the carrying amount of the
site asset group of $119.8 million and the estimated fair value of
the site asset group of $60.5 million, resulting in an impairment
of the facility site’s property, plant and equipment of $59.3
million for both the three and nine months ended September 30,
2022. Refer to the discussion of long-lived asset impairments in
Note 2 for additional information regarding the inputs and
methodology used to estimate the fair value.
Goodwill and other intangible assets
On June 30, 2022 and September 30, 2022, the Company evaluated its
reporting units for impairment and recorded an impairment of
goodwill and other intangible assets of $266.0 million and
$1.05 billion for three and nine months ended
September 30, 2022, respectively, of which $207.8 million
and $996.5 million was related to the Mining reporting unit
for the three and nine months ended September 30, 2022,
respectively, and $58.2 million was related to the Equipment
Sales and Hosting reporting unit for both the three and nine months
ended September 30, 2022. Refer to Note 4 for additional
information regarding the inputs and methodology used to estimate
the fair value.
Fair value of financial instruments
The Company’s financial instruments include cash and cash
equivalents, restricted cash, accounts receivable, net, accounts
payable, notes payable and certain accrued expenses and other
liabilities. The carrying amount of these financial instruments,
other than notes payable discussed below, approximates fair value
due to the short-term nature of these instruments.
The fair value of the Company’s notes payable (excluding the
Convertible Notes carried at fair value described above), which are
carried at amortized cost, was determined based on a discounted
cash flow approach using market interest rates of instruments with
similar terms and maturities and an estimate for our standalone
credit risk. We classified the other notes payable as Level 3
financial instruments due to the considerable judgment required to
develop assumptions of the Company’s standalone credit risk and the
significance of those assumptions to the fair value measurement.
The estimated fair value of the Company’s other notes payable,
including both the current and noncurrent portion, was
$293.7 million at September 30, 2022 and
$184.7 million at December 31, 2021. The carrying values
of the notes payable, including both the current and noncurrent
portion, was $294.8 million and $171.2 million at
September 30, 2022 and December 31, 2021,
respectively.
Core Scientific, Inc.
Notes to Unaudited Consolidated Financial Statements
9. LEASES
The Company has entered into non-cancellable operating and finance
leases for office, data facilities, computer and networking
equipment, electrical infrastructure and office equipment, with
original lease periods expiring through 2033. In addition, certain
leases contain bargain renewal options extending through 2051. The
Company recognizes lease expense for these leases on a
straight-line basis over the lease term, which includes any bargain
renewal options. The Company recognizes rent expense on a
straight-line basis over the lease period. In addition to minimum
rent, certain leases require payment of real estate taxes,
insurance, common area maintenance charges, and other executory
costs. Differences between rent expense and rent paid are
recognized as adjustments to operating lease right-of-use assets on
the unaudited Consolidated Balance Sheets. For certain leases the
Company receives lease incentives, such as tenant improvement
allowances, and records those as adjustments to operating lease
right-of-use assets and operating lease liabilities on the
unaudited Consolidated Balance Sheets and amortizes the lease
incentives on a straight-line basis over the lease term as an
adjustment to rent expense.
The components of operating and finance leases are presented on the
Company’s Consolidated Balance Sheets as follows (in
thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Financial statement line item |
|
September 30, 2022 |
Assets: |
|
|
|
|
Operating lease right-of-use assets |
|
Other noncurrent assets |
|
$ |
20,926 |
|
Finance lease right-of-use assets |
|
Property, plant and equipment, net |
|
$ |
88,042 |
|
Liabilities: |
|
|
|
|
Operating lease liabilities,
current portion |
|
Accrued expenses and other |
|
$ |
849 |
|
Operating lease liabilities, net
of current portion |
|
Other noncurrent liabilities |
|
$ |
14,594 |
|
Finance lease liabilities, current portion |
|
Finance lease liabilities, current portion |
|
$ |
73,045 |
|
Finance lease liabilities, net of
current portion |
|
Finance lease liabilities, net of current portion |
|
$ |
— |
|
The components of lease expense were as follows (in
thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Financial statement line item |
|
Three Months Ended September 30, 2022 |
|
Nine Months Ended September 30, 2022 |
|
|
|
|
|
|
|
Operating lease expense |
|
General and administrative expenses |
|
$ |
589 |
|
|
$ |
898 |
|
Short-term lease expense |
|
General and administrative expenses |
|
195 |
|
|
671 |
|
Finance lease expense: |
|
|
|
|
|
|
Amortization of right-of-use assets |
|
Cost of revenue |
|
9,040 |
|
|
27,563 |
|
Interest on lease liabilities |
|
Interest expense, net |
|
2,278 |
|
|
6,617 |
|
Total finance lease expense |
|
|
|
11,318 |
|
|
34,180 |
|
Total lease expense |
|
|
|
$ |
12,102 |
|
|
$ |
35,749 |
|
In determining the discount rate used to measure the right-of-use
asset and lease liability, we use rates implicit in the lease, or
if not readily available, we use our incremental borrowing rate.
Our incremental borrowing rate is based on an estimated secured
rate with reference to recent borrowings of similar collateral and
tenure when available. Determining our incremental borrowing rate,
especially if there are insufficient observable borrowings near the
time of lease commencement, may require significant
judgment.
Core Scientific, Inc.
Notes to Unaudited Consolidated Financial Statements
Information relating to the lease term and discount rate is as
follows:
|
|
|
|
|
|
|
September 30, 2022 |
Weighted Average Remaining Lease Term (Years) |
|
Operating leases |
10.7 |
Finance leases |
2.3 |
Weighted Average Discount Rate |
|
Operating leases |
6.5 |
% |
Finance leases |
12.7 |
% |
The following table summarizes the Company’s supplemental cash flow
information (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended September 30, 2022 |
|
Nine Months Ended September 30, 2022 |
Lease Payments |
|
|
|
Operating lease payments |
$ |
272 |
|
|
$ |
474 |
|
Finance lease payments |
$ |
6,760 |
|
|
$ |
34,287 |
|
Supplemental Noncash Information |
|
|
|
Operating lease right-of-use assets obtained in exchange for lease
obligations1
|
$ |
14,195 |
|
|
$ |
21,574 |
|
Finance lease right-of-use assets obtained in exchange for lease
obligations |
$ |
— |
|
|
$ |
10,557 |
|
Increase in finance lease right-of-use assets as a result of lease
modification |
$ |
693 |
|
|
$ |
693 |
|
1
Includes operating lease right-of-use assets of $6.7 million
that were recorded upon adoption of Topic 842 on January 1, 2022.
Refer to Note 2 for further information.
The Company’s minimum payments under noncancelable operating and
finance leases having initial terms and bargain renewal periods in
excess of one year are as follows at September 30, 2022, and
thereafter (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating leases |
|
Finance leases |
Remaining 2022 |
$ |
332 |
|
|
$ |
5,533 |
|
2023 |
2,082 |
|
|
38,518 |
|
2024 |
1,810 |
|
|
36,497 |
|
2025 |
1,866 |
|
|
4,509 |
|
2026 |
1,924 |
|
|
3 |
|
2027 |
1,985 |
|
|
— |
|
Thereafter |
12,037 |
|
|
— |
|
Total lease payments |
22,036 |
|
|
85,060 |
|
Less: imputed interest |
6,593 |
|
|
12,015 |
|
Total |
$ |
15,443 |
|
|
$ |
73,045 |
|
Operating leases
In September 2021, the Company entered into operating lease
agreements with Minnkota Power Cooperative to develop a hosting
facility in Grand Forks, North Dakota as well as enter into a power
supply purchase agreement to purchase 100 megawatts of power supply
once construction of the hosting facility is complete. As a result
of the agreements being entered into contemporaneously and in
contemplation of one another, the agreements are considered to be a
single unit of account and consideration has been allocated between
lease and non-lease components based on relative standalone selling
price with approximately $5.3 million allocated to the lease
components and $2.6 million allocated to the non-lease
components. Substantially all of the payments for the intended
leases would be for a five-year to thirty-year term (comprising an
initial five-year term with five five-year bargain renewal options
to renew) with purchase options exercisable at any time for
approximately $5.6 million less any rent paid to date and
subject to certain other adjustments.
Core Scientific, Inc.
Notes to Unaudited Consolidated Financial Statements
In addition to the above, in December 2021, the Company entered
into an agreement to lease office space for its new corporate
headquarters that commenced in July of 2022. The lease includes
base rent of approximately $14.0 million to be paid over a
period of 130 months.
Finance leases
In December 2021, the Company entered into finance lease agreements
with Liberty Commercial Finance LLC totaling $40.9 million for
the purchase of bitcoin mining equipment, with a weighted average
term of 3.2 years. The leases bear interest at a weighted average
rate per annum of 12.6% and the Company is required to make monthly
payments of principal and interest. Interest expense on the lease
has been recognized based on a weighted average effective interest
rate of 12.6%.
In December 2021, the Company entered into finance lease agreements
with MassMutual Asset Finance LLC totaling $50.0 million for
the purchase of bitcoin mining equipment, with a weighted average
term of 3.2 years. The leases bear interest at a rate per annum of
10% and the Company is required to make monthly payments of
principal and interest. Interest expense on the leases has been
recognized based on an effective interest rate of 10%.
In August 2022, the Company amended the finance lease agreements
with MassMutual Asset Finance LLC to defer lease payments for a
period of six months beginning with payments due in August 2022.
The amendments result in no change to the term of the finance
leases and the remaining principal will amortize over the remaining
life of the leases beginning in February 2023. The amendments also
requires an additional amount blockchain computing equipment to be
provided as collateral. The leases under the amended agreements
bear interest at a rate of 13.0% per annum. Interest expense on the
amended leases has been recognized based on an effective interest
rate of 12.5%. As a result of the lease modification, the lease
liabilities decreased by $7.7 million with a corresponding
decrease to finance lease right-of assets of
$7.7 million.
Balance Sheet Classification
As discussed in Note 6, in October 2022 the Company determined not
to make certain payments with respect to several of its debt
facilities, equipment financing facilities and leases and other
financings, including its two bridge promissory notes. As a result,
the creditors under these debt facilities may exercise remedies
following any applicable grace periods, including electing to
accelerate the principal amount of such debt, suing the Company for
nonpayment, increasing interest rates to default rates, or taking
action with respect to collateral, where applicable. The Company
does not believe it was in default under any of its finance lease
agreements as of September 30, 2022. In the event of a default, the
Company may become subject to certain additional provisions in its
finance lease agreements such as higher default interest rates. As
a result of these factors, the Company has determined that it is
probable that its finance lease liabilities will become due within
one year and has therefore classified all of its finance lease
liabilities as current liabilities as of September 30,
2022.
Core Scientific, Inc.
Notes to Unaudited Consolidated Financial Statements
10. COMMITMENTS AND CONTINGENCIES
Legal Proceedings—The
Company is subject to legal proceedings arising in the ordinary
course of business. The Company accrues losses for a legal
proceeding when it is probable that a loss has been incurred and
the amount of the loss can be reasonably estimated. However, the
uncertainties inherent in legal proceedings make it difficult to
reasonably estimate the costs and effects of resolving these
matters. Accordingly, actual costs incurred may differ materially
from amounts accrued and could materially adversely affect the
Company’s business, cash flows, results of operations, financial
condition and prospects. Unless otherwise indicated, the Company is
unable to estimate reasonably possible losses in excess of any
amounts accrued.
In July 2022, one of the Company’s largest customers, Celsius
Mining LLC (“Celsius”), along with its parent company and certain
affiliates, filed for voluntary relief under chapter 11 of the
United States Bankruptcy Code
in the Bankruptcy Court for the Southern District of New York. On
September 28, 2022, Celsius filed a motion in the chapter 11 case
alleging that the Company is violating the automatic stay with
respect to the Master Services Agreement between Celsius and the
Company (the “Celsius Agreement”). Celsius is also using its
Chapter 11 proceeding to withhold payment of certain charges billed
to Celsius pursuant to the Celsius Agreement. The Company strongly
disagrees with the allegations made in the Celsius motion and the
interpretation of the Celsius Agreement espoused therein and is
vigorously defending its interests, including seeking resolution
from the bankruptcy court and payment of any outstanding amounts
owed under the Celsius Agreement (subject to applicable bankruptcy
law in the Celsius chapter 11 case). The parties have agreed to
stay the proceedings, including the evidentiary hearing scheduled
for November 18, 2022. There can be no guarantee that the
bankruptcy court will rule in the Company’s favor in a timely
manner or that Celsius will honor the terms of the Celsius
Agreement. An adverse ruling by the bankruptcy court that provides
Celsius the benefits of the Company’s hosting services without
Celsius fully paying the costs of such services would have a
material effect on the Company’s business, financial condition,
results of operations and cash flows. As of September 30, 2022, the
Company had accrued $5.2 million as an allowance against amounts
due from Celsius.
In November 2022, Sphere 3D Corp. filed a demand for arbitration
with JAMS alleging the existence and breach of a contract for
hosting services. The arbitration demand alleges that the Company
has failed to provide contracted for services and to return
approximately $35 million in prepayments made by Sphere 3D for
such services. The Company denies the allegations contained in
Sphere 3D’s arbitration demand and intends to vigorously defend its
interests.
In November 2022, McCarthy Building Companies, Inc. filed a
complaint against the Company in the United States District Court
for the Eastern District of Texas, alleging breach of contract for
failing to pay when due certain payments allegedly owing under a
contract for construction entered into between the
parties.
In November 2022, plaintiff Mei Peng filed a putative class action
in the United States District Court, Western District of Texas,
Austin Division, asserting that the Company violated the Securities
Exchange Act by failing to disclose to investors, among other
things, that the Company was vulnerable to litigation, that certain
clients had breached their agreements, and that this impacted the
Company's profitability and ability to continue as a going concern.
The Company denies the allegations contained in the complaint and
intends to vigorously defend its interests.
As of September 30, 2022 and December 31, 2021, there
were no other material loss contingency accruals.
Leases—See
Note 9 for further information.
Purchase obligations—As
of September 30, 2022, the Company had outstanding agreements
to purchase blockchain mining equipment totaling approximately
$49.9 million before considering variable price adjustments,
substantially all of which are expected to be settled within one
year.
Loss on legal settlement—The
Company recognized a loss of $2.6 million during the three and nine
months ended September 30, 2021 related to a settlement with a
former customer.
Core Scientific, Inc.
Notes to Unaudited Consolidated Financial Statements
11. CONTINGENTLY REDEEMABLE CONVERTIBLE PREFERRED
STOCK
The Company is authorized to issue 2.00 billion shares of
preferred stock, $0.0001 as of September 30, 2022. Prior to
the Merger with XPDI, the Company was authorized to issue
50.0 million shares of preferred stock, $0.0001 par value. As
of December 31, 2021, 10.8 million shares of preferred stock
were issued and outstanding.
Upon the closing of the merger with XPDI on January 19, 2022, each
share of Series A and Series B Preferred Stock automatically
converted into one share of Core Scientific common stock and each
outstanding share of common stock issued as a result of the
conversion of Series A and Series B Preferred Stock in connection
with the Merger was cancelled and extinguished and converted into
the right to receive a number of shares of New Core Common Stock
equal to the Exchange Ratio of 1.6001528688. All of the Company’s
shares of contingently redeemable convertible preferred stock were
converted into 10.8 million shares of the Company’s common
stock during the nine months ended September 30,
2022.
Core Scientific, Inc.
Notes to Unaudited Consolidated Financial Statements
12. STOCKHOLDERS' EQUITY
Authorized Capital—As
of September 30, 2022, the Company was authorized to issue
10.00 billion shares of common stock, $0.0001 par value. The
holders of the Company’s common stock are entitled to one vote per
share.
In January 2021, in connection with the stockholder loan described
in Note 6, the Company issued a warrant to the stockholder to
purchase up to 0.2 million shares of common stock at an
exercise price of $4.21 per share. The warrant is set to expire in
January 2023 and is exercisable and unexercised as of
September 30, 2022.
As a result of the Merger, all of XPDI’s Class A Common Stock and
Class B Common Stock automatically converted into 30.8 million
shares of New Core Common Stock on a one-for-one basis. XPDI’s
8.6 million public warrants issued in its initial public
offering (the “Public Warrants”) and 6.3 million warrants
issued in connection with private placement at the time of XPDI’s
initial public offering (the “Private Placement Warrants”) became
warrants for New Core Common Stock.
Following the Merger with XPDI, each share of common stock or
warrant was converted to shares of New Core Common Stock or a
warrant to purchase shares of New Core Common Stock based on an
exchange ratio of 1.6001528688.
Equity Line of Credit
In July 2022, the Company entered into a common stock purchase
agreement (the “Equity Line of Credit”) and a Registration Rights
Agreement (the “Registration Rights Agreement”) with B. Riley.
Pursuant to the Equity Line of Credit, subject to the satisfaction
of the conditions set forth in the Equity Line of Credit, the
Company will have the right to sell to B. Riley, up to
$100.0 million of shares of the Company’s common stock, par
value $0.0001 per share (the “Common Stock”), subject to certain
limitations and conditions set forth in the Equity Line of Credit,
from time to time during the term of the Equity Line of Credit.
Sales of Common Stock pursuant to the Equity Line of Credit, and
the timing of any sales, are solely at the Company’s option, and
the Company is under no obligation to sell any securities to B.
Riley under the Equity Line of Credit.
The per share purchase price that B. Riley is required to pay for
shares of the Company’s Common Stock in a Purchase effected by the
Company pursuant to the Equity Line of Credit, if any, will be
determined by reference to the volume weighted average price
(“VWAP”) of the Common Stock, calculated in accordance with the
Equity Line of Credit, for the period (the “Purchase Valuation
Period”) beginning at the official open (or “commencement”) of the
regular trading session on Nasdaq on the applicable Purchase Date
(as defined in the Equity Line of Credit) for such Purchase, and
ending at the earliest to occur of (i) 3:59 p.m., New York City
time, on such Purchase Date or such earlier time publicly announced
by the trading market as the official close of the regular trading
session on such Purchase Date, (ii) such time that the total
aggregate number (or volume) of shares of Common Stock traded on
Nasdaq during such Purchase Valuation Period (calculated in
accordance with the Equity Line of Credit) reaches the applicable
share volume maximum amount for such Purchase (the “Purchase Share
Volume Maximum”), calculated by dividing (a) the applicable
Purchase Share Amount for such Purchase, by (b) 0.20, and (iii)
such time that the trading price of a share of Common Stock on
Nasdaq during such Purchase Valuation Period (calculated in
accordance with the Equity Line of Credit) falls below the
applicable minimum price threshold for such Purchase specified by
the Company in the Purchase Notice for such Purchase, or if the
Company does not specify a minimum price threshold in such Purchase
Notice, a price equal to 75.0% of the closing sale price of the
Common Stock on the trading day immediately prior to the applicable
Purchase Date for such Purchase (the “Minimum Price Threshold”),
less a fixed 3.0% discount to the VWAP for such Purchase Valuation
Period.
The net proceeds to the Company from sales that the Company elects
to make to B. Riley under the Equity Line of Credit, if any, will
depend on the frequency and prices at which the Company sells
shares of the Company’s Common Stock to B. Riley. The Company
expects that any proceeds received by the Company from such sales
to B. Riley will be used for general corporate
purposes.
There are no restrictions on future financings, rights of first
refusal, participation rights, penalties or liquidated damages in
the Equity Line of Credit or Registration Rights Agreement, other
than a prohibition (with certain limited exceptions) on entering
into specified “Variable Rate Transactions” (as such term is
defined in the Equity Line of Credit) during the term of the Equity
Line of Credit. Such transactions include, among others, the
issuance of convertible securities with a conversion or exercise
price that is based upon or varies with the trading price of the
Company’s Common Stock after the date of issuance, or the Company’s
effecting or entering into an agreement to effect an “equity line
of credit” or other substantially similar continuous offering with
a third party, in which the Company may offer, issue or sell Common
Stock or any securities exercisable, exchangeable or convertible
into Common Stock at a future determined price.
Under the applicable Nasdaq rules, in no event may the Company
issue to B. Riley under the Equity Line of Credit more than
70.3 million shares of Common Stock, which number of shares is
equal to approximately 19.99% of the shares of the Common Stock
outstanding immediately prior to the execution of the Equity Line
of Credit (the “Exchange Cap”), unless (i) the Company
obtains
Core Scientific, Inc.
Notes to Unaudited Consolidated Financial Statements
stockholder approval to issue shares of Common Stock in excess of
the Exchange Cap in accordance with applicable Nasdaq rules, or
(ii) the average price per share paid by B. Riley for all of the
shares of Common Stock that the Company directs B. Riley to
purchase from the Company pursuant to the Equity Line of Credit, if
any, equals or exceeds $1.75 per share (representing the lower of
the official closing price of the Company’s Common Stock on Nasdaq
on the trading day immediately preceding the date of the Equity
Line of Credit and the average official closing price of the
Company’s Common Stock on Nasdaq for the
five consecutive trading days ending on the trading day
immediately preceding the date of the Equity Line of Credit, as
adjusted pursuant to applicable Nasdaq rules). Moreover, the
Company may not issue or sell any shares of Common Stock to B.
Riley under the Equity Line of Credit which, when aggregated with
all other shares of Common Stock then beneficially owned by B.
Riley and its affiliates (as calculated pursuant to Section 13(d)
of the Securities Exchange Act of 1934, as amended (the “Exchange
Act”), and Rule 13d-3 thereunder), would result in B. Riley
beneficially owning more than 4.99% of the outstanding shares of
Common Stock.
The Equity Line of Credit will automatically terminate on the
earliest to occur of (i) the first day of the month next following
the 24-month anniversary of the Commencement Date (as such term is
defined in the Equity Line of Credit), (ii) the date on which B.
Riley shall have purchased from the Company under the Equity Line
of Credit shares of Common Stock for an aggregate gross purchase
price of $100.0 million, (iii) the date on which the Common
Stock shall have failed to be listed or quoted on Nasdaq or another
U.S. national securities exchange identified as an “eligible
market” in the Equity Line of Credit, (iv) the 30th trading day
after the date on which the Company commences a voluntary
proceeding or any third party commences a bankruptcy proceeding
against the Company that is not discharged or dismissed prior to
such trading day, and (v) the date on which a bankruptcy custodian
is appointed for all or substantially all of the Company’s property
or the Company makes a general assignment for the benefit of
creditors.
The Company has the right to terminate the Equity Line of Credit at
any time after Commencement, at no cost or penalty, upon
five (5) trading days’ prior written notice to B. Riley. B.
Riley has the right to terminate the Equity Line of Credit upon
five (5) trading days’ prior written notice to the Company
upon the occurrence of certain events set forth in the Equity Line
of Credit. The Company and B. Riley may also agree to terminate the
Equity Line of Credit by mutual written consent, provided that no
termination of the Equity Line of Credit will be effective until
the fifth trading day immediately following the settlement date
related to any pending purchase that has not been fully settled in
accordance with the Equity Line of Credit. Neither the Company nor
B. Riley may assign or transfer their respective rights and
obligations under the Equity Line of Credit or the Registration
Rights Agreement.
As consideration for B. Riley’s commitment to purchase shares of
Common Stock at the Company’s direction upon the terms and subject
to the conditions set forth in the Equity Line of Credit, upon
execution of the Equity Line of Credit in July 2022, the Company
issued 0.6 million shares to B. Riley with a fair value of
$1.1 million at issuance which was recorded
within other non-operating expenses, net on the Company’s
Consolidated Statements of Operations
and presented as equity line of credit expenses on the Consolidated
Statements of Cash Flows. In addition, the Company reimbursed
$0.1 million of reasonable legal fees and disbursements of B.
Riley’s legal counsel in connection with the transactions
contemplated by the Equity Line of Credit and the Registration
Rights Agreement.
During the three and nine months
ended
September 30, 2022,
the Company issued 7.3 million shares under the Equity Line of
Credit for a total sales price to B. Riley of $12.8 million,
consisting of (a) cash proceeds received of $11.7 million and (b)
$1.1 million of proceeds due from B. Riley as of September 30,
2022 that was recorded within prepaid expenses and other current
assets on the Consolidated Balance Sheets. The total sales price of
$12.8 million for issuances during
the three and nine months
ended
September 30, 2022
is net of $0.3 million for the
fixed 3.0% discount to the VWAP described above which was
recorded within other non-operating expenses, net on the Company’s
Consolidated Statements of Operations and presented as
equity line of credit expenses on the Consolidated Statements of
Cash Flows.
As of
September 30, 2022,
63.0 million
shares of Common Stock were available to be issued under the Equity
Line of Credit.
As discussed in Note 6,
25% of the net cash proceeds received for shares issued under the
Equity Line of Credit is required to be applied by the Company to
repay the outstanding principal amount of the Amended Bridge Notes.
As of September 30, 2022, the Company owed
$2.9 million on the Amended Bridge Notes related to proceeds
received under the Equity Line of Credit.
Warrant Exercises
In March 2020, the Company issued warrants to the Company’s
president and chief executive officer and a member of the board of
directors to purchase up to 6.4 million shares of the
Company’s common stock at an exercise price of $0.84 per share (as
amended). In March 2022, a warrant holder exercised their warrant
to purchase 3.2 million shares in a cashless exercise
resulting in 2.9 million net shares issued to the warrant
holder after withholding 0.3 million shares for the exercise
price.
In March 2020, the Company issued warrants to service providers in
exchange for services provided related to the issuance of Series A
Convertible Preferred Stock. The warrants were for an aggregate of
0.2 million shares at an exercise price of $4.27 per
share.
Core Scientific, Inc.
Notes to Unaudited Consolidated Financial Statements
In February 2022, 0.2 million of the warrants were exercised
in a cashless exercise resulting in 0.1 million net shares
issued to the warrant holders.
Convertible Note Exercises
As discussed in Note 6, the Company issued $514.8 million of
Convertible Notes in 2021 along with issuing an additional
$31.0 million from issuance through September 30, 2022 as
payment-in-kind interest on convertible notes outstanding. The
Convertible Notes became convertible into common shares at the
option of the holder at a conversion price equal to $8.00 per share
upon the closing of the Merger Agreement with XPDI in January 2022.
During the nine months ended September 30, 2022,
$1.6 million of Convertible Notes were exercised resulting in
0.2 million shares issued to the holders of the Convertible
Notes that were exercised.
SPAC Vesting Shares
1.7 million common shares are subject to vesting requirements, as
described further in Note 1. These contingently issuable shares do
not require future service in order to vest and do not result in
stock-based compensation expense. The SPAC Vesting Shares are
accounted for as an equity contract, and meet the criteria for
equity classification. The Company has recorded the SPAC Vesting
Shares within additional paid-in capital on the Consolidated
Balance Sheet as of September 30, 2022.
Vendor Settlement
In March 2022, the Company issued 1.6 million shares of the
Company’s common stock related to a vendor liability that had been
assumed by the Company in July 2021 as part of the Blockcap
acquisition. In addition, the vendor liability requires settlement
in cash based on the difference between the weighted average of the
closing price of the Company’s common stock for each day there was
a closing price during the
thirty consecutive days immediately prior to the expiration
of the lockup period (defined in the agreement as 180 days from the
date from the closing of the XPDI merger) and the
$21.3 million contractual amount of the liability. During the
three and nine months ended September 30, 2022 we recorded
$0.1 million and $9.5 million, respectively, within Other
non-operating expenses, net on the Consolidated Statements of
Operations related to changes in the fair value of the vendor
liability. As of September 30, 2022, the fair value of the
liability of $18.1 million was recorded within Accrued
expenses and other on the Consolidated Balance Sheet.
Equity Incentive Plans
The Company has outstanding awards under the 2018 Omnibus Incentive
Plan (the “2018 Plan”). No new awards can be made under the 2018
Plan subsequent to the XPDI Merger, as described below. Awards that
were granted under the 2018 Plan included incentive stock options
(must meet all statutory
requirements), non-qualified stock options and restricted
stock units. Awards granted under the 2018 Plan were subject to a
minimum vesting period of at least one year commencing from the
date of grant. Additionally, options granted under the plan must
expire within ten years of the grant date and were required to be
granted with exercise prices of no less than the fair value of the
common stock on the grant date, as determined by the Company’s
board of directors.
In July 2021, the Company acquired Blockcap. Under the terms of the
Blockcap merger agreement, (i) each stock option granted, whether
vested or unvested, and each award of restricted stock under the
Blockcap, Inc. Equity Incentive Plan (the “Legacy Blockcap Plan”)
was assumed by the Company.
In addition, the Radar Relay, Inc. Amended and Restated 2018 Equity
Incentive Plan (the “RADAR Plan”) provides for the grant of stock
options, restricted stock awards, and other awards to eligible
employees, non-employee directors and consultants. On June 4, 2021,
prior to its acquisition by the Company, Blockcap entered into an
agreement and plan of merger with RADAR for all the issued and
outstanding equity interests of RADAR, which merger closed on July
1, 2021 (the “Blockcap/RADAR Merger”). The RADAR Plan was assumed
by us upon the closing of the Blockcap/RADAR Merger and the
Blockcap acquisition.
No new awards may be made under the Legacy Blockcap Plan and the
RADAR Plan (the “Blockcap Plans”) subsequent to the closing of the
Blockcap acquisition.
At the Special Meeting in connection with the XPDI Merger, the
stockholders of XPDI approved the Core Scientific, Inc. 2021 Equity
Incentive Plan (the “2021 Plan”). Awards granted under the 2021
Plan may be incentive stock options (must meet all statutory
requirements), non-qualified stock options, stock
appreciation rights, restricted stock and stock units, performance
awards and other cash-based or stock-based awards. Awards granted
under the 2021 Plan are subject to a minimum vesting period of at
least one year commencing from the date of grant. Additionally,
options granted under the plan must expire within ten years of the
grant date and must be granted with exercise prices of no less than
the fair value of the common stock on the grant date, as determined
by the